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Introduction to hematopoiesis, bone marrow 










GENERAL INTRODUCTION  
 
Acute leukemias are a diverse group of blood cell malignancies that arise from the 
clonal expansion of myeloid (acute myeloid leukemia, AML) or lymphoid (acute 
lymphoid leukemia, ALL) leukemic hematopoietic progenitor cells. Leukemic cells are 
characterized by aberrant intracellular processes that lead to a block in cellular 
differentiation and abnormal cell proliferation, resulting in accumulation of immature 
cells in the bone marrow (BM) and peripheral blood (PB)1–4. Leukemic cells are non-
functional and interfere with normal blood cell production, resulting in weakness, 
predisposition to bleeding and infection, among other symptoms and life-threatening 
complications5,6. 
In the healthy/non-malignant cell, a series of synchronized checkpoints must be 
passed before cell division can occur. Leukemic cells fall away from this tightly 
orchestrated progression and acquire new capabilities which allows them to 
reprogram nutrient metabolism, evade cell cycle checkpoints and achieve replicative 
immortality7–10. By resisting apoptosis, cells proliferate continuously, loose function, 
and destroy healthy tissue architecture7. 
Emerging evidence suggests that the surrounding extracellular BM microenvironment 
is also relevant in leukemic transformation and progression by stimulating cellular 
proliferation and angiogenesis11–13. From this perspective, leukemia, similar to many 
types of malignancies can be seen as a process that takes place in two basic 
compartments: an intracellular and extracellular compartment, composed by the or 
BM niche or microenvironment (BMM). Under normal conditions the BMM, composed 
by stromal cells, endothelial cells, osteoblasts/osteoclasts, nervous fibers, and 
pericytes among other cell types14–17 create a protective and nurturing niche for the 
hematopoietic stem cells (HSC)7,14. For example, specialized BM endothelial cells 
provide paracrine signalling that promote stem cell proliferation and BM regeneration 
after injury14,18–20. Leukemic stem cells (LSC) compete with healthy HSC for the BM 
niche, to further support proliferation7,15,16,21,22. 
The HSC and BMM constitute two compartments separated by the cellular membrane, 
through which they interact (either via cell-cell adhesion, microvesicle packaging or 
ligand-receptor interaction). Malignant cells are able to highjack and manipulate these 
intracellular and extracellular compartments to promote their own proliferation and 
survival7,8, while expressing membrane proteins, such as ATP-binding 
cassette transporters (ABC transporters), among others, that restrict control of drug 
transport from one compartment to another. This tighter control over transport systems 
of xenobiotics allows leukemic cells to become multidrug resistant7,8,23,24. 
The dynamic interaction between these compartments contributes to leukemogenesis 
by stimulating cell self-renewal, manipulating nutrient/drug metabolism and transport, 
supporting developmental arrest, and cell cycle dysregulation1,7,22. 
Under normal conditions the BM microenvironment, composed by stromal cells, 
endothelial cells, osteoblasts/osteoclasts and pericytes among other cell types14–17 
creates a protective and nurturing niche for the hematopoietic stem cells (HSC)7,14. 
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For example, specialized BM endothelial cells provide paracrine signalling that 
promote stem cell proliferation and BM regeneration after injury14,18–20. Leukemic stem 
cells (LSC) compete with healthy HSC for the BM niche, to further support 
proliferation7,15,16,21,22. 
The dynamic interaction between these compartments contributes to leukemogenesis 
by stimulating cell self-renewal, manipulating nutrient/drug metabolism and transport, 
supporting developmental arrest, and cell cycle dysregulation1,7,22. 
 
Figure 1: Schematic representation of hematopoiesis. The bone marrow niche is a complex 
microenvironment composed of structures such as arterioles, sinusoids and nerve fibers, 
along with diverse cell types such as bone cells, (osteoblasts and osteoclasts), adipocytes, 
endothelial cells (composing arterioles and sinusoids), pericytes, mesenchymal stromal cells 
among others, all of which sustain HSCs and hematopoiesis. 
 
Bone marrow, hematopoiesis and leukemia  
Hematopoiesis takes place within the BM, which is a highly innervated and 
vascularized tissue25. HSCs reside within the endothelial sinusoids and nerve fibers 
of the BM, and are responsible for all blood cell restitution. Under healthy/normal 
conditions, HSC divide in a highly regulated manner to produce myeloid or lymphoid 
progenitors which in turn will generate the different lineages of blood cells, on 
physiological demand15. The BM microenvironment cells supports hematopoiesis by 
secretion of proliferative factors (such as IL-33 by endothelial cells) which stimulates 




Epidemiology of leukemia  
In 2018, leukemia was ranked as the 11th most common cancer worldwide and 
accounting for 3.5% of all cancers26,27. In the Netherlands, it is the 14th most common 
cancer and its yearly incidence in 2018 of around 1600 cases27. Even though adult 
and childhood-onset leukemia have distinct epidemiological differences, many 
common environmental risk factors (RF) have been identified (radiation and chemical 
exposure, as well as certain retroviral infections). Genetic conditions such as Down 
syndrome, Li-Fraumeni, and neurofibromatosis are also well known RF. Still, most 
patients with leukemia have no previous history of genetic or environmental RF3,28. 
 
Epidemiology of ALL in children and adults 
Overall, ALL is more common in children and AML is more common in adults. ALL 
has a bimodal distribution in the population, affecting both children and the elderly, yet 
it is much more frequent in childhood2. In fact, childhood ALL is the most common type 
of cancer in childhood, with a prevalence of up to 25% of all diagnosed cancers in 
patients <15 years old29. Most childhood ALL cases are of B-cell lineage (85%), 
followed by T-cell ALL (10-15%) while NK (<1%) cell leukemias are very rare5. The 
therapy outcome of pediatric ALL has improved outstandingly in the last decades. Fifty 
years ago, the survival of children with ALL was as low as 10%–20%30 but with current 
treatment regimes, 8 to 9 out of every ten children with ALL are cured in high-income 
countries31. Nonetheless, there are still 10-20% of high risk group of children with ALL 
who have a poor outcome, mainly due to multidrug resistance, such as in t(4;11) MLL-
rearranged leukemias, Philadelphia chromosome positive cases t(9;22) BCR/ABL, or 
hypoploidy (≤44 chromosomes)32,33. On the other hand, ALL is uncommon in adults 
where patients face a poor long-term survival (30–40%) which worsens with age, even 
with an initial positive response to induction therapy34,35.  
 
Epidemiology of AML in children and adults  
AML is much more common in adults and it becomes more frequent as the population 
ages (accounting for  ̴ 80% of leukemia cases)3,26. Adult-onset AML has a worse 
prognosis than pediatric AML, with a 5-year overall survival (OS) of around 40% which 
gradually declines with age, until it reaches around 4% for patients >75 years36,37. In 
contrast, childhood-onset AML only accounts for 15% of pediatric leukemia cases, yet, 
the long-term OS is around 60-70%, which warrants new treatment strategies38.  
 
Treatment and Prognosis in ALL 
Treatment of ALL is also risk-stratification dependant. The current treatment protocol 
of adult ALL has been adapted from pediatric protocols34. In pediatric patients, current 
chemotherapeutic treatment, consists of induction, consolidation and long-term 
maintenance and central nervous system (CNS) prophylaxis. This treatment strategy 
results in high cure rates in children (~ 90%)2,34. The backbone of induction therapy 
typically includes vincristine, corticosteroids and an anthracycline. The goal of 
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induction therapy is to achieve complete remission and to restore normal 
hematopoiesis34,39. Unfortunately, the 5-year OS ranges between 30- 40% in patients 
> 75 years old, and in children with ALL, approximately 20% will relapse and face a 
poor survival with current treatment options2,28,34 
 
Treatment and prognosis in AML 
Treatment of leukemia depends on risk stratification. Childhood AML treatment often 
includes two courses of intensive induction chemotherapy followed by either a 
cytarabine-based consolidation therapy or hematopoietic cell transplantation (HCT). 
For standard induction chemotherapy, an anthracycline (for example, daunorubicin or 
idarubicin) plus cytarabine (Ara-C) is frequently used38,40. The cure rate with current 
treatment protocols reaches between 60-70% and depends on risk stratification38,40. 
Still, 30-40% of pediatric AML patients relapse and have a poor prognosis41. 
For induction therapy in adults, the “7+3” regime is frequently used, which includes 
cytarabine (administered continuously for seven days) plus anthracycline on days 1 to 
3 of treatment. This is followed by a consolidation phase comprising one or more high-
dose Ara-C (HiDAC) courses or HCT6. 
 
Multidrug resistance and leukemia: where treatment fails 
Even though the development of new drugs and treatment combinations has improved 
the cure rate of patients with leukemia, a major challenge that cancer patients face is 
drug resistance. Multidrug resistance (MDR), defined as the pharmacological 
resistance to multiple chemically unrelated drugs, remains one of the contributing 
factors in chemotherapy failure in leukemia42. Both intrinsic (primary) or acquired MDR 
in leukemic cells can lead to low intracellular drug concentration, resulting in ineffective 
treatment24,43. 
One of the most studied mechanisms of drug resistance is the expression of ATP-
binding cassette (ABC) transporters, usually expressed at the cellular membrane. This 
superfamily of drug efflux transporters includes 49 genes identified in the human 
genome- encoding for transmembrane transporters44,45. while expressing membrane 
proteins, such as ATP-binding cassette transporters (ABC transporters), that restrict 
control of drug and nutrient traffic, which allows them to become multidrug 
resistant7,8,23,24.  
P-glycoprotein (P-gp, ABCB1), breast cancer resistance protein (BCRP, ABCG2), and 
multidrug resistance proteins 1-5 (MRP1-5, ABCC1-5) represent the most relevant 
ABC transporters in the context of drug resistance. The physiological function of ABC 
transporters is to detoxify cells from toxic xenobiotics. Not surprisingly, they are highly 
expressed in the gut, at the blood-brain barrier, kidney and lungs. Due to their broad 
transport capacity, ABC transporters allow the active extrusion of hydrophobic, 
hydrophilic, conjugated or unconjugated drugs, positively or negatively charged, 
across the cell membrane. Drugs targeted by ABC transporters include important 
drugs such as methotrexate (MTX)46,47, tyrosine kinase inhibitors (TKIs), vincristine, 
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cytarabine (Ara-C), dexamethasone (Dex) among many others used in 
leukemia24,43,44,48. Some ABC transporters seem to have a higher expression in 
malignant cells of multiple cancer types, including leukemia, where it can impact 
survival23,24,49,50 
The clinical significance of the expression of these transporters singularly, in cancer 
cells, is still controversial51, even though many of them have been found to have higher 
expression in malignant cells of multiple cancer types, including leukemia24,49. 
Nevertheless, the orchestrated expression of multiple ABC transporters has been 
shown to can affect intracellular MTX concentration ex vivo and lower patient survival, 
as seen in childhood leukemia50. Another example in childhood AML is the expression 
of nucleoside transporters hENT1 and hCNT1, which contribute 80% of cytarabine 
uptake and are widely expressed at diagnosis45,52,53,54. Notably, BCRP and P-gp 
expression have been identified previously in drug-resistant LSC in AML and chronic 
myeloid leukemia (CML)55,56. Furthermore, pharmacological strategies have been 
studied to bypass drug efflux in LSC “side populations”, as a strategy to overcome 
MDR in leukemia55,57,58. 
Extracellular contributions to MDR are also important, as the BM niche has a key role 
in oncogenesis and multidrug resistance12,59. Proliferative factors, (such as IL-33) 
have been identified as important contributors to BM and bone regeneration post-
chemotherapy14,60. This suggests that if LSC persist after myeloablation, they can 
potentially sequester the proliferative capacity of the BM niche and exploit it to further 
leukemogenesis. 
 
Experimental therapeutics in leukemia: Cannabidiol as an emerging anti-cancer drug 
Cannabidiol (CBD) is a non-psychoactive plant-derived phenol cannabinoid, which 
possesses remarkably low toxicity. Due to its ability to penetrate the blood-brain barrier 
and its potent anti-inflammatory61–63, anti-oxidative61,64 and anti-ischemic protective 
effects65,66, CBD has emerged as an interesting pharmaceutical target in CNS 
diseases such as epilepsy67 and Alzheimer’s disease68. CBD interacts with the 
endocannabinoid system (ECS), which is composed of endocannabinoids (such as 
anandamide and 2-arachidonoyglyerol) and cannabinoid receptors CN1/CN2 and 
putative receptors GPR55, GPR119 and TRPV1 among others. The ECS is involved 
in sleep, attention, appetite, lipid metabolism, regulation and immunomodulation. CBD 
has a series of pleiotropic non-toxic effects in all of these physiological functions69, 
and thus represents a potential pharmaceutical target in a myriad of diseases70–72 
(Table 1, Figure 2 and Figure 3). 
It has been shown that CBD possesses anti-tumor effects against various cancer cells 
(Figure 3) that express a wide array of resistance mechanisms (such as CNS tumors, 
lymphoma, thyroid, breast, uterus, ovary, prostate, colon and lung cancer, as well as 
malignant leukemic cell lines such as HL-60 and Jurkat102–104). Leukemic cells 
exposed to CBD undergo oxidative stress via up-regulation of NAD(P)H oxidases, 
p22phox and Nox 4 resulting in apoptosis103 .  
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Figure 2: Pleiotropic effects of cannabidiol (CBD) on various receptors and receptor 
localization. Left: CBD interacts with wide range of receptors localized in all systems and 
tissues. This pleiotropic activity explains the complex pharmacodynamic profile of CBD and 
its multiple therapeutic uses. Right: the diverse localization of various putative and canonical 
cannabinoid receptors (CB1,CB2) in multiple tissues and systems. Abbreviations: transient 
receptor potential cation channel subfamily V member 1-4 (TRPV1-4), peroxisome 
proliferator-activated receptor gamma (PPAR-γ), transient receptor potential ankyrin 
1 (TRPA1), serotonin receptors (5HT), glycine receptor (GLyR), Mu and delta opioid receptors 
(µ-OR, δ-OR), gamma-aminobutyric acid receptor type A (GABAA), cannabinoid receptor type 
1 and 2 (CB1, CB2), G-protein coupled receptor (GPR), transient receptor potential channels 
type 8 (TRPM8), adrenoreceptor alfa (α-AR), dopamine receptor D2 (D2R). This figure was 
created with Biorender.com 
 
CBD exposure also down-regulates pivotal pathways involved in leukemic 
transformation, such as MAPK/ERK, PI3K/AKT/mTOR and Id-1105–107. Intrinsic and 
extrinsic pathways of apoptosis were found to be activated upon CBD treatment in 
Jurkat, colon cancer, glioma and breast cancer cell lines102,103,105,106,108. CBD is able 
to inflict selective mitochondrial membrane damage ensuing cytochrome-c furthering 
stimulating apoptosis activation103,109,110. Notably, a few studies reported the CBD may 
exert cell proliferative effects and the concentration range between toxicity and 
proliferation is very small, suggesting that it should be handled carefully in an 
oncological setting111,112.  
Furthermore, MDR efflux proteins, such as P-gp/MDR1, ABCG2/BCRP are negatively 
modulated by CBD at the protein and mRNA level in chemo-resistant cells in vitro. 
Sub-toxic concentrations of CBD sensitized MDR-protein overexpressing cells to 
cytotoxic effects of chemotherapy and increased the intracellular concentration of 
chemotherapeutic agents116,117. Moreover, in the malignant microenvironment, CBD 
reduces inflammation and blocks angiogenesis by inhibiting inflammatory factor HIF-
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1α (hypoxia-inducible transcription factor) resulting in reduced tumorigenesis13,108. The 
anti-inflammatory and immunomodulating properties of CBD in the BM are currently 
being explored in the clinical setting to prevent graft-versus-host disease post HCT 
118. The potential anti-cancer properties of CBD are currently being studied in several 
clinical trials (clinical trial #: NCT01812616 & NCT01812603 for glioblastomas, 
NCT02255292 for solid tumors, NCT02432612 for pharmacokinetics of CBD in 
advanced cancer, NCT02423239 for hepatocellular carcinoma & pancreatic cancer). 
 
Figure 3: Known signaling pathways involved in (endo)cannabinoids induced apoptosis in 
cancer cells. Activation of cannabinoid receptors (CB1 and CB2) induces inhibition of 
intracellular cAMP, resulting in reduced PKA activity. This in turn alters gene expression by 
multiple mechanisms, including transcription inhibition via the reduced cAMP response 
binding element (CREB)113 and protein tyrosine phosphatase activation which also initiates 
the ERK1/2 signaling cascade114. CBD stimulation of TRPV1 mobilizes Ca2+ and alters 
mitochondrial Ca2+ homeostasis (independently of membrane Ca2+ channels) leading to 
apoptosis in T cell leukemia115. Activation of CB2 leads to accumulation of proapoptotic 
sphingolipid ceramide, which is able to induce ER stress and inhibit mTOR pathway and 
activating apoptosis69. However, CBD is also capable of generating ROS in many types of 
cancer cells, thereby inducing cytotoxicity or apoptosis and autophagy69. Many CBD induced 
activities are independent of canonical cannabinoid receptor activity (CB1/CB2) and known 
non-canonical receptors. Abbreviations: adenylyl cyclase(AC), cannabidiol (CBD), 
endocannabinoids (eCBs), reactive oxygen species (ROS), endoplasmic reticulum (ER), 9-
tetrahydrocannabinol (THC); protein kinase A (PKA), protein kinase B (AKT), 
phosphatidylinositol 3-kinase (PI3K), extracellular regulated kinase (ERK), mitogen-activated 
protein kinase (MAPK), mammalian target of rapamycin (mTOR), factor 4E (eIF4E)-binding 
protein 1 (4E-BP1), myristoylated alanine-rich C-kinase substrate (MARCKS), cyclin-
dependent kinase inhibitor proteins (p27/p21). Figure modified and adapted from Ligresti et 
al, 201669. This figure was created with BioRender.com 
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Table 1: Clinical effects of CBD and their effector receptors 
Abbreviations: Central nervous system (CNS), peripheral nervous system (PNS), systolic 
blood pressure (SBP), adenosine receptor A1 and A2A (A1, A2A), cannabinoid receptors 
(CB1,CB2), transient receptor potential cation channel subfamily V member 1-4 (TRPV1-4), 
peroxisome proliferator-activated receptor gamma (PPAR-γ), transient receptor potential 
ankyrin 1 (TRPA1), serotonin receptors 1A, 3 (5-HT3, 5-HT1A), glycine receptor (GLyR), delta 
opioid receptors (µ-OR, δ-OR), gamma-aminobutyric acid receptor type A (GABAA), 
cannabinoid receptor type 1 and 2 (CB1, CB2), G-protein coupled receptor (GPR). 
 
Even though, backbone drugs for leukemia treatment such as MTX which have been 
around for over 70 years, and contributed to an increased life span of patients, toxicity 
issues and development of chemoresistance development, warrant continuous 
research for novel treatment strategies, for which CBD may be attractive candidate. 
  
System/Organ Action Possible 
receptors 
Refs 
Nervous system  
 CNS Anxiolytic 5-HT1A, CB1, TRPV1 73,74 





Anti-psychotic CB1, D2, 5-HT1A, 5-
HT2A 
78,79 
 PNS Analgesia, (neuropathic pain) TRPV1, δ OR, GLyR 80–82 
Respiratory system 
 Lungs Anti-inflammatory, anti-fibrotic CB1, CB2 83,84 
Cardiovascular  
 Heart Cardioprotective (antioxidant in ischemia 
and arrhythmia models) 
Adenosine A1, CB2 85–87 
 Arteries ↓SBP, ↓ arterial stiffness  5-HT3, 5-HT1A 88 
Gastrointestinal 
 Gut anti-inflammatory, analgesic PPAR-γ, GPR55 89–91 
 Pancreas anti-inflammatory, antioxidant, anti-
neoplastic 
GPR55, CB1, CB2, 
PPAR-γ 
91–93 











 Immune cells hENT inhibition, adenosine modulation, 
immunomodulation 
A2A, TRPV1, CB2 97,98 
Musculoskeletal 
 Bones/joints ↑ fracture healing, ↑ collagen production 
↓ bone resorption, Anti-inflammatory 
Anti-arthritic 
GPR55, CB1, CB2 
 
99,100 
 Muscles Analgesic, myorelaxant CB1, CB2 100,101 
Chapter 1 
10 
INTRODUCTION TO THE CHAPTERS 
Chapter 2 describes the identification and molecular characterization of endothelial 
cells associated with hematopoietic niche formations in humans. Notably, CD105+ 
endothelial cells showed the ability to secrete regenerative factors (such as IL-33) and 
were associated with bone marrow recovery after chemotherapy in AML in adults and 
during early fetal bone marrow development.  
Chapter 3 covers a review on how to overcome ATP-binding cassette (ABC) drug 
efflux transporter mediated drug resistance. This review discusses the clinical impact 
of the main ABC transporters BCRP (ABCG2), MRP1 (ABCC1) and P-gp (ABCB1) in 
chemotherapy resistance and summarizes the current mechanisms and strategies of 
transporter inhibition to reverse this resistance modality. 
In chapter 4, we describe correlations between the expression of multiple ABC 
transporters - BCRP (ABCG2), MPR1 (ABCC1), MRP4 (ABCC4) and MRP5 (ABCC5) 
- and the intracellular accumulation of polyglutamate forms of the anti-leukemic 
methotrexate polyglutamate accumulation as contributors to ex vivo resistance in 
primary childhood acute lymphoblastic leukemia cells. In particular, overexpression of 
MRP4 appeared to be related to ex vivo methotrexate resistance, while a combination 
of MRP4 and BCRP overexpression was associated with low intracellular 
accumulation of methotrexate polyglutamates and poor survival in children with acute 
lymphoblastic leukemia. 
In chapter 5, we report on the immunohistochemical expression of the nucleoside 
transporter hENT1 (SLC29) and hCNT1 (SLC28) in primary pediatric acute myeloid 
leukemia samples at diagnosis and correlated these parameters with in vitro drug 
sensitivity for nucleoside analogs such as cytarabine.  
Chapter 6 describes the effect of dexamethasone on the antileukemic effect of 
cytarabine, and in particular the role of deoxycytidine kinase as cytarabine-activating 
enzyme. Studies in a rat model of acute myeloid leukemia showed that 
dexamethasone did not affect the efficacy of cytarabine treatment, even though it had 
a down-regulatory effect on deoxycytidine kinase activity.  
In chapter 7, experimental therapeutic studies were performed with cannabidiol 
(CBD) to assess its potential effect as anti-leukemic drug and its ability to target drug-
resistant leukemia cells. CBD could inhibit growth of leukemia cells in vitro at 
concentrations round 10 µM, but it conferred growth stimulatory effects at around 1 
µM concentrations. Intriguingly, chronic exposure of leukemia cells to CBD induces 
addiction to CBD for their growth. CBD displayed cross-resistance to leukemia cells 
with acquired resistance to the proteasome inhibitor bortezomib. These beneficial and 
adverse effects of CBD warrant further investigations to position its role in leukemia 
treatment.  
Chapter 8 provides a summary, general discussion and future perspectives of the 
results described in this thesis.   
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Bone marrow formation requires an orchestrated interplay between osteogenesis, 
angiogenesis, and hematopoiesis that is thought to be mediated by endothelial cells. 
The nature of the endothelial cells and the molecular mechanisms underlying these 
events remain unclear in humans. Here, we identify a subset of endoglin-expressing 
endothelial cells enriched in human bone marrow during fetal ontogeny and upon 
regeneration after chemotherapeutic injury. Comprehensive transcriptional 
characterization by massive parallel RNA sequencing of these cells reveals a 
phenotypic and molecular similarity to murine type H endothelium and activation of 
angiocrine factors implicated in hematopoiesis, osteogenesis, and angiogenesis. 
Interleukin-33 (IL-33) was significantly overexpressed in these endothelial cells and 
promoted the expansion of distinct subsets of hematopoietic precursor cells, 
endothelial cells, as well as osteogenic differentiation. The identification and molecular 
characterization of these human regeneration-associated endothelial cells is thus 
anticipated to instruct the discovery of angiocrine factors driving bone marrow 
formation and recovery after injury. 
 
INTRODUCTION 
Endothelial cells (ECs) govern tissue development and regeneration by signaling 
molecules on their cell surface and the release of factors, such as cytokines and 
extracellular matrix proteins. This angiocrine function of the endothelium drives tissue 
development and regeneration in multiple organs. In the hematopoietic system, 
studies in mice have revealed pivotal contributions of ECs to the formation and 
regeneration of bone and bone marrow (BM) (Hooper et al., 2009; Ramasamy et al., 
2016). Coordinated activation of osteogenesis, angiogenesis, and hematopoiesis is 
required for BM regeneration after tissue injury (Rafii et al., 2016; Ramasamy et al., 
2015) induced by irradiation or chemotherapy. ECs support the proper regeneration 
of the hematopoietic system after myeloablation (Butler et al., 2010; Hooper et al., 
2009; Kobayashi et al., 2010). Engraftment and repopulation of hematopoietic stem 
and progenitor cells (HSPCs) in mice is dependent on the regeneration of sinusoid 
ECs, which are vulnerable to toxic injury (Hooper et al., 2009). Sinusoid regeneration 
is mediated through vascular endothelial growth factor receptor 2 (VEGFR2) signaling, 
the blockage of which resulted in delayed reconstitution of peripheral blood values in 
irradiated mice (Hooper et al., 2009). ECs do not seem to be created equally in their 
ability to drive or contribute to bone and hematopoietic development and regeneration. 
Recent studies in mice have identified a specialized endothelial subset that controls 
the number of HSPCs in addition to coupling angiogenesis and osteogenesis 
(Kusumbe et al., 2014, 2016; Ramasamy et al., 2014). This endothelial subtype, 
dubbed type H endothelium for its high expression of endomucin and CD31, is 
enriched in the bone metaphysis at the endosteal surface, where it is adjacent to 
osteoprogenitor cells and gives rise to sinusoidal endothelial vessels. Importantly, 
insight into the molecular programs underlying the capacity of this endothelial subtype 
to drive angiogenesis and osteogenesis enabled its pharmacologic manipulation in 
mice, resulting in increased bone formation (Kusumbe et al., 2014; Ramasamy et al., 
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2015). Taken together, various studies indicate that specified EC-derived signals can 
orchestrate complex multicellular network interactions in the mammalian marrow, 
driving bone formation and regeneration under stress conditions. These findings in 
murine models open the perspective of EC-instructed strategies to regenerate bone 
and marrow in humans, both in degenerative conditions as well as after injury, such 
as chemotherapy and irradiation. Translation of these important findings to human 
regenerative medicine, however, will be critically dependent on our ability to identify 
and interrogate molecularly equivalent human ECs driving ontogeny and regeneration. 
Here, we describe the identification of a human EC subtype that is strongly associated 
with human fetal BM development and regeneration after chemotherapeutic injury. 
This EC displays striking immunophenotypic and molecular commonalities with type 
H endothelium in mice, including transcriptional activation of programs and angiocrine 
factors previously related to BM recovery in mice. Interleukin 33 (IL-33) is identified as 
a putative regenerative factor facilitating hematopoietic expansion and bone 
mineralization ex vivo, thus supporting the notion that the transcriptome of this human 
EC may serve as an important resource instructing discovery as well as validating the 




Identification of Endoglin (CD105)-Expressing ECs Associated with BM 
Regeneration after Chemotherapeutic Injury. 
To identify niche cells potentially implicated in the regeneration of the hematopoietic 
system in humans, we interrogated the composition of the hematopoietic niche during 
recovery after chemotherapeutic injury. Chemotherapeutic exposure causes damage 
to endothelial, hematopoietic, and osteolineage cells within the BM (Hooper et al., 
2009; Kopp et al., 2009; Lerner and Harrison, 1990; Xian et al., 2006), resulting in a 
prolonged neutropenia associated with considerable morbidity and mortality in 
humans. Flow cytometric assessment of the niche (7AAD- CD45- CD235a-; Figure 
1A) composition in the regenerating BM of acute myeloid leukemia (AML) patients 
(see Experimental Procedures) revealed an unaltered frequency of ECs 
(CD31+CD9+) (Barreiro et al., 2005) in comparison to marrow under homeostatic 
conditions (healthy donors) (22.1% ± 2.24% versus 31.57% ± 9.66%; p = 0.15 by 
unpaired Student’s t test) (Figures 1A and 1B). To identify putative immuno-markers 
of EC subtypes emerging during regeneration, we performed massive parallel RNA 
sequencing (RNA-seq) of the fluorescence-activated cell sorting (FACS)-purified 
endothelial compartment (CD31+CD9+) (Figure 1A). A total of 903 transcripts were 
found to be significantly differentially expressed in ECs in the regenerative marrow in 
comparison to ECs from normal, steady-state marrow (glmLRT function, EdgeR; false 
discovery rate [FDR] < 0.05). The top 200 overexpressed transcripts contained 16 
genes encoding for cluster of differentiation (CD) molecules, among which CD105 
(endoglin) (Table S1), a co-receptor for transforming growth factor b (TGF-b) 
promoting angiogenesis (Cheifetz et al., 1992; Duff et al., 2003) (Miller et al., 1999) 
and previously associated with tissue injury (Wang et al., 1995).  
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Figure 1. Identification of CD105 (Endoglin)-Expressing ECs Associated with BM 
Regeneration after Chemotherapeutic Injury BM obtained by aspirates on recovery after 
chemotherapeutic injury (AML D17) was compared with normal adult BM. (A) Gating strategy 
for identification and isolation of ECs. After doublet exclusion, 7AAD- mononuclear cells 
(MNCs) were gated based on low/negative CD45 and CD235a expression to identify niche 
cells. ECs were identified as CD31+CD9+ cells within the niche. (B) Frequency of ECs within 
the niche in adult steady-state (n = 9) and regenerative (n = 48) BM. (C) Representative FACS 
plots revealing the existence of a CD105-expressing endothelial subset in regeneration. (D) 
The frequency of CD105+ cells in the endothelial niche in normal BM (n = 9) and during 
regeneration after chemotherapy (n = 48). (E) The frequency of CD105+ cells in the 
endothelial niche in BM aspirates of AML patients at diagnosis (n = 4) and after recovery in 
complete remission (n = 3). Data represent mean ± SEM. *p < 0.05, 2-tailed unpaired 
Student’s t test. AML, acute myeloid leukemia; CR, complete remission; D17, day 17. 
Characterization of Endothelial Cells Associated with Hematopoietic Niche Formation in Humans Identifies IL-33 as an Anabolic Factor 
 21 
CD105 protein levels, assessed by FACS analysis (Figure 1C), identified a distinct 
subset of CD105-expressing ECs strongly enriched in the regenerative marrow 
compared with normal BM (10.81% ± 2.14% versus 0.48% ± 0.24% of CD31+CD9+; 
p = 0.043) (Figure 1D). The presence of this endoglin-expressing subset was 
temporally restricted, as it was (virtually) absent in AML patients at diagnosis (0% 
±0%of CD31+CD9+ cells) or after full recovery of peripheral blood values (in complete 
remission) (1.27% ± 0.66% of CD31+CD9+ cells) (Figure 1E). 
 
Endoglin-Expressing ECs Are Enriched in the Mouse BM after 
Chemotherapeutic Myeloablation  
To confirm our observation that the CD105-expressing subset of ECs is enriched 
during BM regeneration and establish a broader relevance for mammalian biology, we 
next translated our observations. to an experimental setting in which we exposed 
C57BL/6 wild-type mice to a myeloablative dose of the chemotherapeutic agent 5-
fluorouracil (5FU) or PBS (vehicle control). The endoglin expressing subset 
constituted a rare subpopulation of endothelial (CD31+) cells in the steady-state adult 
BM niche (0.05% ± 0.02% of CD45- Ter119- cells) and in the collagenased bone niche 
(0.42% ± 0.12% of CD45-Ter119- cells) (Figures 2A, 2B, S1A, and S1B). This fraction 
increased significantly after administration of 5FU in the BM (0.65% ± 0.15% of CD45-
Ter119- cells, fold-change (FC) increase of 13.6 ± 3.2, p = 0.026) and collagenased 
bone (8.18% ± 1.43% of CD45-Ter119- cells, FC increase of 19.6 ± 3.4, p = 0.007) 
(Figures 2A, 2B, S1A, and SB), confirming a relative increase of this specific subset 
in the regenerative phase after myeloablation. Of note, the absolute number of 
CD31+CD105+ ECs in the BM did not increase after exposure to 5FU (Figure 2C), 
suggesting that selection of these cells under chemotherapeutic pressure (rather than 
absolute expansion) may be implicated. 
 
CD105 (Endoglin)-Expressing ECs Are Enriched in the Human BM during Fetal 
Development 
The temporally restricted enrichment of CD105-expressing ECs during recovery after 
chemotherapeutic injury suggests that this cell type could potentially be implicated in 
regeneration and hematopoietic niche formation. To corroborate this notion, we 
sought to define other conditions in human biology where angiogenesis, osteogenesis, 
and hematopoiesis are synergistically activated. In human fetal bone development, 
hematopoiesis shifts from the fetal liver to the bones starting at week 10 after 
gestation. During this process, angiogenesis, osteogenesis, and hematopoiesis are 
tightly coupled to allow coordinated bone and hematopoietic development (Cosxkun 
et al., 2014; Jagannathan-Bogdan and Zon, 2013; Medvinsky et al., 2011). Invasion 
of blood vessels into the mesenchymal condensate is crucial for the coordinated 
activity of chondrocytes and osteoblasts, and each of these cell types stands in spatial 
and molecular interaction with ECs (Maes, 2013; Salazar et al., 2016). Flow cytometric 
dissection of the endothelial composition of fetal BM at gestational week 15–20 
revealed a striking predominance of CD105-expressing cells within the endothelial 
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compartment (62.8% ± 5.9% of CD31+CD9+ cells) (Figures 3A and 3B). Massive 
parallel sequencing of these cells confirmed overexpression of genes encoding CD 
markers identified in the ECs in regenerating BM (Figure S2A), supporting the notion 
that the enrichment of these transcripts in ECs in the regenerative marrow is caused 
by overexpression in the subset of CD105+ ECs. The frequency of CD105-expressing 
ECs within the endothelial compartment was even higher when examining 
collagenased fetal bone fractions (average 82.65% ± 2.5% of CD31+ CD9+ cells) 
(Figures 3A and 3B), suggesting that this endothelial subpopulation might 
preferentially localize to the endosteal surface of fetal long bones. In line with this, 
CD105-expressing ECs were identified, albeit at a considerably lower frequency, in 
collagenased bone fractions of human adult postnatal bone (average 25.9% ± 5.0% 
of CD31+CD9+ cells) (Figures 3A and 3B).  
Figure 2. CD105-Expressing ECs Are Enriched in Mice during Regeneration after 
Chemotherapeutic Injury (A) Representative FACS plots for identification of murine BM ECs. 
After doublet exclusion, 7AAD- mononuclear cells (MNCs) were gated based on low/negative 
CD45/ Ter119 expression to select for BM niche cells. BM ECs were identified by CD31 and 
CD105 expression. (B) Frequency of CD105+ ECs within the murine BM niche during S.S (n 
= 3 mice) and on recovery after 5-FU (n = 5 mice). (C) Numbers of CD105+ BM ECs during 
S.S (n = 3) and after 5-FU treatment (n = 5). (D and E) CD105+ BM ECs differentially express 
IL-33 on injury. (D) Representative FACS plots. (E) IL-33 expression in CD105+ BM ECs and 
CD105- BM ECs in S.S (n = 3) and after 5-FU treatment (n = 5). Data represent mean ± SEM. 
*p < 0.05, 2-tailed unpaired Student’s t test. 5-FU = 5-fluorouracil. S.S = steady-state. 
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Figure 3. CD105-Expressing ECs Are Enriched in Fetal Development and Collagenized 
Bone Fractions (A) Representative FACS plots identifying CD105- expressing ECs in fetal BM, 
fetal bone, and adult bone. (B) Frequency of CD105+ cells in the endothelial compartment in 
healthy adult BM aspirates (n = 9), Fetal BM (n = 15), fetal bone (n = 21), and adult bone (n = 
9). Data represent mean ± SEM. **p < 0.01, ***p < 0.001, 1-way ANOVA (p < 0.0001) followed 
by Bonferroni’s multiple comparison test. (C) In situ immunofluorescence demonstrating the 
existence of capillary structures in the trabecular area of fetal long bone comprised of 
CD31+CD105+ ECs (arrowheads). Sinusoid structures are CD31lo CD105+. In human adult 
BM, the majority of CD31+ ECs lacks CD105 expression (asterisks). The area within the 
dotted line in the adult BM represent bone tissue. Magnification, 20x. White scale bar 
represents 100 mm. 
 
To provide anatomical context for this CD31+CD105+ EC subset, we performed in 
situ immunohistochemistry and immunofluorescence on fetal femurs and core hip 
bone biopsies obtained from adults. CD31+CD105+ ECs were observed in the 
trabecular bone area of the metaphysis of fetal femurs (Figures 3C, S3A, and S3B) at 
a significantly higher frequency than in the trabecular bone of adult BM. The majority 
of vascular structures in both fetal and adult human bone were lined with CD31- 
CD105+ ECs, previously shown to be sinusoid ECs. CD31+CD105- cells were present 
sporadically in adult bone. Collectively, these findings identify a human endothelial 
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subtype that is enriched in collagenased bone fractions, prevalent during human fetal 
bone development, declines in frequency on aging, and emerges, in a temporally 
restricted fashion, in the BM during regeneration after chemotherapeutic injury. 
Henceforward, we will refer to this EC type as “human regeneration associated ECs” 
(hRECs). 
 
hRECs Share Immunophenotypic and Molecular Similarities with Murine Type 
H Endothelium and Express Key Regulators of Angiogenesis and Osteogenesis 
Interestingly, similarities exist between hRECs and the recently described specialized 
endothelium coordinating osteo- and angiogenesis in mice, termed type H 
endothelium (Kusumbe et al., 2014, 2016; Ramasamy et al., 2014). These include 
enrichment at the bone surface, reduced frequencies on aging, and an increase in 
frequency on genotoxic stress, suggesting that hRECs may reflect human equivalents 
of mouse type H endothelium. To further investigate this, differentially expressed 
transcripts in CD31+CD9+CD105+ hRECs isolated from human fetal bone (in 
comparison to steady-state postnatal CD31+CD9+CD105- cells) were related to 
genes reported to be overexpressed in type H endothelium. This confirmed elevated 
expression of many transcripts previously reported to be enriched in type H 
endothelium, including genes encoding the signature markers CD31 (PECAM1) and 
mucin-like sialoglycoprotein endomucin (EMCN) (Figure 4A) and vessel guidance 
molecules (Ramasamy et al., 2014) (Figure 4B). Most of these genes were similarly 
enriched in the CD31+CD9+ fraction of regenerative BM (Figures 4A and 4B) (the 
limited number of CD105+ cells precluded RNA-seq of this specific subset). In total, 
3,718 genes were differentially expressed (glmLRT function, EdgeR; FDR < 0.05) in 
fetal bone hRECs in comparison to steady-state postnatal BM ECs. Among the 
overexpressed genes were HSPC niche factors (Figure 4C) and known angiocrine 
anabolic regulators of osteogenesis and angiogenesis (Figure 4D), further suggesting 
that hRECs might be involved in hematopoietic niche formation. Next, transcriptional 
programs and signatures were interrogated in hRECs using gene set enrichment 
analysis (GSEA) (Subramanian et al., 2005). Activated Notch signaling and 
stabilization of HIF1a have been identified in type H endothelium as key promotors of 
the formation of type H capillaries and the release of osteogenic factors that enhance 
osteogenesis (Kusumbe et al., 2014; Ramasamy et al., 2014). In line with this, key 
NOTCH regulators, such as Jagged-1, DLL4, NOTCH1, and NOTCH4 (receptors of 
DLL4), were upregulated in fetal hRECs (Figure 4E), reflected in the activation of 
downstream transcriptional NOTCH signaling, as demonstrated by GSEA (Figure 4F). 
Similarly, gene sets related to the HIF1a pathway were enriched in fetal hRECs 
according to GSEA (Figure S2B). Other relevant molecular signatures that were 
identified to be significantly enriched in hRECs include ‘‘angiogenesis’’ and 
‘‘stemness’’ signatures, among which VEGF and WNT signaling (Figure S2C). 
Together, the data indicate that hRECs share immunophenotypic and molecular 
commonalities with murine type H ECs and have a transcriptional wiring that may be 
congruent with the view that these cells are implicated in the coupling of 
hematopoiesis, osteogenesis, and angiogenesis in regeneration.  
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Figure 4. hRECs Express Transcriptional Programs Defining Niche-Forming ECs in Mice. 
Transcriptomes of hRECs isolated from human fetal bone (CD45- CD235-CD31+ CD9+ 
CD105+) (n = 3) and regenerative BM (CD45- CD235- CD31+ CD9+) (n = 3) were compared 
with postnatal steady-state BM ECs (CD45- CD235- CD31+ CD9+) (n = 7). (A and B) 
Expression of genes encoding arterial and venous markers (A), and vessel guidance 
molecules previously reported to be overexpressed in murine type H ECs (B) (Itkin et al., 2016; 
Kusumbe et al., 2014, 2016; Ramasamy et al., 2014). Note, Sca-1 has no known human 
homolog (Holmes and Stanford, 2007). (C) Expression of established hematopoiesis 
supporting cytokines (Broudy, 1997; Sugiyama et al., 2006; Zhang et al., 2006). (D) 
Expression of genes encoding anabolic regulators of angiogenesis and osteogenesis 
(Blumenfeld et al., 2002; Clines et al., 2007; Edwards and Mundy, 2008; Oshima et al., 2002; 
Salani et al., 2000; Salvucci and Tosato, 2012; Serini et al., 2003; Shao et al., 2004; 
Shigematsu et al., 1999; Tamagnone and Giordano, 2006). (E and F) Expression of genes 
encoding critical NOTCH pathway components (E) and activation of Notch- signaling (F) as 
demonstrated by gene set enrichment analysis (GSEA). *FDR < 0.05. FDR, false discovery 
rate; FPKM, fragments per kilobase million; NES, normalized enrichment score. 
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IL-33 Is Expressed by hRECs and Promotes Angiogenesis, Osteogenesis, and 
the Expansion of Hematopoietic Precursor Cells 
We thus hypothesized that elucidation of the transcriptome of ECs related to 
hematopoietic niche formation might instruct the discovery of pathways or proteins 
facilitating niche formation. In particular, angiocrine factors may be identified that 
facilitate angiogenesis, osteogenesis, and hematopoiesis. To provide proof of 
principle for this assumption, we focused our attention on genes encoding secreted 
factors that were significantly enriched in both fetal hRECs and regenerative BM ECs. 
In total, 237 genes were significantly enriched, of which 34 are genes encoding known 
secreted factors with a strong correlation in levels of expression (Figure 5A). Of 
interest, the canonical receptors of many of these secreted proteins were 
overexpressed in fetal hRECs, (MMRN2-CLEC14A, BMP4-BMPR2, EFNA1-
EPHA2/EPHA4/ EPHA7, EDN1-EDNRB, SEMA3A-NRP1/NRP2/PLXNA2, and ADM-
RAMP2/ CALCRL) (Figure S2D), suggesting the possibility of autocrine signaling. In 
addition to secreted factors with a known role in regulating HSPC behavior, such as 
plasminogen activator (PLAT) (Ibrahim et al., 2014) and tissue factor pathway inhibitor 
(TFPI) (Khurana et al., 2013), we found significant overexpression of IL-33 in hRECs 
(Figure 5A). IL-33 is a pro-inflammatory cytokine and a chromatin-associated nuclear 
factor (Carriere et al., 2007). IL-33 protein expression in fetal hRECs was confirmed 
using fluorescence microscopy (Figure 5B), and IL-33 was differentially 
overexpressed in murine CD31+CD105+ ECs in comparison to their CD105- 
counterparts during regeneration (Figures 2D and 2E). The inability to propagate 
sorted hRECs ex vivo (data not shown) precluded the possibility to perform co-culture 
blocking experiments to assess the contribution of hREC-derived IL-33 to 
angiogenesis, hematopoiesis, and osteogenesis. As an alternative strategy, we 
exposed relevant cell types to recombinant human IL-33 (rhIL-33). 
 
Hematopoiesis 
To test if IL-33 facilitates human hematopoiesis in vitro, we exposed cord blood (CB) 
CD34+ HSPCs to rhIL-33 or vehicle control for one week in serum-free medium 
containing stem cell factor (SCF). rhIL-33 expanded the total number of hematopoietic 
cells (total mononuclear cells [MNCs]) (3.4-fold increase ± 0.29; p < 0.01) with a 
concomitant expansion of hematopoietic progenitor cells (HPCs), specifically 
immunophenotypic multipotent progenitors (MPPs) (2.5-fold increase ± 0.43; p < 0.05) 
and multi lymphoid progenitors (MLPs) (2.7-fold increase ± 0.15; p < 0.01) (Figures 
5C and S4). Immunophenotypic HSC numbers were not affected by exposure to IL-
33. Expansion of myeloid progenitor cells was confirmed in colony-forming unit cell 
assays (CFU-C assays, demonstrating an increase in granulocyte-macrophage 
colony-forming units (CFU-GMs) (2.27-fold increase ± 0.21; p < 0.05) (Figure 5D). 
 
Osteogenesis 
Next, we interrogated a potential role of IL-33 in bone formation. In human fetal bone 
development (endochondral ossification), vascular invasion of chondrocytes coincides 
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with expansion of osteoblasts and mineralization of the matrix (Charbord et al., 1996; 
Ramasamy et al., 2016). To test the role of IL-33 in this process, the effect of rhIL-33 
on the osteogenic differentiation of human BM-derived stromal cells (BMDSCs) was 
assessed. The addition of rhIL-33 to osteogenic induction medium accelerated 
terminal differentiation of BMDSCs toward matrix-depositing osteoblasts, as 
suggested by Alizarin red-staining (Figure 6A), indicating increased calcific matrix 
deposition. To confirm this finding, we performed colorimetric assessment of calcium 
deposition, demonstrating a striking 3.61-fold ± 0.63 (p < 0.02) increase in calcium 
deposition of IL-33-exposed BMDSCs in comparison to BMDSCs cultured in 
osteogenic induction medium alone (Figure 6B). The proliferation of BMDSCs was not 
affected by rhIL-33 (Figures S5A and S5B), suggesting that IL-33 exerted its 
osteogenic effect by promoting osteoblastic differentiation or the secretion of matrix 
proteins by osteoblasts rather than by expanding primitive mesenchymal cells. 
 
 
Figure 5. Identification of IL-33 As a Hematopoietic Niche Factor. (A) Transcript expression 
of 34 genes encoding secreted factors significantly enriched (FDR <0.05) in fetal bone and 
regenerating BM ECs (Log2 fold change in comparison to steady-state BM). FDR: false 
discovery rate. FC: Fold Change. (B) Cropped pictures (magnification, 633) of immunostained 
fetal hRECs demonstrating protein expression of IL-33. White scale bar represents 20 mm. (C 
and D) IL-33-mediated expansion of cord blood-derived myeloid and lymphoid progenitor cells 
as demonstrated by (C) flow cytometric cell counting (n = 4 independent experiments) and (D) 
CFU-C confirming an increase in CFU-GMs (n = 3 independent experiments). Data represent 
mean ± SEM. *p < 0.05, 2-tailed unpaired Student’s t test. HSC, hematopoietic stem cell, 




Figure 6. IL-33 Promotes Osteogenesis and Angiogenesis In Vitro. (A and B) IL-33 
accelerates terminal differentiation of mesenchymal cells toward matrix-depositing osteoblasts 
as demonstrated by (A) Alizarin red staining and (B) colorimetric assessment of calcium 
deposition (n = 3 independent experiments). (C) Knockdown of IL-33 inhibits expansion of 
HUVECs. Quantification of the total number of HUVECs over time (combined data of n = 3 




In line with earlier reports (Choi et al., 2009), we confirmed that IL-33 is an angiogenic 
factor. shRNA-mediated knockdown of IL-33 (Figures S5Cand S5D) from human 
umbilical vein ECs (HUVECs) dramatically impaired their expansion in culture (Figure 
6C), indicating that IL-33 promotes angiogenesis in an autocrine fashion.  
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IL-33 Promotes Expansion of Hematopoietic Precursor Cells and Alters the 
Architecture of the BM Niche in Mice 
We next studied the in vivo relevance of these effects of IL-33 on distinct cellular 
components of human BM. The administration of recombinant murine IL-33 (rmIL-33) 
compared with PBS control resulted in expansion of immature (Lin-) (Figure S6A) and 
primitive progenitor (Lin-, c-KIT+, Sca-1+ [LKS]) hematopoietic cells, in particular the 
HPC-1 population (Figures 7A and 7B), earlier shown to contain restricted 
hematopoietic precursor cells with myeloid and lymphoid lineage potential (Oguro et 
al., 2013). Expansion of a myeloid progenitor population was confirmed with CFU-C 
assays (Figure S6B). Total BM cellularity and Lin-Kit+Sca1- cell counts remained 
unchanged (Figure S6C). In addition, the number of granulocyte-macrophage 
progenitors (GMPs) and myeloid cells increased after IL-33 administration (Figures 
7A, 7B, S6D, and S6E), recapitulating the expansion of human hematopoietic myeloid 
precursors in vitro. Congruent with our findings in human hematopoietic cells, 
immunophenotypic HSCs were not numerically affected by IL-33 (Figures 7A and 7B). 
Interestingly, IL-33 also significantly expanded the population of Lin-Kit-Sca1+ BM 
cells, previously shown to contain early lymphoid-committed precursors with T cell, B 
cell, and natural killer (NK) cell potential (Kumar et al., 2008) and innate lymphoid cells 
(Brickshawana et al., 2011). Hematopoietic changes were accompanied by a relative 
increase, albeit not reaching statistical significance, in CD31+CD105+ ECs as well as 
Lin-Ter119-CD51+Sca- cells (earlier shown to contain lineage- committed/ 
osteoblastic cells) (Schepers et al., 2012) within the niche compartment (Figures S7A 
and S7B). Collectively, the in vitro and in vivo data indicate that IL-33 modulates 
distinct cellular components of hematopoietic tissue and has the potential to facilitate 
angiogenesis, hematopoiesis, and osteogenesis, supporting the view that elucidation 




Injury to the hematopoietic system, caused by chemotherapy or irradiation, is a 
significant cause of morbidity and mortality in the treatment of malignant hematopoietic 
disease. Studies in mice have demonstrated a pivotal role of specific BM niche cells 
and secreted molecules in hematopoietic recovery. Translation of these findings to the 
clinic, however, is hampered, principally by insufficient understanding of the niche cells 
and molecular programs governing niche formation and hematopoietic recovery in 
humans. Here, by cellular dissection of the BM niche in humans during fetal 
development and regeneration after chemotherapeutic injury, we reveal the existence 
of a specific EC type (hRECs) associated with these conditions. hRECs share 
phenotypic and molecular similarities with specialized ECs driving hematopoietic 
niche formation in mice, expressing critical regulators of hematopoiesis, osteogenesis, 
and angiogenesis. The data comprise, to our knowledge, the first comprehensive 
molecular characterization of human ECs on tissue regeneration after injury. We 
identified the TGF-b1 receptor endoglin (CD105) as a marker of endothelium 
associated with BM (re)generation in fetal development and after chemotherapeutic 
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injury. Endoglin-expressing ECs have earlier been associated with angiogenesis in 
tumors and inflammation (Kumar et al., 1996), and loss of endoglin results in defective 
angiogenesis in mice (Li et al., 1999), supporting the view that it mediates signals 
governing blood vessel formation. The data indicate that endoglin with concomitant 
CD31 expression marks a specific subset of angiogenic ECs, which is further 
supported by observations that endoglin expression is strongly elevated in ECs of 
small, capillary-like vessels at tumor edges (Miller et al., 1999; Yoshitomi et al., 2008). 
Endoglin thus likely identifies a subset of endothelium during ontogeny and 
regeneration that marks an angiogenic subset, in line with observations in different 
settings. This subset revealed remarkable molecular congruence with EC subsets 
identified in murine studies driving bone and BM regeneration after injury. 
 
 
Figure 7. Recombinant IL-33 Expands Hematopoietic Progenitors In Vivo. (A) Representative 
FACS plots of PBS versus IL-33-treated mice depicting the distribution of hematopoietic 
(progenitor) populations. CMP, LK, CD16/32-, CD34+ cells, common myeloid progenitor; 
GMP, LK, CD16/32+, CD34+ cells, granulocyte-macrophage progenitor; HSC, LKS, CD48-
CD150+ cells, hematopoietic stem cell; HPC-1, LKS, CD48+, CD150- cells, hematopoietic 
progenitor-1; HPC-2, LKS, CD48+, CD150+ cells, hematopoietic progenitor-2; Lin_, Lineage-
negative cells; LK, Lin-, c-KIT+, Sca-1- cells; LKS, Lin-, c-KIT+, Sca-1+ cells; LS, Lin-, c-KIT-, 
Sca-1+ cells. MEP, LK, CD16/32-, CD34- cells, megakaryocyte-erythroid progenitor; MPP, 
LKS, CD48- CD150- cells, multipotent progenitor. (B) Total BM counts of GMP, LKS, HPC-1, 
HSC, and LS populations in PBS treated (n = 10) and IL-33-treated (n = 5) mice. Data 
represent mean ± SEM. *p < 0.05, **p < 0.01, 2-tailed unpaired Student’s t test. 
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ECs in mice support the regeneration of the hematopoietic system after injury, such 
as myeloablation (Butler et al., 2010; Hooper et al., 2009; Kobayashi et al., 2010), and 
in recent years, several markers of specified endothelial subsets exerting this function 
as well as the underlying mechanisms have been revealed. Interestingly, hRECs 
share many characteristics with the ECs described in these studies, including 
expression of the cell surface proteins Tie2/TEK (Figure S2E) (Doan et al., 2013; Kopp 
et al., 2005), EMCN (Kusumbe et al., 2014; Ramasamy et al., 2014), and Jagged1 
and activation of specific signaling pathways, including NOTCH (Butler et al., 2010; 
Poulos et al., 2013). Also, hRECs express many molecules previously shown to 
regulate HSPC behavior in mice, such as PLAT (Ibrahim et al., 2014), TFPI (Khurana 
et al., 2013), E-selectin (ESELE) (Figure S2E) (Winkler et al., 2012), thrombomodulin 
(TMBD) (Figure S2E) (Gur-Cohen et al., 2015), and tenascin C (TNC) (Figure S2E) 
(Nakamura-Ishizu et al., 2012). In particular, hRECs displayed striking commonalities 
with type H endothelium, a murine EC subtype that has recently been functionally 
implicated in EC-driven formation of the niche through activation of NOTCH and HIF1 
signaling (Kusumbe et al., 2014; Ramasamy et al., 2014). Commonalities with the now 
identified hRECs include enrichment at the bone surface, reduction in frequency on 
aging, resistance to stress conditions, expression of markers typical for both arterial 
(Ephn2b, Nestin, Nrp1, Sox17, and VEGFR2), and sinusoidal vessels (VEGFR3 and 
EMCN), and activation of the NOTCH and HIF1 pathways driving regeneration. 
Expression of CD105 was not addressed 
in the studies on type H endothelium, but our data in mice show that a rare population 
of endoglin-expressing ECs increases in frequency in the regenerative phase after 
chemotherapy, likely reflecting increased resistance to myeloablative stress. It is 
noteworthy that CD105+ ECs associated with elevated HIF-1a expression have been 
described in the BM of mice on regeneration after 5-flourouracil (5-FU) treatment 
(Nombela-Arrieta et al., 2013), making it tempting to hypothesize that these represent 
similar or overlapping cell types. Taken together, these immunophenotypic and 
molecular similarities between hRECs and murine endothelial subtypes implicated in 
hematopoietic niche formation point toward evolutionary conservation of these cells 
between mammalian species. They thus provide human relevance to findings in 
murine studies, supporting the notion that ECs are implicated in niche regeneration in 
humans. Providing experimental support for this view is challenging due to limitations 
inherent to the study of human cells as well as the inability to propagate highly purified 
hRECs ex vivo, precluding co-culture studies. As an alternative approach, we 
exploited elucidation of their transcriptome to identify candidate factors driving EC-
driven formation of the hematopoietic niche and regeneration of HSPCs. We identified 
IL-33, a cytokine typically associated with innate immunity and inflammation (Cayrol 
and Girard, 2014), as a candidate factor. IL-33 was overexpressed in human hRECs, 
and expression was increased in murine CD31+CD105+ ECs on exposure to 5FU. 
Hematopoietic niche regenerating properties of IL-33 were demonstrated by its ex vivo 
capacity to facilitate hematopoiesis (increased numbers of HPCs), osteogenesis 
(accelerating terminal differentiation of BMDSCs toward matrix-depositing 
osteoblasts), and angiogenesis (expansion of HUVECs). The data follow recent 
reports demonstrating IL-33 to predominantly act as an ‘‘alarmin’’ released by cells 
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undergoing necrosis after tissue damage or active secretion (Kakkar et al., 2012; Lee 
et al., 2015) and playing anabolic roles in angiogenesis (Choi et al., 2009; Shan et al., 
2016) and osteogenesis (Saleh et al., 2011). Our finding that rhIL-33 increased the 
numbers of HPCs ex vivo seems congruent with recent observations in mice, where 
administration of IL-33 promoted myelopoiesis (Kim et al., 2014). Of considerable 
interest, rhIL-33 in our experiments expanded both immunophenotypic MLPs and 
MPPs, in line with observations in experiments in mice where expansion of splenic 
lymphoid progenitors after IL-33 administration resulted in enhanced defense against 
opportunistic infection (Kim et al., 2014). Formal demonstration that secretion by a 
defined subset of ECs is required for the regenerative actions of IL-33 will have to 
await in vivo targeted deletion experiments, because it is currently challenging to 
maintain this particular subset of ECs ex vivo to enable co-culture experiments. The 
profound effect of IL-33 knockdown on HUVEC proliferation and maintenance 
precluded the use of this ex vivo system to address this question. The combined 
findings point to a unique role of IL-33 in mammalian species in facilitating the 
reconstitution of both hematopoietic lineages, which may be of considerable 
importance to prepare the hematopoietic system for the extra-uterine environment in 
ontogeny, but also for immune reconstitution after injury (e.g., hematopoietic stem cell 
transplantation characterized by long-term lymphocyte depletion and ensuing 
opportunistic infections). The exact molecular mechanisms by which IL-33 exerts 
these effects (either direct or indirect) remain to be fully elucidated. IL-33 expression 
in HUVECs has been associated with a quiescent cellular state (Küchler et al., 2008), 
and although we did not examine the cell cycle status of CD31+CD105+, IL-33high 
hRECs, this might help explain the notion that they may be relatively resistant to 
chemotherapeutic myeloablation. We can speculate that quiescent CD31+CD105+, 
IL-33high hRECs survive chemotherapy and are ‘‘activated’’ to release IL-33 as an 
anabolic hematopoietic factor. In this context, it is noteworthy that hRECs display 
transcriptional activation of DLL4 and the Notch pathway, earlier shown to be an 
important driver of IL-33 expression (Sundlisaeter et al., 2012). Regardless of the 
underlying molecular mechanisms of IL-33 expression, the data support the notion 
that elucidation of the transcriptome of hRECs may instruct the identification of the 
proteins and pathways driving niche formation after injury. It is conceivable that 
receptor-ligand interactions allow targeting of these cells to drive regeneration (as 
previously shown by pharmacologic modulation of NOTCH signaling in mice 
[Ramasamyet al., 2014]). In this context, it is noteworthy that transcriptional profiling 
of fetal hRECs revealed overexpression of genes encoding secreted factors as well 
as their receptors, suggesting the potential relevance of autocrine signaling in the 
biology of hRECs. Alternatively, it would be worthwhile to test the ability of identified 
secreted factors to expand human HSPCs ex vivo, either directly or in co-culture 
settings with mesenchymal elements. Collectively, the identification of human ECs 
associated with hematopoietic niche formation and the elucidation of their 
transcriptome are anticipated to provide a valuable resource for the regenerative 
community to relate findings in animal models to human biology and to instruct in vivo 
and ex vivo approaches to foster EC-driven regeneration of the hematopoietic system 
after injury. 
Characterization of Endothelial Cells Associated with Hematopoietic Niche Formation in Humans Identifies IL-33 as an Anabolic Factor 
 33 
EXPERIMENTAL PROCEDURES 
Human BM Samples 
BM aspirates of AML patients were collected at diagnosis, 17 days after the start of 
chemotherapy (3+7 schedule of chemotherapy with anthracycline and cytarabin), and 
on achievement of complete remission (median age: 65 years, range: 28–76 years). 
The time point of 17 days after the start of chemotherapy represents the neutropenic 
phase, 10 days after administration of chemotherapy and, on average, 4 days before 
recovery of neutropenia. Control marrow was obtained by aspiration from donors for 
allogeneic transplantation (median age: 40 years, range: 39–48 years) after obtaining 
written informed consent. In addition, trabecular hip bone samples were collected from 
patients undergoing hip replacement surgery (median age: 55 years, range: 22–71 
years). Human fetal long bones (median age: 18 gestational weeks, range: 15–20 
gestational weeks) were obtained from elective abortions. Gestational age was 
confirmed by ultrasonic measurement of skull diameter and femoral length. The use 
of human samples with informed consent was approved by the Institutional Review 
Board of the Erasmus Medical Center (the Netherlands) in accordance with the 
Declaration of Helsinki. 
 
RNA-seq and GSEA Analysis  
RNA of sorted cells was extracted according to the manufacturer’s instructions for 
RNA isolation with GenElute LPA (Sigma). cDNA was prepared using the SMARTer 
procedure (SMARTer Ultra Low RNA Kit, Clonetech). Library preparation and RNA-
seq was performed as previously described and validated for low input (Chen et al., 
2016). Finally, GSEA was performed on the fragments per kilobase million (FPKM) 
values using the curated C2 collection of gene sets within the Molecular Signatures 
Database (MSigDB) (Subramanian et al., 2005). 
 
Mice and In Vivo Procedures  
C57BL/6JOlaHsd wild-type mice were purchased from Envigo. Animals were 
maintained in specific pathogen-free conditions in the Experimental Animal Center of 
Erasmus MC (EDC). To study the murine niche in regenerative conditions, adult mice 
(7–12 weeks old) were intraperitoneally administered 250 mg/kg 5-FU and then 
sacrificed 7 days after 5-FU treatment. To study the effect of rmIL-33 on steady-state 
hematopoiesis and the BM niche, adult mice (7–14 weeks old) were intraperitoneally 
injected with 2 mg of recombinant IL-33 (catalog no. 580504, BioLegend) or PBS 
vehicle control daily for 6 consecutive days and then sacrificed. All mice were 
sacrificed by cervical dislocation. Mouse BM and bone fraction cells were isolated as 
previously described (Zambetti et al., 2016). Peripheral blood was collected from the 
submandibular vein in K2EDTA-coated microtainers (BD) and analyzed using a Vet 
ABC counter (Scil Animal Care). Animal studies were approved by the Animal 
Welfare/Ethics Committee of the EDC in accordance with legislation in the 
Netherlands (approval no. EMC 4015).  
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Liquid Culture of CD34+ CB Cells 
A total of 20,000 CD34+ CB cells in 200 mL per well were cultured in StemSpan SFEM 
(Stem Cell Technologies, catalog no. 9600) with SCF (50 ng/mL, Cellgenix, Freiburg, 
Germany), in a flat-bottom, 96-well plate at 37C and 5% CO2. Two mL mQ solution 
containing only rhIL-33 protein (ProSpec, catalog number CYT-425) or just mQ 
(vehicle control) was added to the medium for a final concentration of 25 ng/mL rhIL-
33 or 1% mQ, respectively. The medium was refreshed every 3 or 4 days, and cells 
were collected at day 7 for FACS analysis or for hematopoietic colony forming-unit 
assay. 
 
Culture of Human BMDSCs 
Human BMDSCs (catalog no. PT-2501, Lonza) were cultured as described previously 
(Brum et al., 2015). For osteogenic differentiation, BMDSCs were cultured in 
osteogenic induction medium (aMEM medium containing 10% heat-inactivated fetal 
calf serum [FCS] supplemented with 100 nM dexamethasone and 10mMb-
glycerophosphate) with rhIL-33 (250 ng/mL) or mQ vehicle control for 3 weeks. 
Medium was refreshed every 3–4 days. 
 
Culture and shRNA-Mediated Knockdown of IL-33 in HUVECs 
HUVECs were expanded in EGM-2 Bulletkit medium (CC-3156 and CC-4176, Lonza). 
RNAi was achieved by lentiviral transduction. Briefly, shRNAs against IL-33 (sh19: 
TRCN0000135845 and sh20: TRCN0000135846) and a non-target control (shControl: 
SHC002 [SHC]) cloned in the pLKO.1 backbones were obtained from the Mission TRC 
shRNA library (Sigma-Aldrich). Lentiviral shRNAs were produced in HEK293T cells 
after co-transfection of shControl, sh19, or sh20 together with the packaging plasmids 
pSPAX2 and pMDG.2. HUVECs were infected with lentivirus for 24 hr and selected 
for 5 days with 2mg/mL of puromycin.  
 
Statistics 
Statistical analyses were performed using Prism 5 (GraphPad Software). Unless 
otherwise specified, unpaired, 2-tailed Student’s t test (single test for comparison of 2 
means) or 1-way ANOVA followed by Bonferroni correction for multiple comparisons 
were used to evaluate statistical significance, defined as p < 0.05. All results in bar 
graphs are means ± SEMs. 
 
DATA AND SOFTWARE AVAILABILITY 
The accession number for the RNA-seq data derived from human healthy adults, AML 
day 17 patients, and fetal bone specimens is European Genome-phenome Archive: 
EGAS00001002736.   
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SUPPLEMENTAL INFORMATION 
Supplemental Table 1 
Supplemental Table 1. Related to Figure 1. Differential expression of candidate 
membrane markers of endothelial cells associated with regeneration after 
chemotherapy.  
Genes encoding cluster of differentiation antigens overexpressed in endothelial cells 
(CD45-CD235-CD31+CD9+) in aspirates obtained from regenerative marrow (n= 3) 
compared to postnatal steady-state BM (n= 7). FC: Fold change. FPKM: fragments 










Supplementary Figure S1. Related to Figure 2. CD105-expressing endothelial 
cells are enriched in collagenased bone of mice after chemotherapeutic injury 
 
 
Supplementary Figure S1 
(a) Representative FACS plots revealing the enrichment of a CD105-expressing endothelial 
cells (ECs) in collagenased bone after administration of 5-fluoroucil. Gating strategy for 
identification of murine ECs is also depicted (see also figure 2). BF=Bone fraction.  
(b) Frequency of CD105+ ECs within collagenased bone of mice in steady-state (n=3) and 
after administration of 5-fluoroucil (n=5). Data represent mean ± s.e.m. **p <0.01, two-tailed 
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Supplementary Figure S2 
 
Supplementary Figure S2. Related to Supplemental Table 1, Figure 4 and 5. 
Transcriptional signatures of fetal CD105+ ECs  
a. Transcript expression of membrane proteins (CD markers) in fetal bone CD31+CD105+ ECs 
compared to steady-state BM ECs. The overlap with transcripts identified in ECs isolated from 
D17 BM (Table S1) supports the notion that the enrichment of these transcripts in ECs in the 
regenerative marrow is caused by overexpression in the subset of CD105+ ECs. 
b,c. GSEA plots demonstrating activation of HIF1a signaling (b) and gene sets associated with 
VEGF, WNT and stem cells (c) in fetal hRECs compared to steady-state BM. GSEA: gene 
sets enrichment analysis.  
d. Transcript expression (Log 2 fold change) of cognate receptors of candidate secreted 
proteins (Figure 5A) in fetal hRECs and ECs of regenerative marrow compared to steady-
state bone marrow.  
e. Transcript abundance of molecules associated with regeneration previously described in 
murine studies (Doan et al., 2013; Gur-Cohen et al., 2015; Kopp et al., 2005; Nakamura-Ishizu 
et al., 2012; Winkler et al., 2012). *<FDR 0.05. FDR: false discovery rate. 
*<FDR 0.05. FDR: false discovery rate. FPKM: fragments per kilobase of exon per million 
fragments mapped. BM: bone marrow. NES: normalized enrichment score. FC: Fold Change.  
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Supplementary Figure S3. 
 
Supplementary Figure S3. Related to Figure 3. In situ immunohistochemistry of 
CD31+CD105+ endothelial cells in human fetal and postnatal bone marrow.  
a. Hematoxylin and eosin, CD31, and CD105 staining in consecutive serial sections of fetal 
and adult trabecular bone. CD31+CD105+ vessels (indicated by black arrowheads) were 
readily detected in the fetal bone, but at much lower frequency in postnatal trabecular bone. 
Asterisks highlight sinusoidal endothelium, marked by CD105 expression and concomitant low 
or lack of CD31 expression. Note: hematopoietic elements with high CD31 expression 
(indicated by black arrows) represent megakaryocytes. Representative 5x and 20x magnified 
images. Scale bars represent 100 µm. 
b. Quantified total number of CD31+CD105+ vessels per 5x magnification field in trabecular 
areas of human fetal (n=5) and postnatal trabecular bone (n=4). Data represent mean ± s.e.m. 
**p <0.01, two-tailed unpaired t-test.  
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Supplementary Figure S4 
 
Supplementary Figure S4. Related to Figure 5. Representative FACS plots of cord blood 
stem/progenitor cells exposed to recombinant IL-33 for one week. 
Top, representative example of the single platform flow cytometric assay to quantify total cell 
number. Total number of mononuclear cells were calculated using the total number of MNC 
and beads events recorded using the quantification formula described in Experimental 
Procedures. Note that the MNC/Beads ratio in the vehicle control (VC) sample approximates 
0.5, whereas the IL-33 treated sample is 2.0, indicating an a 4-fold increase of MNC in 
comparison with VC.  
Bottom, characterization of the MNCs based on CD marker expression. CD34+CD38lo MNCs 
were identified as hematopoietic stem and progenitor cells (HSPCs). HSPCs were further 
subdivided based on CD90 and CD45RA expression. CD90+CD45RA- cells were defined as 
hematopoietic stem cells (HSCs), CD90-CD45RA- cells classified as multipotent progenitor 
cells (MPP), and CD90-CD45RA+ cells as multilymphoid progenitors (MLP). 
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Supplementary Figure S5 
 
Supplementary Figure S5 
a,b. The total number of bone marrow-derived mesenchymal cells (BMDSCs) and their CFU-
F capacity is not affected after treatment with recombinant IL-33 in osteogenic conditions. (a) 
Quantification of the total number of BMDSCs kept in regular culture medium (n=2), 
osteogenic induction medium (n=2) and osteogenic induction medium containing recombinant 
IL-33 (n=2). (b) Quantification of the colony-forming unit-fibroblast (CFU-F) capacity of 
BMDSCs kept in regular culture medium (n=2), osteogenic induction medium (n=2) and 
osteogenic induction medium containing recombinant IL-33 (n=2).  
c,d. Validation of shRNA-mediated IL-33 knockdown in HUVECs. (c) Transcript analysis of IL-
33 by quantitative polymerase chain reaction (qPCR) demonstrates efficient knockdown of IL-
33 in HUVECs transduced with two independent shRNA (sh19 and sh20) compared to a 
scramble hairpin control (SHC). (n= 4 independent experiments). (d) Representative Western 
Blot analysis confirming knockdown of IL33 at the protein level. R.P=recombinant protein IL-
33. Protein ladder has been cropped out from both gel figures.  
Data represent mean ± s.e.m. *p <0.05, two-tailed unpaired t-test. 
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Supplementary Figure S6 
 
Supplementary Figure S6. Related to Figure 7. IL-33 promotes expansion of myeloid 
cells.  
a. Total lineage-negative cell counts in PBS (n=10) and IL-33 treated (n=5) mice. Data 
represent mean ± s.e.m. *p<0.05, unpaired t-test. 
b. Colony-forming assay (CFU-C) on total BM of PBS (n=2) and IL-33 (n=2) treated mice. Data 
represent mean ± s.e.m. Experiments were performed in triplicate. 
c. Total bone marrow cellularity and Lin-, c-KIT+, Sca-1- cell counts in PBS (n=10) and IL-33 
treated (n=5) mice. Data represent mean ± s.e.m.  
d. Representative FACS plots demonstrating an increased frequency of 
monocytes/macrophages in the peripheral blood (PB) and bone marrow (BM) of IL-33 treated 
mice.  
e. Total PB and BM counts of monocytes/macrophages and neutrophils in PBS-treated (n=3 
for PB and n=2 for BM) and IL-33 treated (n=3 for PB and n=2 for BM) mice. Data represent 
mean ± s.e.m. **p<0.01, two-tailed unpaired t-test. 
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Supplementary Figure S7 
 
Supplementary Figure S7. Related to Figure 7. Recombinant IL-33 alters the 
architecture of the BM niche. 
a,b. Representative FACS plots of PBS (n=3) vs IL-33 treated (n=3) mice depicting the 
distribution of niche (CD45-Ter119-) cells within the BM. ECs were identified by CD31. Stromal 
(CD31-) cells were further defined as SCA-1+CD51+ cells (MSCs) or SCA-1-CD51+ cells 
(OBCs). IL33 administration resulted in a relative increase of CD31+CD105+, MSC and OBC 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Cell isolation from human bone (marrow) 
Freshly obtained BM aspirates of AML Day 17 patients were diluted 1:25 with red 
blood cell lysis solution (NH4Cl 0.155 M, KHCO3 0.01 M, EDTA-Na2.2H2O 0.1 M, pH 
7.4) and incubated for 10 min at room temperature. Mononuclear cells (MNCs) were 
collected by centrifugation and washed once with PBS+0.5%FCS.  
Fetal BM MNCs were isolated by gently crushing fetal long bones (femora, tibiae, 
fibulae, humeri, radii and ulna) in PBS+0.5%FCS using a mortar and pestle and 
passing subsequent cell suspension through a 40-µm filter in a 50 ml collection tube. 
Simultaneously, bone fragments were digested with 0.25% collagenase type I (Stem 
Cell. Cat#07902) for 45 minutes at 37°C, vortexing every 15 minutes. Excess PBS 
was added to the solution and filtered through a 40-µm filter in a collection tube. Next, 
both BM and bone fragment cell suspensions were washed once with PBS+0.5%FCS 
and were subsequently cleared from erythrocytes with IOtest3 lysing solution 
(Beckman Coulter. Cat#A07799), according to manufacturer’s instructions.  
For adult hip bone cells, trabecular bone was gently crushed using a mortar and pestle 
and resulting bone fragments were processed as described for fetal bone cells. 
 
Fluorescence active cells-sorting (FACS) of human BM niche cells 
Prior to cell sorting, FACS antibody incubations were performed in PBS+0.5%FCS for 
20 minutes on ice in the dark with the following antibodies using optimized dilutions: 
CD45 (clone HI30, 1:100), CD271 (clone ME20.4, 1:100), CD235a (clone HI264, 
1:100), CD31 (clone WM59, 1:100), CD9 (clone HI9a, 1:100) from Biolegend, and 
CD105 (clone SN6, 1:50) from eBioscience. The indicated populations of interest were 
sorted using a FACS ARIAIII Cell Sorter (BD Biosciences). Dead cells were gated out 
using 7AAD (Stem-Kit Reagents) after MNC selection and doublets exclusion. For 
RNASeq, cells were directly sorted in 800µl Trizol (Ambion) for RNA isolation. RNAse 
free non-stick micro-tubes (Ambion) were used to prevent pre-digestion of RNA.  
 
Flow cytometry on murine peripheral blood and bone (marrow) cells 
To identify murine hematopoietic stem and progenitor cells (HSPCs), BM cells were 
first co-stained with a cocktail of biotin-labelled antibodies against the following lineage 
(Lin) markers: Gr1 (RB6-8C5), Mac1 (M1/70), Ter119 (TER-119), CD3e (145-2C11), 
CD4 (GK1.5), CD8 (53-6.7) and B220 (RA3-6B2) (all from BD Biosciences). After 
washing, cells were incubated with Pacific Orange-conjugated streptavidin (Life 
Technologies) and the following antibodies: APC anti-c-Kit (2B8), PE anti-CD34 
(HM34), Pacific Blue anti-Sca1 (D7), Alexa Fluor 700 anti-CD48 (HM48-1), PE-Cy7 
anti-CD150 (TC15-12F12.2) (all from Biolegend), and APC/Cy7 anti-CD16/32 (56054, 
from BD Biosciences). To analyze murine differentiated cells, we used APC anti-Gr1 
(RB6-8C5), PE-Cy7 anti-Mac1 (M1/70), Pacific Blue anti-B220 (RA3-6B2) antibodies 
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(all from Biolegend). To define murine niche cells, BM and bone fraction cell 
suspensions were stained with the following antibodies: APC-Cy7 anti-CD45.2 (104), 
BV510 anti-Ter119 (TER-119), PE-Cy7 anti-CD105 (MJ7/18), PE anti-CD51 (RMV-
7), Pacific Blue anti-Sca1 (D7) (all from Biolegend), and PE-CF594 anti-CD31 (MEC 
13.3, BD Biosciences). IL-33 expression was assessed in BM cells fixed and 
permeabilized with Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD 
Biosciences) by incubating cells with PE anti-IL33 (IC3626P, R&D Systems) diluted in 
1X Perm/Wash buffer (BD Biosciences). 
 
CD31 and CD105 in situ immunofluorescence and immunohistochemistry  
4 μm thick sections of paraffin-embedded BM biopsies were obtained from benign 
lymphoma patients without evidence of intramedullary localization. Fetal femurs were 
fixed in 4% formaldehyde for 24 hours and decalcified in 12.5% EDTA overnight. Fetal 
femurs were subsequently embedded in paraffin and sliced with a Micron 
HM355Smicrotome (Thermo Scientific) to create 4 μm thick sections.  
For in situ immunofluorescence, deparaffinizing and antigen retrieval of the sections 
were performed with CC1 (Ventana 900-124) at 97oC for 64 minutes in a Ventana 
BenchMark ULTRA automatic staining system (Ventana Medical Systems, Tuscon, 
AZ). Next, murine anti-human CD31 (Cell Marque 760-4378) and rabbit anti-human 
CD105 (Genetex GTX100508_25ul,1:100) primary antibodies were manually added 
to the sections and incubated in the Ventana BenchMark ULTRA automatic staining 
system for 60 minutes at 36oC. After thorough washing with PBS/Tween 0.1%, 
sections were incubated for 30 minutes with a biotinylated rabbit anti-mouse 
secondary antibody lacking the FC fragment (DAKO E413), followed by washing in 
PBS/Tween20 0.1% and a 30 minute incubation with Cy™3-streptavidin (Jackson 
ImmunoResearch 016-0160-084). Next, avidin/biotin blocking was performed (Vector 
Laboratories P-2001). After thorough washing with PBS/Tween 0.1%, sections were 
incubated for 30 minutes with a biotinylated swine anti-rabbit secondary antibody 
(DAKO E431), followed by washing in PBS/Tween20 0.1% and a 30 minute incubation 
with FITC- streptavidin (Jackson ImmunoResearch 016-010-084). Finally, sections 
were mounted with DAPI-containing (1:2.000) vectashield (Vector Laboratories H-
1000). 20x magnified Z-series images were acquired with a Leica TCS SP5 confocal 
microscope using the LAS software (Leica Microsystems). Briefly, after 
deparaffinization sectioned specimens were processed for 64-minute antigen retrieval 
with CC1. After 20-minute incubation at 36oC with either previously described primary 
antibodies for CD31 and CD105 (1:500), detection was performed using UltraView 
DAB IHC Detection Kit (760-500, Ventana). The sections stained with CD31 and 
CD105 were counterstained with hematoxylin II (Ventana Ref.: 790-2208). Images 





Characterization of Endothelial Cells Associated with Hematopoietic Niche Formation in Humans Identifies IL-33 as an Anabolic Factor 
 49 
IL-33 immunofluorescence  
FACS-isolated hRECs, obtained from fetal bones and BM, were collected in PBS, 
cytospun on a glass slide for 3 minutes at 500 rpm using a Cytospin 4 centrifuge 
(Thermo Scientific), and fixed in 3% PFA/PBS for 15 minutes on ice. After washing 
with PBS 3 times, cells were permeabilized for 2 minutes in 0.15% Triton-X100/PBS 
and then incubated in 1%BSA/PBS for 1 hour at room temperature to block aspecific 
binding sites. Cells were next stained overnight at 4°C with polyclonal goat anti-human 
IL‑33 antibody (AF3625, R&D, 20 µg/ml in 1%BSA/PBS ) or goat IgG isotype control 
antibody(Catalog # AB-108-C). Slides were washed twice with PBS for 5 minutes and 
incubated for 1 hour at 37°C with Alexa Fluor 488- conjugated donkey anti-goat 
antibody (A-11055, Invitrogen, 1:200, in 1%BSA/PBS). After 2 washes in PBS, slides 
were mounted in VECTASHIELD Mounting Medium with DAPI (Vector Laboratories). 
63x magnified Z-series images were acquired with a Leica TCS SP5 confocal 
microscope using the LAS software (Leica Microsystems). For in situ 
immunohistochemistry consecutive serial sections of the benign lymphoma patients 
and fetal femur biopsies were stained for hematoxylin and eosin, CD31 and CD105 
separately with the Ventana Benchmark Ultra automated staining system.  
 
Hematopoietic stem progenitor cell isolation from umbilical cord blood 
Umbilical cord blood (CB) was collected in a 300 ml bag filled with 20ml of the 
anticoagulant citrate phosphate dextrose (T2950, Fresenius Kabi), after receiving 
informed consent from the mother, and retrieved within 24 hours after collection. 
MNCs were obtained by using a standard Ficoll gradient protocol (1114547, Axis-
Shield). CD34+ CB HSPCs were further isolated by magnetic-activated cell sorting 
(MACS). Briefly, MNCs were incubated with a magnetically coated anti-CD34 antibody 
(120-000-268, Miltenyi Biotec) and FcR blocking reagent (120-000-265, Miltenyi 
Biotec) in MACS buffer at 4°C for 30 minutes. After washing, CD34+ CB HSPCs were 
isolated using a LS column (130-042-401, Miltenyi Biotec) and purity was further 
enriched by performing an additional MACS selection using two MS columns (130-
042-201, Miltenyi Biotec). Purity of the isolated cell population was confirmed with 
fluorescence-activated cell sorting (FACS).  
 
Quantification and multiparametric immunophenotyping of cultured CB CD34+ 
cells 
Cultured CB cells were thoroughly resuspended and collected for the single platform 
flowcytometric assay (to determine absolute cell counts) and for immunophenotyping 
(to specify HSPC subpopulations), respectively. For the single platform flowcytometric 
assay, cultured cells were incubated with CD34-PE-Cy7 (348811, BD Biosciences, 
1:50) and CD45-PE-Cy5 (557075, BD Biosciences, 1:50) antibodies, and a calibrated 
number of flow-count fluorosphere beads (7547053, Beckman Coulter). In addition, 
4',6-diamidino-2-phenylindole (DAPI) (1:5.000) was used to distinguish between living 
and dead cells. The total number of living MNC per µl in (n) a well was calculated using 
the following formula: n= ((number of MNC events recorded * bead 
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concentration)/number of recorded single beads)/ (volume cells/ volume beads). For 
immunophenotyping, cultured cells were incubated with Lin-FITC (22-7778-72, 
eBiosciences, 1:25), CD34-PE-Cy7 (348811, BD Biosciences, 1:50), CD38-PerCP-
Cy5.5 (561106, BD Pharmingen, 1:60), CD90-PE (12-0909-42, eBiosciences, 1:30), 
CD45RA-APC-H7 (560674, BD Pharmingen, 1:30) and DAPI. Antibody incubation for 
FACs took place as previously described. The total number of a specific 
subpopulations was determined by multiplying the absolute number of living MNCs 
with the frequencies of the populations, determined with immunophenotyping, of 
interest. Flowcytometric analysis was performed using a BD LSRII (BD Biosciences, 
San Jose, CA, USA) and data was analyzed using FlowJo software (Tree Star Inc, 
Ashland, OR, USA).  
 
Human hematopoietic colony forming-unit assay 
To further assess the effect of recombinant human IL-33 on the hematopoietic 
potential of cultured CB cells, we performed a colony-forming unit assay (CFU). Input 
equivalent of 2000 7-days cultured CD34+ cells of each condition (rhIL-33 vs vehicle 
control) was resuspended in 400 µl Iscove's Modified Dulbecco's Medium (IMDM) and 
transferred to 3.6 ml of methylcellulose (MethoCult H84434, StemCell Technologies). 
Cells were then plated in triplicate in 1 cm² petri-dishes(1 ml/dish) and were kept at 
37ºC and 5% CO2. Colonies were counted after 12-14 days.  
 
Osteogenic differentiation and mineralization assays 
BMDSC extracts were harvested at the end of culture by scraping the cells in 
PBS/triton 1% and storing them at −80 °C for biochemical analyses (Bruedigam et al., 
2011). After scraping, PBS/triton 1%/0.24 M HCL was added to the wells and kept 
overnight at 4 °C to release calcium ions from the matrix deposition. Cell extracts were 
briefly sonicated (Soniprep 150, Sanyo) to produce cell lysates and incubated 
overnight with 6 M HCL. In short, calcium content was determined colorimetrically by 
adding o-cresolphthalein complexone to the well contents and cell lysates and 
measuring the absorbance of the resulting chromophore-complex at 595 nm. 
Alternatively, cells were fixed in 70% ethanol (vol/vol) on ice for an hour and after 
washing with PBS, stained for 10–20 min with alizarin Red S solution (saturated 
Alizarin Red S (Sigma) in demineralized water adjusted to pH 4.2 using 0.5% 
ammonium hydroxide).  
 
Human bone marrow fibroblast colony-forming unit assay 
BMDSCs were first either cultured in αMEM medium containing 10% heat-inactivated 
FCS, or osteogenic induction medium containing recombinant human IL-33 (250 
ng/ml) or mQ vehicle control for 1 week. After culture, total number of cells per 
condition were quantified with a Bürker counting chamber. Next, 50 cells per 0.32 cm2 
(1 well of a 96-well plate) were seeded in ɑMEM supplemented with 20% fetal bovine 
serum and 1% penicillin/streptomycin. On day 14, dishes were fixed with 70% ethanol 
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(vol/vol) and stained with Giemsa. CFU-F colonies were counted as previously 
described (Chen et al., 2016). 
 
Validation of IL-33 knockdown in HUVECs 
For transcriptional analyses, HUVECs were harvested and collected after puromycin 
selection in TRIzol Reagent (Life Technologies). RNA isolation, conversion to cDNA 
and qPCR were performed accordingly to previously described methods (Zambetti et 
al., 2015) using the SuperScript II Reverse Transcriptase (Thermo Fisher Scientific). 
For qPCR, expression levels were obtained using the ddCt method using GAPDH as 
an internal control. The following primers were used:  
GAPDH-Fw: GTCGGAGTCAACGGATT;  
GAPDH-Rv: AAGCTTCCCGTTCTCAG;  
IL-33-Fw: GGAAGAACACAGCAAGCAAAGCCT;  
IL-33-Rv: TAAGGCCAGAGCGGAGCTTCATAA. 
For protein analyses, cells were lysed in Carin lysis buffer (20 mM Tris-HCl pH 8.0, 
138 mM NaCl, 10mM EDTA, 100 mM NaF, 1% Nonidet P-40, 10% glycerol, 2mM NA-
vanadate) supplemented with 0.5 mM DTT and the protease inhibitor SigmaFast 
(Sigma Aldrich). Equal amounts of proteins were denatured and separated on a Novex 
NuPage 4-12% Bis-Tris Gradient gel (Life Technologies) and transferred to Protran 
BA83 blotting paper (GE Healthcare Sciences). After blocking with 5% BSA, 
membranes were incubated overnight at 4°C with a polyclonal goat anti-IL-33 primary 
antibody (AF3625, R&D systems). Actin was used as a loading control and detected 
with a mouse anti-actin antibody (A5441 Sigma Aldrich). Western blots were scanned 
and processed using an Odyssey Infrared Imager (Li-COR Biosciences). 
To monitor the expansion of HUVECs after shRNA mediated knockdown of IL-33 after 
puromycin selection, HUVECs were re-plated and seeded at 300.000 cells in a T-25 
flask and grown in EGM-2 medium containing 2µg/ml of puromycin. HUVECs were 
passaged every 2 to 4 days and total number of cells were quantified using a Casy 
counter (Roche Innovatis). 
 
Murine hematopoietic colony forming-unit assay 
To assess the myeloid progenitor capacity of whole BM from mice treated with PBS 
or IL-33, BM cells were cultured in methylcellulose containing murine SCF (10 ng/ml), 
IL-3 (100 ng/ml, purified from supernatant of CHO cells), IL-6 (10 ng/ml) and GM-CSF 
(10 ng/ml). Cytokines were purchased from PeproTech, if not otherwise mentioned. 
Specifically, 20000 BM cells per condition were resuspended in 400 µl IMDM and 
transferred to 3.6 ml of Methocult 3231 (StemCell Technologies). Cells were then 
plated in triplicate in 1 cm² petri-dishes(1 ml/dish) and were kept at 37ºC and 5% CO2. 
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P-glycoprotein (ABCB1), multidrug resistance protein-1 (ABCC1) and breast cancer 
resistance protein (ABCG2) belong to the ATP-binding cassette (ABC) superfamily of 
proteins that play an important physiological role in protection of the body from toxic 
xenobiotics and endogenous metabolites. Beyond this, these transporters determine 
the toxicity profile of many drugs, and confer multidrug resistance (MDR) in cancer 
cells associated with a poor treatment outcome of cancer patients. It has long been 
hypothesized that inhibition of ABC drug efflux transporters will increase drug 
accumulation and thereby overcome MDR, but until now no approved inhibitor of these 
transporters is available in the clinic. In this review we present molecular strategies to 
overcome this type of drug resistance and discuss for each of these strategies their 
promising value or indicate underlying reasons for their limited success. 
Keywords: Breast cancer resistance protein, ATP-binding cassette transporters, 
multidrug resistance, multidrug resistance protein. 
 
INTRODUCTION  
One of the most challenging obstacles in cancer treatment is multidrug resistance 
(MDR). Despite having achieved lower mortality rates due to recent advances in 
cancer therapy, the long term survival rate remains poor, primarily due to 
chemotherapy resistance[1-3]. Resistance can be caused by numerous mechanisms in 
cancer cells, such as activation of drug-metabolizing enzymes (e.g., cytochrome 
P450), activation of DNA repair mechanisms, disruptions in apoptotic signaling 
pathways, reduced drug influx and increased activity of drug efflux pumps[4-6]. 
Specifically, several members of the ATP-binding cassette (ABC) superfamily mediate 
the efflux of multiple chemotherapeutic drugs and so contribute to MDR. The ABC 
superfamily represents one of the largest protein families in biology, including 49 ABC 
genes identified in the human genome[7,8]. This superfamily is subdivided into seven 
distinct groups (ABCA through ABCG) and currently at least 15 ABC transporters have 
been implicated to confer resistance to clinically active drugs, notably P-glycoprotein 
(P-gp, ABCB1), multidrug resistance-associated protein-1 (MRP1, ABCC1) and 
breast cancer resistance protein (BCRP, ABCG2)[9]. 
Structurally, each ABC transporter is composed of at least one hydrophobic 
membrane-spanning domain (MSD) consisting of 6 α-helices and 1 hydrophilic 
nucleotide binding domain (NBD). All ABC proteins share a highly conserved region 
in the ATP binding domain, including the Walker A and Walker B sequences, the ABC 
signature motif, the H loop and the Q loop[8]. Depending on the clustering of the MSD 
and the NBD in the transporters, these are grouped into full transporters (e.g., ABCB1 
and ABCC1, consisting of 2 MSDs and 2 NBDs), half transporters (e.g., ABCG2, 
containing only 1 MSD and 1 NBD) and non-transporters, which possess two NBDs, 
without the MSDs[10]. The subfamily ABCE belongs to the non-transporters, whose 
proteins play a role in the assembly of the pre-initiation complex and RNAse[11,12] 
inhibition. ABCF subfamily members also encode non-transporters, they are involved 
in ribosome assembly and protein translation[13,14]. 
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ABC transporters are present in all living species, in prokaryotes they function as drug 
importers or exporters, in eukaryotes solely as drugs exporters[15]. By coupling ATP 
binding and hydrolysis these transporters are able to extrude substrates out of cells or 
into cellular compartments like cytoplasmic vesicles and lysosomes[8]. This 
superfamily transports a wide range of substrates, including lipids, bile salts, sugars, 
amino acids, steroids, peptides, nucleotides, endogenous metabolites, ions and 
toxins, including antibiotics and chemotherapeutic drugs. Collectively, ABC 
transporters fulfill both physiological and pharmacological functions impacting drug 
transport, tumor growth modulation and regulatory pathways (e.g., apoptosis and 
complement-mediated cytotoxicity[16-18] and immune cell-regulatory pathways[19]. This 
review focuses on current developments in drug discovery to circumvent MDR 
induced by P-gp, MRP1 and BCRP in cancer cells. 
 
P-GLYCOPROTEIN  
P-glycoprotein (or ABCB1 or MDR1) was originally identified as the first mammalian 
ABC multidrug transporter in 1976, when Juliano and Ling[20] observed that Chinese 
hamster ovary cells displayed pleiotropic cross-resistance to a wide range of 
amphiphilic drugs. This transporter was named P-gp and is also known as ABCB1 or 
MDR1. 
P-gp is encoded by a single polypeptide chain with 2 homologous NBD and 2 
homologous transmembrane domains (TMD)[21,22]. The 2 homologous TMD are joined 
by a linker region of about 60 amino acids[23]. Each TMD contains 6 transmembrane 
(TM) α-helices and 1 NBD [Figure 1]. 
Aller et al.[24] reported the X-ray structure of mouse P-gp, which shares 87% sequence 
identity with the human P-gp. The structure revealed that the inward facing 
conformation is formed by 2 bundles of 6 TMs arranged as TMs 1-3, 6, 10, 11 and 
TMs 4, 5, 7-9, 12. This conformation results in a large internal cavity, which is open to 
the cytoplasm and the inner leaflet. There are 2 portals (formed by TMs 4/6 and 10/12) 
that allow hydrophobic molecules to enter the cavity directly from the inner leaflet. The 
drug binding pocket generally contains hydrophobic and aromatic residues and is 
large enough to accommodate at least two substrate molecules simultaneously[25]. 
In fact, this was supported by the X-ray structure reported by Aller et al.[24]. Expanding 
on these observations, Pajeva and Wiese[26] compared the inward facing homology 
model of human P-gp based on the earlier mentioned mouse structure with the 
outward facing homology model of human P-gp based on Sav1866 structure. It 
appeared that residues in TM4 and TM10 face the cavity in the inward facing 
conformation are completely buried in the outward facing form, while the ligands 
remain bound to the same residues of TM6 and TM12 in both conformations. This 
implies that each of the portals has different roles: TM4 and TM10 as “portal keepers” 
(preventing substrates that entered to escape back to the inner leaflet) and TM6 and 
TM12 as “portal carriers” (these are mainly responsible for substrate interactions). 
Together, this model suggests that ligands remain bound to the same residues during 
the transition from the inward to the outward facing conformation. 
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The expression pattern of P-gp indicates that its main function is the protection of the 
body from toxic substances and xenobiotics by excreting them into bile, urine, feces 
and avoiding their entry into fetus, brain and testes. To this end, P-gp is expressed on 
the canalicular surface of hepatocytes in the liver, the apical surface of epithelial cells 
of proximal tubules in the kidneys, columnar epithelial cells of the intestine, epithelial 
cells of placenta, and the luminal surface of capillary endothelial cells in brain and 
testes[27,28]. Next to this important physiological function, pharmacologically P-gp 
constitutes a considerable obstacle to the delivery of various clinically used drugs to 
their targets, such as anti-cancer drugs, anti-epileptics, immunosuppressive agents, 
cardiac glycosides, cholesterol-lowering statins, human immunodeficiency virus (HIV) 
protease inhibitors, anti-hypertensives, calcium channel blockers, anti-histamines and 
antibiotics[15]. From knockout mice studies it became clear that P-gp plays a major role 
in determining the drug ADME (absorption, distribution, metabolism, excretion) 
profile[29,30]. These P-gp knock-out mice showed increased absorption and decreased 
elimination of drugs, which gave rise to severe toxicity. In addition, P-gp works 
synergistically with the major phase I drug metabolizing enzyme P450 (CYP3A4), as 
they share a remarkable similarity between their substrates and regulation, to 
decrease the oral drug bioavailability. 
 
Figure 1: Schematic representation of the domain structure of P-gp, MRP1 and BCRP. P-gp 
has 2 TMD consisting of 6 α-helices each and 2 ATP bindings sites. MRP1 also contains 2 
ATP-binding regions and 2 TMD containing 6 α-helices and it is extended by 1 additional TMD 
consisting of 5 α-helices and 1 amino terminus loop (L0). The half transporter ABCG2 contains 
1 TMD of 6 α-helices and 1 ATP-binding domain. The ATP-binding site of this transporter is 
found on the amino-terminal side (N) in contrast to P-gp and MRP1. P-gp: P-glycoprotein; 
MRP1: multidrug resistance protein-1; BCRP: breast cancer resistance protein; TMD: 
transmembrane domain 
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High expression levels of P-gp have been identified in various solid tumor 
malignancies, e.g. kidney, colon, liver, ovarian, breast and sarcomas[4] [Table 1]. P-gp 
overexpression has been reported to be an independent negative prognostic factor in 
clinical outcome. In high grade osteosarcoma, increased levels of P-gp correlated with 
a > 3-fold increased risk of adverse events and shorter event-free survival[31]. MDR1 
RNA levels increased after lung perfusion with doxorubicin of patients with 
unresectable sarcoma pulmonary metastases[32]. Furthermore, Gregorcyk et al.[33] 
reported that P-gp positive breast cancer patients are at significantly higher risk for 
relapse. In hematological malignancies, P-gp mRNA expression and protein function 
are increased after chemotherapy treatment. Expression of P-gp in myeloid blasts is 
correlated with treatment failure and shorter survival in adult acute myeloid leukemia 
(AML) patients[34,35]. However, childhood acute lymphoblastic leukemia (ALL) results 
have shown contradictory results, some found no association between high P-gp 
expression and prognosis[36,37], while other groups showed prognostic impact for P-gp 
in ALL[38,39]. These differences can at least partially be attributed to different treatment 
strategies and methods used to detect P-gp[40].  
 
MULTI-DRUG RESISTANCE-ASSOCIATED PROTEIN 1  
A decade after the discovery of P-gp, the first member of the C subfamily, MRP1 
(systematic name, ABCC1) was discovered[41]. MRP1 is widely expressed in normal 
tissues, with relatively high levels in the kidney, lung, testis, heart and placenta, while 
there is a low expression in colon, brain, and small intestine and peripheral blood 
mononuclear cells[42,43] [Table 1]. Notably, in the above-mentioned tissues, MRP1 
expression can vary between different cell types of the same tissue[44]. The highest 
expression is found in cells with specialized barrier function, e.g., the choroid cells in 
the blood cerebrospinal fluid barrier[45], or cells with a high proliferative status, e.g., 
reactive type II pneumocytes in hyperplastic alveoli of the lung[46]. In contrast to P-gp 
and BCRP, MRP1 is mainly expressed at the basolateral membrane of polarized cells, 
with the exception of brain capillary endothelial cells. Consequently, it has been 
suggested that MRP1 functions to protect cell types from xeno- and endobiotics and 
pumping them into the interstitial space of the body, instead of their expulsion into bile, 
urine or gut[47]. In addition, studies with mrp1 (-/-) mice revealed other physiologic 
functions of MRP1 than transporters. For example, MRP1 plays a role in 
immunological responses by its involvement in leukotriene extrusion[48]. Furthermore, 
being a transporter of glutathione (GSSG) and glutathione-conjugates, MRP1 plays a 
crucial role in the elimination of toxic substances formed during oxidative stress[49,50].  
Despite the fact that both P-gp and MRP1 can confer resistance to a wide range of 
drugs, P-gp prefers neutral, or positively charged, hydrophobic compounds, while 
MRP1 binds and transports anionic substrates, can also be co-transported with free 
glutathione[50]. Some examples of MRP1 substrates are: various anticancer drugs, 
antibiotics, pesticides, HIV protease inhibitors, peptides, heavy metals, glutathione 




Table 1. Characterization of P-gp, MRP1 and BCRP 
ABC transporter Localization High Expression Low Expression Substrates 




















Anionic substrates in the 
form of anionic 
glutathione, glucoronate 
or sulfate conjugates 
BCRP (ABCG2) Apical Placenta, breast, 




+ or – charged, 
hydrophobic/hydrophilic, 
conjugated/unconjugated 
BBB= blood-brain barrier; P-gp: P-glycoprotein; MRP1: multidrug resistance protein-1; BCRP: breast 
cancer resistance protein; ABC: ATP-binding cassette 
 
The currently accepted MRP1 topology consists of the following domain arrangement: 
TMD0-L0-TMD1- NBD1-TMD2-NBD2 [Figure 1]. Compared to P-gp, this transporter 
is extended by an additional TMD0 containing 5 TM helices and 1 amino terminus loop 
(L0) consisting of 32 amino acids, which links TMD0 to TMD1. The exact function of 
the TMD0 still needs to be fully elucidated. It was previously thought that TMD0 had 
no role in trafficking to the plasma membrane or efflux function, but this view has been 
revisited by several mechanistic and cell biological reports[52]. It has been shown that 
TMD0 is important for the processing and trafficking of human MRP1[53]. Additionally, 
by mutation studies, Yang et al.[54] reported that the amino terminus is required for 
proper MRP1 function and structure. It has also been suggested by Chen et al.[55] that 
the amino terminus forms a U-shaped structure which might serve as a gate to 
regulate the substrate transport activity of MRP1. Finally, TMD0 and L0 seem to 
contribute to MRP1 homo-dimerization, but whether the functional form of MRP1 is a 
homodimer or a monomer needs to be determined[56].  
Depending on expression levels, MRP1 can confer resistance to a variety of 
antineoplastic drugs, including vinca alkaloids, anthracyclines, epipodophyllotoxins, 
saquinavir, methotrexate, mitoxantrone, camptothecins, paclitaxel, glucuronide, 
doxorubicin, epirubicin, and tyrosine kinase inhibitors such as imatinib[57,58]. High 
MRP1 expression levels have been identified in different cancer types, e.g., lung 
cancer, breast cancer, prostate cancer, gastrointestinal carcinoma, melanoma, 
neuroblastoma, ovary and hematological malignancies[44,59] (AML, ALL and chronic 
lymphoblastic leukemia). In these results, it has been difficult to define statistically 
significant correlations between high MRP1 expression in the indicated tumors and 
acquired resistance or prognosis. This was largely due to the fact that tumor samples 
contained a variable number of MRP1 expressing normal cells, cells, while other drug 
efflux transporters might contribute as well[44]. However, a prospective study 
demonstrated that MRP1 is an independent prognostic indicator of outcome in 
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? 
 61 
neuroblastoma patients[60]. In addition, a high expression of MRP1 was associated 
with shorter tumor-free survival (TFS) and overall survival (OS) in non-small cell lung 
cancer (NSCLC)[61]. Similarly, in breast cancer MRP1 expression was related to 
shorter relapse-free survival (RFS) and overall survival[62]. 
 
BREAST CANCER RESISTANCE PROTEIN  
ABCG2, also known as BCRP, ABCP or MXR, is expressed in a variety of normal 
tissues, including epithelial cells of the gastrointestinal tract and liver, placental 
syncytiotrophoblast cells, prostate epithelium, kidney cortical tubules, endothelial cells 
of the blood-brain barrier (BBB) and hematopoietic stem cells[10,63] [Table 1]. Like P-
gp, ABCG2 is expressed on the apical surface of epithelial cells and since it is 
expressed in tissues with secretory and barrier function, this suggests that its function 
is similar to P-gp, which is protecting the body from toxic compounds. ABCG2 mRNA 
expression was higher compared to other efflux transporter in the human small 
intestine, which is a rate-limiting barrier to oral drug absorption[64]. The significant 
impact of ABCG2 on the intestinal absorption was further supported by several 
knockout mice research, which have indicated that ABCG2 affects the 
pharmacological and toxicological behavior of many drugs[65-67]. Also, polymorphisms 
might influence the role of ABCG2 in intestinal absorption. For example, ABCG2 
c.421C> polymorphism renders BCRP more than 75% less active than its wild-type 
variant. Since ABCG2 c.421C>A is a common polymorphism, present in more than 
30% of the Asian and 15% of European population, decreased drug absorption due 
to BCRP polymorphisms deserves clinical attention[68]. Additionally, Kruijtzer et al.[69] 
reported that ABCG2 affect the bioavailability and systemic concentration of topotecan 
in patients. Inhibition of ABCG2 by elacridar (GF120918), a dual inhibitor of P-gp and 
ABCG2, increased the bioavailability of topotecan from 40% to 97% after oral 
administration and reduced the biliary and renal excretion of topotecan after 
intravenous administration. It has also been noted that the polymorphic variant 
421C>A of ABCG2 can alter the pharmacokinetics of several drugs, including 
diflomotecan, teriflunomide, sulfasalazine, gefitinib, imatinib, and many statins[63]. 
Furthermore, it has been suggested that ABCG2 plays a role in the maintenance of 
human pluripotent stem cells in an undifferentiated state and their protection from toxic 
xenobiotics and hypoxia[10].  
BCRP exhibits broad substrate specificity and can transport either positively or 
negatively charged drugs, hydrophobic or hydrophilic and conjugated or unconjugated 
substrates[70]. Examples are a wide range of anticancer drugs, sulfate and glucuronide 
conjugates of xenobiotics, tyrosine kinase inhibitors (TKIs), statins, fluorescent dyes 
and flavonoids[10,63]. In vitro assays showed that ABCG2 might have more than two 
binding sites, since ABCG2 inhibitors displayed different inhibition profiles, depending 
on the tested substrate[71-73]. For instance, the inhibitor Ko143 inhibited the transport 
of all the substrates tested by Giri et al.[72], which suggested its binding to a region that 
allosterically inhibits the transport of these substrates. However, the ABCG2 inhibitors 
elacridar, nelfinavir and Pluronic P85 seemed to bind to a different region, which 
inhibited the transport of the nucleoside analogs abacavir and zidovudine, but showed 
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no or a partial effect on the transport of prazosin and imatinib. Muenster et al.[73] 
showed that two different substrates, such as topotecan and albendazole sulfoxide, 
could simultaneously be transported without hindering each other’s transport, which 
also suggest multiple binding sites in ABCG2. Furthermore, using homology modeling 
a complete homodimer ABCG2 model was created based on the crystal structure of 
the bacterial multidrug exporter Sav1866, which also suggested a multiple binding 
site[74]. ABCG2 is a half transporter consisting of 6 putative transmembrane segments 
and 1 NBD [Figure 1]. The simplest functional form of ABCG2 is a homodimer, which 
is bridged by disulfide bridge bonds[75]. Other research has suggested higher order of 
homo-oligomer on plasma membranes, which could also regulate ABCG2 function by 
dynamic association and dissociation of ABCG2 monomers[76]. Accordingly, it is 
currently unknown whether a homodimer or a homo-oligomer is the dominant 
functional unit of ABCG2 in the plasma membrane[77,78].  
Clinically, high expression levels of ABCG2 have been found in many solid tumors, 
especially adenocarcinomas of the digestive tract, endometrium, lung and 
melanoma[77]. In addition, Damiani et al.[79] found that ABCG2 was overexpressed in 
33% of AML patients and that this feature was significantly associated with shorter 
disease-free survival and higher risk of relapse. ABCG2 expression is also higher in 
B-lineage than in T-lineage ALL, while adult ALL patients have a higher expression 
than infant ALL patients[80,81]. Contradictory results have been published on the 
correlation between ABCG2 expression and prognosis of solid tumors and on the 
correlation between ABCG2 expression and prognosis of hematological 
malignancies[10,39,82]. Overall, even though BCRP activity contributes to MDR and drug 
pharmacokinetics in cancer, the exact mechanisms of action and interaction remain 
to be elucidated.  
 
ABC TRANSPORTER INHIBITION  
Since overexpression of some of the ABC transporters was correlated with a poor 
chemotherapeutic response and prognosis of patients with specific cancer types, 
inhibition of ABC transporters appears a logical approach to circumvent MDR and 
improve patient’s outcome[82,83]. However, other than in a preclinical setting where 
ABC transporters could reverse MDR, this promise has still not been fulfilled in clinical 
practice. Inhibition of ABC transporters has been evaluated with rationally designed or 
natural inhibitors, including competitive and non-competitive inhibitors. Competitive 
inhibitors exert their function by tightly binding and blocking the substrate binding 
pockets. Non-competitive inhibitors exert their function by binding to a non-substrate 
binding site thereby inhibiting the ATPase activity or modulating transporters’ function 
allosterically[15,83-85]. Another strategy to circumvent MDR that will be discussed further 
is the application of small interfering RNA (siRNA)[86-88] and microRNA (miRNA)[89,90] 
inoculation to down-regulating ABC transporter expression. Currently, approximately 
30 siRNA candidates are being studied in clinical trial, yet unfortunately their high cost, 
poor stability in vivo, delivery challenges and off-target effects still remain a challenge 
for treatment[89]. A third approach relates to the rational design of new 
chemotherapeutics which are non-substrates for ABC transporters. TKIs are small 
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molecules developed to inhibit the uncontrolled activity of various tyrosine kinases 
(TK) involved in cancer. Many of them can also act as substrates or non-substrates to 
alter efflux mechanisms mediated by ABC transporters[91]. TKIs have been approved 
by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
since 2001 (such as imatinib, gefitinib and erlotinib and more recently ceritinib, 
lenvatinib) while several others are under investigation in clinical trials and can 
potentially be used to inhibit transporter-mediated efflux, as discussed below[92-96]. The 
main focus of this section of the review will be to discuss modulators which are lead 
compounds for clinical application.  
 
OVERCOMING P-GP RESISTANCE  
P-gp specific inhibition is particularly challenging due to its large binding pocket with 
low substrate specificity which enables P-gp to interact with over 200 different known 
substrates[9,97]. Nevertheless, the discovery of new agents to inhibit P-gp is still 
ongoing, building on encouraging in vitro studies and individual clinical trials such as 
the Southwest Oncology Group (SWOG 9126) study that showed a strong benefit of 
the use of the P-gp inhibitor cyclosporine A (CSA) in patients with relapsed or 
refractory AML[98]. To date, three generations of P-gp inhibitors can be distinguished. 
Both, the first-generation agents (including verapamil, tamoxifen, cyclosporine A, 
quinidine and dexverapamil), and the second-generation agents [including VX-710 
(biricodar), GF120918 (elacridar) and PSC833 (valspodar)] ultimately failed to show 
improvement in overall drug efficacy in multiple randomized clinical trials due to poor 
potency and increased toxicity, respectively[99]. Consequently, the third-generation 
agents were developed featuring a high transporter affinity and a low pharmacokinetic 
interaction, including XR-9576 (Tariquidar), LY335979 (Zosuquidar) and R101933 
(Laniquidar), which will be discussed below.  
 
Inhibition of P-gp  
Agents from all the three generations have been tested in clinical trials. Even though 
some of the early trials showed benefit from P-gp inhibition, results of most large 
randomized trials have been disappointing[100,101]. As an illustration, a phase I study of 
tariquidar in combination with vinorelbine showed that tariquidar is a potent P-gp 
inhibitor, with no noteworthy side effects and pharmacokinetic interactions[102]. Similar 
findings were observed for zosuquidar. Phase I research with zosuquidar showed that 
the drug could be administered safely to patients with AML or solid tumors[103,104]. 
However, a randomized placebo-controlled double-blind trial in 449 patients with 
newly diagnosed AML or high-risk myelodysplastic syndrome, showed no 
improvement in OS, or complete remission (CR) rates of drug treatment combined 
with zosuquidar[105].  
The main reason for the initial failures in early clinical trials which started within 10 
years after the discovery of P-gp-mediated MDR, was the lack of full understanding of 
P-gp properties and lack of knowledge on other ABC transporters. A clear example of 
this is tariquidar, which initially was considered as a specific P-gp inhibitor, but later 
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results showed inhibitory effects on BCRP and MRP1 leading to the synthesis of more 
potent tariquidar derivatives[106,107]. Mechanistic studies also showed that tariquidar 
can act, in a dose-dependent manner, both as a substrate or as a transport 
inhibitor[106,108,109]. Furthermore, recent 3-dimensional quantitative structure-activity 
relationship (QSAR) studies of anthranilamide derivatives of tariquidar suggest that a 
hydrophobic domain is needed for increased P-gp specific inhibitory function[26]. Some 
tariquidar analogs with sulfonamide groups are P-gp specific, nevertheless tariquidar 
was toxic to healthy cells[107]. Since its discovery, tariquidar was described as non-
competitive and non-transported inhibitor of P-gp[110], while Bankstahl et al [111]. have 
shown that tariquidar is concentration-dependently transported by P-gp. Recent 
transepithelial drug transport assays using radioactive tariquidar in human and mouse 
cell lines indicate that tariquidar functions as a high-affinity P-gp substrate rather than 
a non-competitive inhibitor[112].  
The insufficient knowledge of the P-gp transporter led to the design of clinical trials 
with inadequate inhibitors and patient selection. Agents such as verapamil belonging 
to the first-generation inhibitors were low in potency, and since dose escalation was 
limited due to toxicity, ineffective dosages were used[113,114]. Other clinical trials failed 
due to their choice of compounds that interfered with the physiological role of P-gp 
and sister proteins. For instance, the dose of the anticancer agents used in 
combination with the second-generation P-gp inhibitor PSC 833 had to be reduced to 
prevent toxicities of the anticancer agent because PSC 833 caused a decreased drug 
clearance via inhibition of its metabolism by cytochrome P450[112]. Regarding patient 
selection, initial clinical trials enrolled patients irrespective of their P-gp 
status, whereas rationally patient selection should be based on adequate 
transporter(s) expression and/or function in tumor specimen and whether the targeted 
transporter is the dominant mechanism of drug resistance[91]. Moreover, early clinical 
trial designs did not take into account the role of P-gp polymorphisms. Polymorphic 
variants of the transporters influence their expression, function and localization and 
thereby might affect the pharmacokinetics of their substrates[115]. Inclusion of patients 
with such polymorphic variants might confuse treatment outcome assessments, since 
these patients might not develop significant MDR via efflux pumps, but face bone 
marrow toxicity in combination therapy with the inhibitor.  
Novel molecules that can successfully interact with P-gp-specific NBDs have been 
identified through in silico and computational studies (compound 19, 29, 45)[116,117]. 
The aim of such approach is to find molecules that can interfere with the energy 
harvesting system of a transporter, avoiding its non-specific drug binding domains. 
Nanayakkara et al.[118] identified through computational studies (compound 29, -34, -
45) which, when co-administrated with vinblastine and paclitaxel decreased viability, 
survival and motility of prostate cancer and other resistant cell lines. Furthermore 
compound 34 and 45 were found to be P-gp specific while inhibitor 45 also had affinity 
for ABCG2[117]. These techniques may be a promising approach in the search for P-
gp specific NBD inhibitors[119].  
 
 
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? 
 65 
Evading P-gp (nanoparticle drug delivery systems)  
Focus has now shifted towards downregulating the transcription of P-gp with 
siRNA[87,120,121] or microRNA[122,123] using nanoparticle (NP) drug delivery systems[124]. 
Hyaluronic acid based nanoparticles can effectively target CD44+ ovarian cancer cells 
and downregulate P-gp and increase intracellular concentration of paclitaxel. High 
CD44+ expression in ovarian cancer cells is related to metastasis and therefore this 
cell-specific approach has the potential to improve the cell sensitivity in ovarian cancer 
patients with poor prognosis[120,121]. Encapsulation drugs in liposomal nanoparticles 
show promising results in the clinical setting. Doxorubicin HCl liposomal injection 
(Doxil) was approved for the treatment of AIDS related Kaposi’s sarcoma (USA in 
1995 and Japan in 2007), and for the treatment of ovarian cancer (USA in 1999 and 
Japan in 2009) after failure of prior systemic chemotherapy or intolerance or after 
failure of platinum-based chemotherapy[125]. In addition, in 2007 the FDA approved 
Doxil for the treatment of multiple myeloma in combination with bortezomib. Another 
candidate is the nanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane), 
which in 2011 has been approved in 42 countries for the treatment of metastatic breast 
cancer after failure of combination chemotherapy for metastatic disease or relapse 
within six months after adjuvant chemotherapy[126]. Additionally, encapsulation of 
doxorubicin in hydrophobic polymeric micelles cause indirect inhibition of P-gp efflux 
and enhance intracellular drug concentration without affecting P-gp expression[127]. 
The BBB is also another target of investigation with NP drug delivery. A recent study 
analyzed the permeability kinetics of siRNA NPs in a BBB monolayer model using 
human brain endothelial cells concluded that NP delivery can inhibit P-gp expression 
by half and increase rhodamine 123 permeability by a third[87]. siRNA-loaded NP 
carriers could be a promising approach to circumvent the human BBB in order to 
facilitate drug penetration in the central nervous system. Unfortunately, side effects 
such as skin and hypersensitivity reactions and neurotoxicity remain common limiting 
factor[128,129]. 
 
The role of microRNAs in P-gp modulation  
MicroRNAs are post-transcriptional regulators composed of noncoding RNAs, which 
can regulate gene expression and have been implicated in drug resistance in many 
cancers[122,123]. MicroRNA can bind to the 3’ untranslated region (UTR) of RNA with 
high precision, causing RNA degradation and inhibition of gene expression[130]. 
Several studies report that miRNAs can regulate MDR by modulating the expression 
of P-gp. For example, it has been shown that miR-451 and miR-27a upregulation was 
P-gp dependent in cell lines representing ovarian cancer, leukemia and hepatocellular 
carcinoma[112,114,115]. In contrast, deregulation rather than upregulation of certain 
miRNAs, such as miR27a and miR 331-5p, can also cause drug resistance reversal 
and decreased P-gp expression, as seen in doxorubicin resistant leukemia cell lines 
K562 and HL60[131-133]. Furthermore one study found a possible prognostic value for 
miR-296, whose expression can distinguish long-term survivors from short-term 




MiRNA mediated P-gp inhibition and drug resistance reversal seems to be dose-
dependent, as seen with colorectal adenocarcinoma and breast cancer cell 
lines[135,136]. For example, Bao et al.[136] reported that P-gp expression could be 
reduced with miR-298 and reversed doxorubicin resistance in breast cancer cells in a 
dose-dependent fashion. In vivo studies also report that miR-873 elicits a dose-
dependent response, measured by tumor growth inhibition and cisplatin sensitization 
in previously resistant cell lines[122]. Other miRNAs with BCRP-modulating capacity 
include miR-122[137], miR-381, miR-495[138], miR-223[139], miR-9[140], and miR-873[122] 
[Table 2]. Unfortunately, full understanding of miRNA post-transcriptional modulation 
is still insufficient and concerns with off target effects on top of which RNA degradation 
still remains an unresolved issue[89]. 
 
Bypassing P-gp: none substrates  
Several approaches have been investigated to evade P-gp mediated MDR with novel 
drugs: (1) decreasing their molecular affinity for P-gp and (2) increasing the affinity to 
drug targets. This has been challenged for microtubule stabilizing agents (e.g., 
epothilones, second- and third-generation taxanes), microtubule destabilizing agents 
(e.g., cryptophycins, halichondrins, hemiasterlins and STX140), inhibitors of 
topoisomerase I (e.g., lipophilic camptothecins, homocamptothecins and 
dibenzonaphthyridinones) and inhibitors of topoisomerase II (e.g., lipophilic 
anthracyclines). Many of these agents have already undergone wide preclinical and 
clinical investigation, and are comprehensively reviewed[141].  
The epothilones including epothilone B (patupilone) and its analogs BMS-310705, 
sagopilone and ixabepilone, and epothilone D and its derivative KOS-1584, are poor 
substrates of P-gp. They show a diverse susceptibility profile to P-gp mediated 
resistance, with ixabepilone the most and sagopilone the less affected by P-gp 
overexpression[142,143]. Currently, ixabepilone is FDA approved for the treatment of 
metastatic breast cancer and has been tested in phase III clinical trials in combination 
with capecitabine[144-146].  
TPI-287, a novel microtubule destabilizing drug of the taxane family designed to 
circumvent MDR, was recently tested in a small group phase I study of children with 
neuroblastoma and medulloblastoma. TPI 287 was well tolerated half of patients with 
neuroblastoma who completed one cycle of treatment with TPI 287 alone showed a 
stable disease although the study was not designed to evaluate treatment 
response[147]. In the case of epothilones, there are a number of active clinical trials to 
test its efficacy in a range of advanced solid tumors such as breast cancer, ovary, 
head and neck, esophagus, lung, gastrointestinal tract cancers and brain tumors 
(clinical trial reference: NCT00030173, NCT0035516 and NCT00450866). Being a P-
gp substrate, ixabepilone might exert its antitumor activity preferentially in tumors 
where the main resistance mechanism is βIII-tubulin or/and BCRP dependent[148,149]. 
The exact working mechanism of these novel agents is still unclear. However, 
bypassing a resistance mechanism such as P-gp-mediated MDR does not imply that 
patients are not at risk of developing other mechanisms of drug resistance which will 
lead to intrinsic or acquired tumor refractoriness. For epothilones, expression of some 
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MRPs, such as MRP7, and β-tubulin mutations has been related to the development 
of tumor drug resistance to these agents[150,151].  
 
Table 2. Novel approaches to P-gp inhibition 
Type Name Remarks Cancer Type References 






Zosuquidar shows robust P-gp 
inhibitoin without affecting survival 
rates; hydrophobic domains in 










29, 34, 45 
High NBD specificity; compound 34 
and 45 are P-gp specific 
Prostate cancer 
and various 










Increases drug concentration and 





siRNA siRNA delivered 
by nanoparticles 
Hyaluronic acid based nanoparticles 
for CD44+ cell, reduces P-gp mRNA 
by half in BBB model with NP 
delivery and > 85% in Caco-2 cells 





cell line  
[87, 120, 
121, 135] 
MicroRNAs miR-27a, 451, 
873, 381, 101, 
229, 495, 9, 296, 
298 
Inhibits P-gp expression through 
post-transcriptional modulation; 
increases drug sensitivity in 

















Taxanes such as ixabepilone is FDA 
approved. Β-microtubulin mutations 
lead to resistance 
Breast cancer [141-149] 
Monoclonal 
antibodies 
MRK 16, 17 Currently undergoing phase I clinical 
trials 






Sensitized primary resistant cells and 
cell lines to chemotherapeutics by 





P-gp: P-glycoprotein; BBB= blood-brain barrier; TKI: tyrosine kinase inhibitor; AML: acute myeloid 
leukemia; ALL: acute lymphoid leukemia; MDS: myelodysplastic syndrome; NBD: nucleotide binding 
domain; MDR: multidrug resistance; NP: nanoparticles  
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Using P-gp to kill cancer cells  
Instead of inhibition of the P-gp function or evading its efflux to overcome P-gp-
mediated MDR, an alternative approach is to actually exploit P-gp expression to 
specifically kill MDR cells. This strategy makes use of the phenomenon of collateral 
sensitivity (CS). which refers to the fact that some agents show preferential activity 
toward MDR cancer cells relative to their non-MDR parental cells, as was previously 
noticed for verapamil, cytosine arabinoside and gemcitabine in MDR small cell lung 
cancer cells lines[152,153]. Different CS agents have been synthesized from lead 
compounds such as NSC73306 (1,1-Isatin-4-(4′-methoxyphenyl)-3-
thiosemicarbazone and the flavonoid desmosdumotin B[154,155]. It has been 
hypothesized that CS agents exert their effect by the generation of reactive oxygen 
species. This strategy is still experimental. Of further interest, within a class of isatins 
drugs, particularly N-alkylisatins were found not to be susceptible to P-gp mediated 
efflux, destabilize microtubule formation and induce apoptosis in P-gp overexpressing 
tumor cells[156].  
Another approach to bypass P-gp is to use drugs that show a higher sensitivity to P-
gp expressing cells compared to P-gp negative cells. Bergman et al.[153,157] showed 
that both small cell lung cancer and NSCLC cells with an overexpression of either P-
gp or MRP1 were more sensitive to the deoxynucleoside analogs cytarabine and 
gemcitabine. This was related to an increased activity of the activating enzyme 
deoxycytidine kinase (dCK) for these nucleoside analogs, leading to an increased 
accumulation of the active metabolites, Ara-CTP and dFdCTP, respectively. It was 
argued that in P-gp cells steroids are effluxed efficiently decreasing their intracellular 
concentration. Since steroids regulate dCK, this may lead to an increased enzyme 
activity[158]. The increased sensitivity was observed in cells with acquired resistance 
to P-gp substrates, such as etoposide, doxorubicin, colchicine, but also in cells 
transfected with the gene for P-gp or MRP1[153,157]. 
 
Increase oral bioavailability by increasing gut epithelial uptake  
A strategy that can benefit of P-gp inhibition is the increase of the oral bioavailability 
of drugs, particularly when a drug is a P-gp substrate and is efficiently being effluxed 
back to the gut leading to a low oral bioavailability. The oral administration of drugs 
has several advantages over intravenous formulation[159]. First of all, patients prefer 
oral chemotherapy over intravenous due to the ease of administration, avoiding the 
discomfort of injection and the related risk of infection[159,160]. Secondly, oral 
medication is cost saving for hospital and health insurance, since there is no need for 
hospitalization. Finally, oral administration of drugs enables metronomic therapy with 
the advantages of chronic exposure of the drugs to its targets and reducing dose-
related toxicities, such as the optimizing of anti-angiogenic efficacy of 
chemotherapeutic agents including paclitaxel and docetaxel[161,162]. Wild-type mice 
showed limited oral bioavailability of paclitaxel compared P-gp knockout mice[163]. 
Following this, multiple preclinical mice results have shown that inhibition of P-gp using 
inhibitors such as cyclosporine, PSC 833 or elacridar improved the oral treatment of 
paclitaxel in mice[164-166]. Therefore, clinical trials were started to explore the effect of 
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the oral administration of paclitaxel in combination with cyclosporine. Three phase ІІ 
trials have tested this combination in patients with NSCLC, advanced gastric cancer 
and breast cancer. These studies have shown promising results, but long-term oral 
use of cyclosporine might be complicated by immunosuppressive effects. Therefore, 
other inhibitors might replace cyclosporine such as elacridar (GF120918) or 
HM30181, respectively[167,168]. Being a P-gp substrate in addition to the encouraging 
results of oral paclitaxel, preclinical studies were also initiated with another taxane, 
namely docetaxel[169]. Different inhibitors were used such as OC144-093 (a P-gp-
inhibitor), cyclosporine (a dual inhibitor of P-gp and CYP3A4) and ritonavir (CYP3A4 
inhibitor), which have shown increased oral bioavailability of docetaxel[170]. In line with 
this observation, which indicates that CYP3A4 is the major determinant of the low oral 
bioavailability of docetaxel, it seems rational that future trials will continue with oral 
docetaxel in combination with ritonavir[167,170].  
Other studies have shown that P-gp restricts the oral bioavailability of the 
topoisomerase II inhibitor, etoposide, and that P-gp inhibition enhances its oral 
bioavailability[171]. The appropriate inhibitor and associated dosages (of both drug and 
inhibitor) still need to be determined to improve the therapeutic outcome with minimal 
toxicities, since P-gp influences the excretion of drugs in addition to its role in 
protecting of vital organs such as the brain, the fetus and the testes. Furthermore, 
attention needs to be paid to specific polymorphisms of P-gp that might impact the 
drug oral bioavailability.  
 
Monoclonal antibodies against P-gp  
Already in the 1986 Hamada and Tsuruo[172] developed two monoclonal antibodies 
against human P-gp in adriamycin-resistant myelogenous leukemia cells (MRK-16 
and MRK-17). Initially, these antibodies were intended to study the membrane 
changes in MDR cells, but later research demonstrated that MRK-16 was able to 
inhibit P-gp mediated efflux of vincristine and actinomycin D in vivo[172,173]. The addition 
of a P-gp inhibitor such as cyclosporine A to MRK-16 treatment, further sensitized 
MDR myelogenous leukemia cells to vincristine and doxorubicin[174,175]. This 
innovative approach with MRK-16 is currently being investigated again in phase I 
clinical trials[9].  
 
OVERCOMING MRP1 RESISTANCE  
MRP1 was identified as a drug transporter 15 years after P-gp, and therefore its role 
in MDR in human tumors has not been fully understood and fewer MRP1-specific 
inhibitors with sufficient potency and efficacy have been identified[176]. Several novel 
strategies that have been applied to P-gp are being tried on MRP1 overexpressing 
cells are listed on Table 3. Nanoparticle drug delivery systems have been also applied 
successfully to inhibit MRP1 mediated resistance[177,178]. For example, Wang et al.[177] 
used redox-responsive polymeric micelles with a disulfide bond that serves as a linker 
for delivery of paclitaxel as chemotherapeutic, and indomethacin, as chemosensitizer. 
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Also, siRNA delivery in porous silicon nanoparticles has shown to effectively 
downregulate MRP1 mRNA[178] yet more studies are needed, especially in vivo.  
As with P-gp, numerous TKIs have been also identified to modulate the efflux of 
MRP1. Cediranib (AZD217) is an orally administered potent small-molecule TKI that 
inhibits the vascular endothelial growth factor (VEGF) family of receptors (VEGFR 1-
3), platelet-derived growth factor receptor (PDGFR) and a stem cell factor receptor, c-
Kit[179]. A study by Tao et al.[180] showed that cediranib inhibited the ATPase activity of 
P-gp in a dose–dependent manner and it also reversed both P-gp and MRP1 
mediated MDR, suggesting that cediranib acts as dual inhibitor. Another TKI, 
vandetanib (ZD6474, Zactima), an inhibitor of VEGFR, epidermal growth factor 
receptor (EGFR) and rearranged during transfection (RET) tyrosine kinases[181], 
stimulated P-gp ATPase activity in a dose-dependent manner and reversed MDR in 
cancer cells by directly inhibiting the function of P-gp, MRP1 and ABCG2[181,182]. Other 
TKIs such as AG-1393 and EKI-785, have also been found to interact and inhibit P-
gp activity[183].  
 
Table 3: Novel approaches to MRP1 inhibition 
Type Name Remarks Cancer Type References 
MRP1 inhibitors Tariquidar, dofequidar, 
cyclosporin A, biricodar, 
CBT1 and derivatives of 
triazolonaphtalimide 
Triazolonaphtalimide is 
antiproliferative in MRP1 













micelles with a disulfide bond 
for delivery of paclitaxel and 
indomethacin. Porous silicon 





TKIs Alectinib, ibrutinib, 
neratinib, AG-1393, 
EKI-785, vandetinib 
Sensitized primary resistant 
cells and cell lines to 
chemotherapeutics by 





P-gp: P-glycoprotein; MRP1: multidrug resistance protein-1; TKI: tyrosine kinase inhibitor; AML: acute 
myeloid leukemia; ALL: acute lymphoid leukemia  
 
Among the three generations of P-gp inhibitors, there are inhibitors that also inhibit 
MRP1 and/or ABCG2. Examples of such inhibitors are cyclosporine A[26,184-187], 
biricodar (VX-710), dofequidar (MS-209), tariquidar and CBT-1. The novel 
triazolonaphtalimide derivatives have been reported to achieve an anti-proliferative 
effect in chemoresistant lung cancer cell lines via MRP1 downregulation without 
affecting P-gp function[188]. Some of these preclinical studies reached phase III clinical 
trials, for instance for dofequidar[189] and CBT-1 (NCT00437749). However, 
inadequate trial design and poor drug specificity might hamper proper assessments 
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of the full potential of these agents. Further investigation is warranted to assess the 
effect of these inhibitors on each targeted ABC transporter in clinical trials, to guide 
selection of the right population of patients to enhance the efficacy and minimize the 
toxicity.  
The scarcity of specific MRP1 inhibitors reflects the fact that there is still no clarity 
about the benefit of P-gp inhibition in the clinical practice, which retards research 
efforts to develop MRP1 inhibitors for clinical use[190]. However, the calcium channel 
blocker verapamil and its derivative NMeOHI2, in addition to the several non-steroidal 
anti-inflammatory drugs (e.g., indomethacin), have shown collateral sensitivity toward 
MRP1 overexpressing cells[191,192]. These agents were proposed to trigger apoptosis 
in cells overexpressing MRP1 via intracellular GSH depletion. Furthermore, through 
high-throughput screening and chemical modification studies, the tricyclic isoxazole 
derivatives were identified to exhibit high potency and specificity to MRP1 inhibition. 
Nevertheless, further studies are needed to address MRP1 inhibition specificity, 
toxicity and effectivity both in vivo and in vitro.  
The scarcity of specific MRP1 inhibitors reflects the fact that there is still no clarity 
about the benefit of P-gp inhibition in the clinical practice, which retards research 
efforts to develop MRP1 inhibitors for clinical use[190]. However, the calcium channel 
blocker verapamil and its derivative NMeOHI2, in addition to the several non-steroidal 
anti-inflammatory drugs (e.g., indomethacin), have shown collateral sensitivity toward 
MRP1 overexpressing cells[191,192]. These agents were proposed to trigger apoptosis 
in cells overexpressing MRP1 via intracellular GSH depletion. Furthermore, through 
high-throughput screening and chemical modification studies, the tricyclic isoxazole 
derivatives were identified to exhibit high potency and specificity to MRP1 inhibition. 
Nevertheless, further studies are needed to address MRP1 inhibition specificity, 
toxicity and effectivity both in vivo and in vitro.  
 
OVERCOMING ABCG2 RESISTANCE  
Ahmed-Belkacem et al.[193] divided ABCG2 inhibitors in four groups: (1) ABCG2-
specific inhibitors; (2) broad-spectrum inhibitors, including inhibitors that inhibit P-gp 
and/or MRP1; (3) TKIs; and (4) naturally occurring flavonoids and derivatives. 
 
ABCG2 inhibitors  
The mycotoxin fumitremorgin C (FTC) was identified as the first ABCG2 specific 
inhibitor, but its neurotoxic effect hampered its further clinical development[194,195]. This 
lead compound was the basis of a new non-toxic tetracyclic analogue of FTC, Ko143, 
which is a highly potent and specific inhibitor of ABCG2[195]. Ko143 increased 
topotecan plasma concentration 4-6-fold in Mdr1a/1b-/- mice. Pick et al.[196] identified 
a new class of specific ABCG2 inhibitors which were structurally related to tariquidar, 
but did not show potency toward P-gp and MRP1. In their research they presented 
evidence for 3 different binding sites on ABCG2, one occupied by the ABCG2 
substrate pheophorbide A (Pheo A), another by the TKI imatinib and a third by the two 
compounds that specifically inhibit ABCG2. Imatinib showed features of an allosteric 
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modulator by increasing the inhibitory effect of the inhibitor compounds. Another 
ABCG2 inhibitor lead compound, PZ-39, was reported by Peng et al.[197]. Interestingly, 
this compound had a dual mode of action; it could effectively inhibit ABCG2 function 
and markedly reduced the half-life of ABCG2 protein from approximately 54 to 5 h by 
accelerating its protein degradation via endocytosis and trafficking to lysosomes. The 
ABCG2 inhibitor specificity of these compounds was confirmed with respect to P-gp 
and MRP1, but not for other ABC transporters. 
Transcriptional down regulation using siRNA or miRNA are also areas of interest in 
ABCG2 inhibition. One study shows that combination of siRNA and PI3K/Akt signaling 
inhibition can reverse chemoresistance in mitoxantrone-resistant BCRP-
overexpressing cells lines[198] [Table 4]. Similarly, nanoparticle drug delivery using 
polyethyleneimine as a carrier for siRNA has been reported to down-regulate ABCG2 
and decrease the mitoxantrone IC(50) values by approximately 14-fold[86]. Other 
efforts to deliver ABCG2 and P-gp inhibitors with nanoparticles show complete 
reversal of resistance in ABCG2 positive MDR cells[199]. 
 
Table 4: Novel approaches to ABCG2 inhibition 




PZ-39, FTC derivatives, 
Ko- 143, imatinib, 
gefitinib  
Ko-143 is highly specific, PZ-






TKIs Imatinib, geftinib  By competitive inhibition, 
TKIs act as substrates at low 
concentrations and have 
inhibitor like properties at high 
concentrations 








Complete reversal of 






siRNA siRNA delivered by 
nanoparticles 
Polyethyleneimine as a 
carrier for siRNA inhibits 
ABCG2 and sensitizes cells 





328, miR -519, 520h, 
212, 181a, 487a and -
302 
Use of microRNA has 
revealed a more complex role 
of ABCG2 in drug resistance 






other cell lines 
[200-207] 
TKI: tyrosine kinase inhibitor; MDR: multidrug resistance; CML: chronic myeloid leukemia; NSCLC: non-
small cell lung cancer 
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There are several miRNA that have been identified in a wide range of cancer cells, as 
potential inhibitors of ABCG2 expression (such as miRNA-328, -hsa-miR-328, -519, -
520h, -212, -181a, 487a and miR-302[200-205]. The use of miRNA to interfere with 
transporter transcription confirmed the role of ABCG2 in drug resistance related 
signaling pathways. For example, it was seen that miR-132 enhanced cisplatin 
resistance in gastric cancer cells by targeting SIRT1 which regulates ABCG2 
expression by promoting the de-acetylation of the transcription factor CREB 
(SIRT1/CREB/ABCG2 pathway). Moreover, Kaplan-Meier survival analysis showed 
that low miR-132 is related to longer survival in chemo resistant gastric cancer[206]. 
Another example is Wnt/β-catenin-ABCG2 pathway, which is modulated by miR-
199a/b in colorectal cancer stem cells, and whose upregulation is related to cisplatin 
resistance[207].  
 
Dual inhibitors  
Some of the broad-spectrum inhibitors of P-gp, including elacridar, reserpine, 
cyclosporine A, tariquidar and PSC 833 also display ABCG2 inhibitory activity[10]. Such 
dual inhibitors will be effective in cases where both transporters participate in MDR 
and the cytotoxic drug is a substrate of both transporters. Conceivably, their inhibition 
will also increase the oral bioavailability of the drug, in addition to its penetration to the 
tumor site. However, since these two transporters are also expressed in sanctuary 
sites, caution for potential toxic side effects should be considered. Moreover, this 
awareness would also hold for cytotoxic drugs with a narrow therapeutic window, as 
minor elevations of drug exposure might lead to adverse reactions.  
 
TKIs as ABCG2 inhibitor or substrate  
Various TKIs are either a substrate, an inhibitor or both, for P-gp, MRP1 and 
ABCG2[168]. TKIs such as the BCR-ABL kinase inhibitors (imatinib, nilotinib and 
dasatinib), EGFRs kinase inhibitors (gefitinib, erlotinib, lapatinib) and others, show 
substrate-like properties at lower concentration and inhibitor-like properties at higher 
concentration via competitive inhibition of the transporters function[208]. In addition to 
the concentration dependent type of interaction, it has been proposed that exposure 
time to TKIs also plays a role[209]. Short exposure (≤ 24 h) to either gefitinib or 
vandetanib demonstrated a synergic interaction when SN-38, whereas prolonged 
exposure (5 days) showed a strong antagonism between gefitinib or vandetanib and 
SN-38. Gefitinib and EK-785 at a low concentration (0.1 to 1 µmol/L) significantly 
stimulated the ATPase activity, suggesting that these TKIs are transported substrates 
of ABCG2 whereas higher concentrations induced strong inhibition of ABCG2[210]. 
Different types of interactions and corresponding possible effects have been 
suggested by different research groups, which are demonstrated in a hypothetical 
model [Figure 2].  
Many combination therapies of TKIs with cytotoxic drugs have been performed (e.g., 
the combination of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients 
with colorectal cancer, the combination of imatinib and cytarabine in newly diagnosed 
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patients with chronic myeloid leukemia, and the combination of gemcitabine/cisplatin 
with gefitinib in NSCLC[95,211-214]. TKIs also interact with ABCG2 that can modify 
ADME-Tox profile of ABCG2 substrates. Gefitinib enhanced the oral bioavailability of 
irinotecan and topotecan, and increased their apparent bioavailability and decreased 
systemic clearance in mice[215,216]. Therefore, studies are needed that investigate the 
exact type of interactions between TKIs and cytotoxic drugs[95,208,209].  
 
Figure 2: Hypothetical model demonstrating the different possible interactions of TKIs with 
ABC transporters. (A) The competitive binding of TKI at the drug binding site and hereby 
preventing the binding of the drug and consequently its efflux; (B) the situation when TKI is 
not a substrate of ABC transporter, but it binds at the NBD or other site inducing allosteric 
modulation of the transporter which leads to its inhibition; (C) the case when the TKI behaves 
as a substrate at low concentration, where the “vacuum cleaner” model is applicable[119]. 
However, when the concentration increases at a given moment saturation takes place and 
TKIs penetrate into the cell and bind at the NBD and thereby inhibiting the transporter. ABC: 
ATP-binding cassette; TKI: tyrosine kinase inhibitor; NBD: nucleotide binding domain 
 
Inhibitors from natural sources  
ABCG2 inhibitors originating from natural products have been referred to as the fourth-
generation inhibitors. Originally, these compounds showed effects in cancer 
prevention[217], but later on they were found to exert sensitizing effects to 
chemotherapeutics. Among them are the flavonoids which are polyphenolic 
compounds found in foods and herbal products. Different flavonoids are potent 
modulators of ABC transporters: kaempferol, apigenin and myricetin are inhibitors of 
MRP1[218], kaempferide, quercetin, diosmin and glabridin are inhibitors of P-gp[219] and 
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silymarin, hesperetin and daidzein are inhibitors of ABCG2[220]. The bioflavonoids 
neochamaejasmin B (NCB)[221] and chamaechromone from the root of Stellera 
chamaejasme L. are able to inhibit the expression and activity of MRP1. Interestingly, 
chamaechromone is MRP1 specific, while NCB is a substrate for MRP1 and P-gp. 
Furthermore NCB and chamaechromone co-administration increased 
chamaechromone bioavailability substantially[166]. However, further investigation is 
needed to define optimal dose schedules of flavonoids capable of inducing ABC 
transporter inhibition[219]. Future studies would also have to take into account flavonoid 
pharmacokinetics, bioavailability and activity of flavonoid metabolites after ingestion, 
which would reduce active flavonoid plasma concentrations[222,223].  
 
CONCLUSION  
Efflux transporters of the ABC superfamily including P-gp, MRP1 and ABCG2 can 
confer MDR in cancer cells. Additionally, overexpression of these transporters in tumor 
tissues has been associated with poor therapy outcome of cancer patients. 
Conceptually, inhibition of these ABC transporters will increase drug accumulation and 
thereby overcome MDR. However, despite accumulating knowledge of ABC 
transporters and their complex interplay, clinical trials evaluating the effect of ABC 
transporter inhibitors did not fulfill their promises. In part, this has also been accounted 
for by poor patient selection criteria. The design of ABC transporter inhibition research 
would require several considerations. The choice for a specific inhibitor will increase 
the likelihood of undesirable side effects when the inhibitor targets multiple ABC 
transporters, although due to redundancy of ABC transporters, sanctuary sites might 
be spared from the toxic insults of the cytotoxic drug. When multiple ABC transporters 
are involved in provoking the MDR phenotype, broad-spectrum inhibitors should be 
preferred, but as a double-edged sword will also impact physiological functions of 
these ABC transporters. The evading strategy may serve an alternative for the ABC 
transporter inhibition dilemma. At this stage, however, the magic bullet that escapes 
each of the 15 ABC transporters implicated in cancer drug resistance has not been 
identified and current studies aim to identify those compounds evading the major ABC 
transporters P-gp, MRP1 and BCRP. Also, MDR evading strategies using 
encapsulation of drugs have potential downsides such as immune reactions. Lastly, 
concerning the exploiting strategy, those drugs which cause collateral sensitivity would 
promote selective targeting of MDR cells, but this concept has not yet been sufficiently 
explored in animal and clinical studies.  
Collectively, each of the MDR reversal strategies has its merits but did not translate in 
successful clinical application. Future directions should therefore be aimed at 
combining our current knowledge of clinically relevant ABC transporters in the field of 
molecular biology (including polymorphic variants), biochemistry, computational 
biology and sensitive detection and imaging techniques, which in conjunction with 
state of the art medicinal chemistry can generate new generation inhibitors for future 
MDR reversal studies. Such an integrated approach may also help to guide 
personalized therapy in cancer patients to achieve the most optimal treatment 
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Chemoresistance is an important factor in the treatment failure of childhood acute 
lymphoblastic leukemia (ALL). One underlying mechanism of chemoresistance 
involves (over)expression of ATP-dependent drug efflux transporters such as 
multidrug resistance protein 1-5 (MRP1-5) and breast cancer resistance protein 
(BCRP), which can extrude the important antileukemia drug methotrexate (MTX). 
Survival of childhood ALL critically depends on the leukemic blasts' capacity for 
intracellular retention of MTX and MTX-polyglutamates. 
This pilot study assessed whether expression of MRP1, MRP4, MRP5 and BCRP 
(real-time PCR) in primary childhood ALL blasts (n=23) correlated with ex vivo 
resistance to MTX (assayed by in situ thymidylate synthase inhibition assay (TSIA)), 
ex vivo accumulation of (radioactive) MTX polyglutamates, and patient survival. 
Results show that high MRP4 expression is correlated with ex vivo MTX resistance 
assayed by TSIA (P=0.01). Moreover, elevated MRP4 and BCRP expression 
correlated with lower accumulation of MTX-PGs (P= 0.004 and P= 0.03, respectively). 
Combined high expression of BCRP and MRP4 even further impacted reduced MTX-
PG accumulation (P= 0.02). Overall survival was lower (P logrank= 0.04) in children 
with ALL cells which featured a relatively high expression of both BCRP and MRP4 
transporters. These results underscore the impact of high drug efflux transporter 
expression, notably MRP4 and BCRP, in diminished MTX response in childhood ALL. 
 
Abbreviations 
Acute lymphoblastic leukemia (ALL), folylpolyglutamate synthetase (FPGS), multidrug 
resistance protein 1-5 (MRP1-5), breast cancer resistance protein (BCRP), 
methotrexate (MTX), methotrexate polyglutamates (MTX-PG), thymidylate synthase 
(TS), thymidylate synthase inhibition assay (TSIA), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). 
 
1. Introduction 
Acute lymphoblastic leukemia (ALL) is the most frequent type of childhood malignancy 
[1]. Current treatment protocols are successful in achieving 5 years overall survival 
rates of 83-94% [2]. However, approximately 20% of children with ALL will relapse and 
face a poor survival (30-50%) [3]. One important factor contributing to relapse is the 
onset of multi-drug resistance (MDR) [4] , mediated by the upregulation of specific 
drug efflux transporters of the ATP-binding cassette (ABC) transporter family [4-7]. 
Active extrusion of cytotoxins by ABC transporters results in lower intracellular 
concentration of chemotherapeutics and confers chemoresistance. 
Methotrexate (MTX) is the most widely used anchor drug for central nervous system 
prophylaxis and in the maintenance therapy for childhood ALL, but emergence of 
resistance to MTX remains an issue of concern for which several mechanisms have 
been hold accountable [8, 9]. With respect to ABC transporters, multidrug resistance 
protein 1-5 (MRP1-5, ABCC1-5) and breast cancer resistance protein (BCRP, 
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ABCG2) have been implicated in cellular extrusion of MTX, thus constituting a critical 
factor in the intracellular accumulation of MTX [10-14]. Intracellular accumulation of 
MTX and its active metabolites, i.e. MTX-polyglutamates (MTX-PGs), is crucial for 
treatment efficacy in leukemia, as it correlates with event-free survival (EFS) [15-19]. 
Upon intracellular entry of MTX via the reduced folate carrier (RFC), MTX is 
metabolized into PG forms via the enzyme folylpolyglutamate synthetase (FPGS) 
which adds 2-6 glutamate residues to the γ-carboxyl group of MTX [20]. 
These polyanionic active metabolites are prevented from efflux by ABC transporters 
[10-14] although BCRP has the ability to extrude short chain polyglutamates (up to 
MTX-PG3) [11, 21]. Ex vivo assessments of MTX sensitivity in primary leukemia 
samples by commonly used MTT-based cell growth inhibition assays have been 
hampered by the release of nucleosides from dying cells which rescue leukemic cells 
from the effects of MTX [22, 23]. To this end, alternative methods based on in 
situ inhibition of TS by MTX-(PGs) have proved useful to distinguish variable MTX 
sensitivity profiles in primary leukemia samples [23-25]. By examining short-term (3 
hrs) versus long-term (21 hrs) MTX drug exposure periods, the in situ TS inhibition 
assay (TSIA) provides insights in the kinetics and dynamics of MTX-PG formation 
reflected by the capacity to inhibit TS [24, 26], which can be complemented with actual 
analysis of MTX-PG levels [16, 19, 23]. 
In the present pilot-study, we explored the association between the ex vivo MTX drug 
sensitivity by TSIA, gene expression of ABC transporters MRP1, 4, 5 and BCRP, and 
intracellular MTX-PG accumulation with survival in a small cohort of newly diagnosed 
childhood ALL patients.  
 
2. Materials & Methods: 
2.1 Reagents: 
RNAzol was purchased from Campro Scientific (Veenendaal, The Netherlands); for 
reverse transcriptase, Moloney murine leukemia virus reverse transcriptase (M-MLV-
RT) and RNase inhibitor were obtained from Promega (Madison, WI, USA). 
Deoxyribonucleotides (dNTPs), random hexamers and Taq polymerase (5 IU/µl) were 
obtained from Pharmacia Biotech (Roosendaal, The Netherlands). RESponse 
Research agarose was purchased from Biozym (Landgraaf, The Netherlands). [3,5,7-
[3H]-MTX (20 Ci/mmol) was obtained from Moravek Biochemicals (Brea, CA, USA). 
 
2.2 Patient samples: 
Diagnostic samples were collected from children with B-cell precursor ALL (n=17) and 
T cell-ALL (n=6) after obtaining informed consent. Patients were enrolled in ALL-8 and 
ALL-9 study protocols [16], coordinated by the Dutch Childhood Oncology Group. 
Induction and consolidation regimes with MTX were comparable among the different 
treatment groups. A detailed description of MTX drug schedules and doses has been 
reported elsewhere [27]. A description of the patient demographics is presented in 
Table 1. Because the various assays required relatively large amounts of cells, sample 
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selection was based on availability white blood cell (WBC) concentration in primary 
diagnostic bone marrow (BM) or peripheral blood (PB) from patients. 
Mononuclear cells were isolated through Ficoll-Paque density gradient centrifugation, 
following manufacturer’s recommendations, within 24 h after collection essentially as 
described by Rots et al [23]. Samples with <80% leukemic cells were enriched for 
blasts by removing non-leukemic cells using magnetic bead bound monoclonal 
antibodies (Dynabeads M-450; Dynal Inc, Oslo, Norway) as described elsewhere [28]. 
Samples were washed twice with RPMI-1640 medium +2% fetal calf serum (FCS) and 
resuspended in culture medium consisting of RPMI-1640 (Dutch modification; GIBCO, 
Uxbridge, UK) supplemented with 20% FCS and antibiotics (all obtained from Flow 
Laboratories, Irvine, UK). For RNA isolation, 5 x 106 cells were lyzed in 1 mL RNAzol 
and stored at -80°C. 
 
Table 1: Patient Characteristics 
 B-cell precursor T-cell ALL Total cases 
Sample size 18 5 23 
Median age (years) 6.1 (0-14) 6.4 (1-11) 6.1 
Sex (male/female) 11/7 3/2 14/9 
Treatment Protocol:    
ALL 8, 9 10 4 14 
Other 3 1 4 
N/A 5  5 
Relapse rate 8 (44%) 2 (40%) 1 (43%) 
Complete remission 10 (56%) 2 (40%) 12 (52%) 
 
2.3 mRNA Extraction and Real Time-PCR:  
For RNA extraction procedure and Real Time-PCR methods, please be referred to the 
supplementary material section.  
 
2.4 Ex vivo drug sensitivity: 
 Sensitivity of primary leukemia cells was assessed ex vivo by the in situ TSIA which 
measures the amount of tritiated water (3H2O) released from the conversion of [5-3H]-
2’-deoxycytidine to [5-3H]-2’-deoxyuridine monophosphate (3H-dUMP) to 
deoxythymidine monophosphate (dTMP) in the reaction catalyzed by TS. MTX, and 
in particular its polyglutamate forms, can effectively inhibit dTMP synthesis and thus 
block the release of tritiated water from [5-3H]-2’-deoxycytidine. The TSIA has been 
used previously as a validated tool for ex vivo assessment of (inhibition of) intracellular 
Ex vivo resistance in childhood acute lymphoblastic leukemia: correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter 
expression and intracellular methotrexate polyglutamate accumulation 
 91 
TS activity in primary cells and cell lines [24-26]. Moreover, TSIA enabled generation 
of dose-response curves and detected differential MTX sensitivity patterns in T-cell 
versus common/pre-B cell ALL patient-derived cells, in accordance to clinical 
observation in patients [23, 29]. To examine the impact of MTX-polyglutamylation, 
leukemic blast cells were exposed to MTX short-term, i.e. 3 hours followed by an 18 
hours drug-free period, or continuously for 21 hours, after which drug sensitivity was 
evaluated by calculation of the concentration of the drug needed to inhibit 50% of the 
TS activity, depicted as TSI50,short and TSI50,cont, respectively [23]. 
 
2.5 MTX accumulation and polyglutamylation analysis. 
For this analysis 107 cells in 10 ml RPMI-1640 medium supplemented with 10% FCS 
were incubated for 24 hours at 37oC with 1 µM [3H]-MTX (2 Ci/mmol). After this period, 
cells were washed three times with 10 mL of ice-cold phosphate-buffered saline (PBS) 
and after cell counting and determining total accumulated [3H]-MTX, analysis of 
intracellular distribution of [3H]-MTX-PGs was performed by high-performance liquid 
chromatography (HPLC) coupled to a radioactivity detector, as described elsewhere 
[16, 23]. 
 
2.6 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
For assessment of drug sensitivity of drugs other than MTX, the MTT colorimetric 
assay was performed on cells suspended in 96-well round bottom plates at a 
concentration of 2 x 106 cells/ml in RPMI-1640 cell culture medium containing 20% 
FCS, 200 µg/ml of gentamycin, 2 mM glutamine, and 0.5ml ITS (insulin: 5µg/ml, 
transferrin: 5µg/ml, sodium selenite: 5ng/ml) [22]. Treatment wells contained 80 µl of 
cell suspension and 20 µl of the drugs of interest (concentration ranges are indicated 
in supplementary Table A.1). Control wells contained 20 µl of RPMI-1640 medium and 
80 µl of cell suspension, while blank controls had 100 µl of RPMI-1640 medium. MTT 
assay was performed in duplicates and plates were incubated at 37°C, in a humidified 
5% CO2 incubator for 4 days. At the end of the incubation period, 10 µl of MTT dye (5 
mg/ml) was added to the each well and placed in the 37oC incubator for an additional 
6 hours, followed by the addition of 100 µl isopropanol. After 5 minutes, plates the 
microplate optical density (OD) was measured at 562 nm. For the analysis, the 
average OD of the blank wells is subtracted from the average OD of the control wells 
or the treatment wells. The lethal concentration 50 (LC50) was then determined by 
calculating cell survival with the following equation [22]: mean OD treatment well 
(minus blank)/mean OD control well (minus blank) x100. 
 
2.7 Statistical analysis 
The Mann-Whitney U test was used to analyze differences in the subtypes of 
childhood ALL (common/B-cell ALL vs. T-ALL, diagnosis vs. remission). The 
Spearman rank correlation test was used to determine associations between mRNA 
expression (of MPR1, MPR4, MRP5 and BCRP) with ex vivo sensitivity, and to detect 
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correlations between the mRNA expression-drug sensitivity ratios. Significance level 
was set at two-sided P value of <0.05. For survival analysis, patients were classified 
as therapy responders when complete remission (CR) was achieved. The time 
between the initial treatment date until the end point (death or censoring) was 
considered as the overall survival (OS). Kaplan-Meier analysis was used to plot OS, 
and the log-rank test to compare differences between survival curves. Statistical 
calculation was performed with SPSS software (SPSS, Inc., IL, USA) and GraphPad 
Prism version 7.0 for Windows (GraphPad Software, CA, USA). 
 
3. Results 
3.1 Patient samples 
Patients were enrolled in several treatment protocols which are listed in Table 1 along 
with the outcome data, remission rate and relapse rate. Due to logistic reasons and 
leukemic blast number limitations, not all of the MTX-related parameters could be 
measured and therefore the number of cases included in the statistical analysis varied 
between parameters (as listed in the various tables). 
  
3.2 ABC transporter expression in childhood leukemia: 
Notwithstanding inter-patient variabilities, mean ABC transporter (MRP1, MRP4, 
MRP5 and BCRP) expression values did not vary significantly amongst childhood 
precursor-B cell (n= 18) and T-cell (n= 5) ALL samples. These expressions were also 
not different between relapsing (n= 10) and non-relapsing patients (n= 11), regardless 
of ALL subtypes (Figure 1A and 1B). Due to the limited cytogenetic/molecular data 
available, further risk stratification could not be performed in relation to ABC 
transporter expression. Spearman rank analysis was performed to detect a pattern of 
correlated expression amongst ABC transporters in all leukemia samples (n=23). 
Significant correlations were found between BCRP and MRP1 expression (R = 
0.44; P = 0.035), BCRP/MRP4 (R = 0.53; P = 0.009), BCRP/MRP5 (R= 0.42; P = 
0.047) and MRP5/MRP1 (R=0.51 P = 0.013). Based on these observations, we 
analyzed the intracellular MTX-PG accumulation, ex vivo MTX resistance, and 
survival of patients with a combination of high or low expression of drug efflux 
transporters.  
 
3.3 Association of intracellular accumulation of MTX polyglutamates and ABC 
transporter expression ex vivo. 
To examine the impact of ABC transporter expression on ex vivo MTX-PG 
accumulation in the cohort of ALL patients (n= 20), we quantified the intracellular 
accumulation of total MTX-PGs (1–6 glutamate residues) and long-chain MTX-PGs 
(4–6 glutamate residues) after 24-hour exposure to 1 µM [3H]-MTX (Figure 2 and 
supplementary Table A2 and A3). High BCRP and MRP4 expression correlated with 
significantly lower accumulation of total MTX-PGs (MTX-Glu1-6) (P= 0.027 and 0.004, 
respectively, Supplementary Table A.2). Significantly lower accumulation of long chain 
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MTX-PGs (MTX-Glu4-6) correlated with higher MRP4 expression (P= 0.003) and 
trended with higher BCRP expression (P= 0.064, supplementary Table A.3). 
Spearman rank correlation analysis revealed that BCRP and MRP4 mRNA expression 
significantly inversely correlated with total MTX-PGs (P = 0.04 and 0.02, respectively) 
(Table 2). In addition, high MRP4 expression was significantly associated with lower 
intracellular concentration of long-chain MTX-PGs (P = 0.01, Table 2). From all 
combined correlation analysis, the most significant effect in total and long-chain MTX-
PG accumulation was seen with the MRP4 high /BCRP high group (P= 0.005). These 
results concord with previous published results that confirm correlations between 
transporter mRNA and its correspondent protein levels[30, 31]. 
 
Fig. 1. (A): mRNA expression levels (relative to β-actin) of BCRP, MRP1, MRP4 and MRP5 
in common/pre-B cell (closed symbols) and T-cell childhood leukemia cells (open symbols). 
(B): mRNA expression levels (relative to β-actin) of BCRP, MRP1, MRP4 and MRP5 in 
patients who underwent relapse (open symbols) compared to patients who remained in 
complete remission (CR) during treatment (closed symbols). Each symbol represents an 
individual patient. Data is depicted as mean ± standard deviation. The median mRNA 
expression level for ABC transporters relative to the mRNA expression of β-actin was used 
as cut-off point [BCRP (0.04), MRP1 (0.38), MRP4 (0.04) and MRP5 (0.14)] to differentiate 
between high and low expression of ABC transporters. Mann Whitney U test was performed 
to analyze differences between means. 
 
 
Fig. 2. (A): Total MTX-PG accumulation and (B) long-chain MTX-PG accumulation in 
childhood ALL samples with high (black bars) or low (white bars) expression of BCRP, 
MRP1, MRP4 and MRP5 ABC transporters. Data are depicted as mean ± standard deviation 




Table 2: Correlation between MTX-PG accumulation and BCRP and MRP4 expression. 
(n = 20) Total MTX-PG LC MTX-PG 
BCRP -0.5; P = 0.04* -0.4; P = 0.1 
MRP4 -0.5; P = 0.02* -0.6; P = 0.01* 
P- value (P), total (total MTX-PG) and long-chain methotrexate polyglutamates (LC MTX-
PG). *= statistically significant (Spearman’s correlation coefficient). 
 
3.4 ABC transporter expression and cellular MTX sensitivity ex vivo  
The TSIA has previously served as a suitable method to generate MTX-dose response 
curves in intact primary leukemia cells. TSIA data available from a former study were 
used here to correlate MTX sensitivity to ABC transporter expression in childhood ALL 
specimens [23]. The short-term, 3-hour MTX exposure (TSI50,short) and the continuous 
21-hour exposure (TSI50,cont) are representative of the leukemic cells’ capacity to efflux 
and to accumulate MTX, respectively. These parameters can be used as indirect 
indicators of the polyglutamylation capacity of leukemic cells and reliably reflect MTX 
sensitivity ex vivo, as shown previously [23]. 
Mann-Whitney U analysis between high and low expression of drug efflux transporters 
MRP1, MRP4, MRP5 and BCRP showed that high MRP4 expression is significantly 
related to diminished MTX sensitivity in both TSI50,cont (P = 0.01) and TSI50,short (P = 
0.05). Notably, an elevated BCRP expression was not significantly related to MTX 
efflux (P = 0.08) but was related to MTX accumulation, as shown by the 
TSI50,cont exposure (P = 0.01, Figure 3A and 3B).  
Next, the impact on MTX resistance was evaluated in relation to all possible paired 
combinations of ABC transporter expression values. In these analyses, higher 
LC50 values (i.e. increased resistance) were observed in TSI50,cont (P = 0.02) and 
TSI50,short (P = 0.03) in leukemia samples with BCRP-high/MRP4-high expression 
when compared with BCRP-low/MRP4-low cells (Figure 3C and 3D). 
 
3.5 Relation between ABC-transporter expression and the sensitivity to other 
chemotherapeutics 
The sensitivity of cells for anti-leukemic drugs other than MTX was measured using 
MTT analysis. Remarkably, the strong relation between MRP4 and BCRP expression 
and sensitivity to MTX was not as pronounced for the other anti-leukemic drugs (Table 
3). Increased MRP1 expression showed a significant relationship to resistance to 
numerous drugs, such as mitoxantrone (P = 0.026), doxorubicin (P= 0.002), vincristine 
(P= < 0.001 ), daunorubicin (P=< 0.001), teniposide (P= 0.001), thiotepa (P= 0.033) 
and cladribine (P= 0.049). MRP4 expression only showed a significant relationship to 
cladribine resistance (P= 0.049), while MRP5 expression was related to thiotepa 
resistance (P= 0.033) and showed a tendency to teniposide resistance (P= 0.052). 
BCRP expression was not related to drug sensitivity in the MTT assay (Table 3).  
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Fig. 3. MTX sensitivity and ABC transporter expression in childhood ALL samples as 
represented by the (A) short term (3 h) MTX exposure and (B) continuous (21 h) MTX 
exposure in the TSIA assay. ABC transporters expression is divided in patient groups with 
either high (black bars) or low (white bars) expression. TSIA results are represented as TSI50 
concentration, the concentration of MTX needed to inhibit 50% of thymidylate synthase (TS) 
activity. (C) TSI50 values following the short-term (3-hr) exposure to MTX and (D) continuous 
(21 h) MTX exposure for patients with MRP4/BCRP double high (++), high/low (+ -) low/high 
(- +) and low/low (- -) expression. Data are depicted as mean ± SD and expressed as μmol/L. 
Mann Whitney U test was performed to analyze differences between means. 
 
 
3.6 ABC transporter expression and survival 
Despite the small sample number, the influence of ABC transporter expression on 
survival was examined by Kaplan Meier analysis. A relatively poor outcome was 
observed for patients with elevated BCRP expression compared to low expression, 
which did not reach statistical significance (Plogrank= 0.30; Figure 4A). Notably, the 
combined expression of BCRP high/MRP4 high had a negative impact on OS (Plogrank 
= 0.04; Figure 4B) compared with the rest of BCRP/MRP4 combinations together. Due 
to the relatively small number of samples and the fact that treatment regimens were 
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4. Discussion 
This study shows that ABC drug efflux transporters MRP4/BCRP contribute to MTX 
accumulation and polyglutamylation, and the clinical outcome data suggest an 
association with response to treatment including MTX in pediatric ALL patients.  
Intracellular accumulation of MTX and its conversion to MTX-PGs is well recognized 
as a predictive factor for response and favorable outcome in childhood leukemia [15-
19]. Consequently, deficient MTX-polyglutamylation due to loss of FPGS activity has 
been associated with MTX resistance [16, 20, 32-34] as non-polyglutamated MTX is 
prone to be extruded from cells by several family members of the ABC, including 
MRP1-5 [12-14] and BCRP [10, 11, 21], rather than by P-gp which effluxes primarily 
non-hydrophilic substrates [10, 14]. To fully unravel the role of MTX polyglutamylation 
in ex vivo assessments of MTX sensitivity in leukemic specimens, short incubation 
periods (e.g. 3 hrs) are more informative than extended (72-96 hrs) incubation periods 
[23-25, 29]. Moreover, ex vivo testing of leukemia specimens for MTX sensitivity is 
hampered by the release of nucleosides and bases from dying cells which rescue the 
cytotoxic effect of MTX [23]. In the present study, these considerations and limitations 
were met by applying the in situ TSIA for MTX in a time and MTX-PG dependent 
manner. Additional analysis of RNA expression levels of MRP1, MRP4, MRP5 and 
BCRP mRNA levels, and analysis of (long-chain) MTX-PG accumulation, and 




Fig. 4. (A): Kaplan-Meier analysis of BCRP high (dashed line) and BCRP low (continuous 
line) expression and overall survival (OS) in childhood ALL. (B): Kaplan-Meier analysis of 
the combined expression of MRP4/BCRP and OS in childhood ALL. MRP4/BCRP survival 
curves are labeled with the mean OS estimate (in months), the percentage of censored 
patients and the number of patients in each subgroup. The continuous line in Fig. 4B 
represents the Kaplan-Meier OS curve of patients with low/high, high/low, low/ low 
combinations of MRP4 and BCRP expression, the dashed line represents the MRP4 
high/BCRP high group of patients. Statistical evaluation is expressed as P-values analyzed 
by logrank test. 
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A considerable inter-patient variability of MRP1, MRP4, MRP5 and BCRP mRNA 
expression levels was observed in childhood ALL samples (Figure 1A), being 
consistent with previously reported data [31, 35-39]. In normal peripheral blood 
lymphocytes, MRP4 and BCRP expression is rather low as compared to other drug 
efflux transporters [40, 41]. Elevated expression levels of MRPs and BCRP in 
leukemia cells have been reported of clinical relevance and associated with worsened 
prognosis and relapse of treatment [38, 39, 42-44]. However, various studies 
employing 3-4 days MTT-based drug testing did not reveal significant correlations with 
MRPs and BCRP expression levels in childhood ALL cells and in vitro drug resistance 
to drugs being bona fide substrates for MRPs and BCRP [37, 42, 45, 46]. Of note, 
these drug testing studies did not include MTX. In the current study we show that 
MRP1 expression in childhood ALL cells was associated with in MTT-in vitro drug 
resistance to known MRP1 substrates doxorubicin, daunorubicin, vincristine and 
mitoxantrone, but not for drugs being substrates for BCRP [7] and MRP4/5 (e.g. 
thiopurines and cytarabine) [13, 47]. The latter may be explained by the fact that in 
long term drug testing conditions these prodrugs are converted to their phosphorylated 
metabolites which are not effluxed by MRP4/5. Previous studies reported monitoring 
of intracellular accumulation of daunorubicin [48], Ara-CTP [47] and thioguanine 
nucleotides [49], but sample size limitations in the present study did not allow us to 
assess intracellular accumulations of drugs other than MTX.  
Many in vitro cell lines studies underscored that overexpression of MRP1-5 and BCRP 
confers MTX resistance after short term drug exposure during which time MTX has 
not been sufficiently converted to long chain polyglutamates which lack substrate 
affinity for MRPs and BCRP [11, 21]. Additionally, decreased RFC mediated MTX 
uptake or diminished FPGS activity can impact to reduced polyglutamylation, 
facilitating extrusion of non-polyglutamated MTX by MRPs and even short chain MTX-
PGs by BCRP [10]. The current study is the first to corroborate that lowered ex vivo 
accumulation of MTX-PGs in childhood ALL cells is significantly correlated with 
increased expression of MRP4 and BCRP, and in vitro MTX drug resistance 
determined by TSIA. Moreover, combined MRP4high/BCRPhigh expression in childhood 
ALL samples proved to be a good indicator of worsened clinical outcome as compared 
to patients with MRP4low/BCRPlow expression. Earlier studies by Bartholomae et al. 
[50] also showed that in childhood AML dual high expression of BCRP and MRP3 was 
strongly associated with therapy response, underscoring the impact of coexpression 
of multiple MDR transporters in drug resistance. Although this study investigated 
multiple parameters contributing to MTX resistance, one limitation is its small sample 
size. Confirmatory studies with greater number of patients are warranted and should 
include transporter protein detection (e.g. with flow cytometry), follow-up at different 
time points and cytogenetic/molecular phenotypes. Suggested additional analysis 
may include polymorphic variants of BCRP and MRP4, which impact their functional 
activity and were implicated in unfavorable clinical outcome [51-55]. Interestingly for 
MRP4, a specific polymorphic variant was associated with aberrant splicing of MRP4 
pre-mRNA [54] and thus expression. Consistently, recent studies by Wojtuszkiewicz 
et al [19, 53] identified aberrant pre-mRNA splicing of FPGS in childhood ALL as a 
molecular basis of reduced FPGS activity and consequently diminished MTX-
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polyglutamylation. Altogether, a combined approach of selected ABC transporter gene 
expression analysis, assessment of aberrant FPGS pre-mRNA splicing, MTX-PG 
analysis and TSIA-based MTX drug sensitivity monitoring could guide a more 
personalized medicine of MTX in childhood ALL patients. 
 
5. Conclusions 
The thymidylate synthase inhibition assay (TSIA) proved a valuable tool to screen for 
MTX drug resistance in primary childhood ALL cells. ABC transporters BCRP and 
MRP4 were identified as determinants associated with reduced MTX accumulation 
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Cellular uptake of clinically important deoxynucleoside analogs is mediated by 
nucleoside transporters including the human equilibrative nucleoside transporter 1 
(hENT1) and the concentrative nucleoside transporter-1 (hCNT1). These transporters 
are responsible for influx of cytarabine and reduced hENT1 expression is a major 
resistance mechanism in acute myeloid leukemia. We determined hENT1 and hCNT1 
protein expression by immunocytochemistry in 50 diagnostic paediatric acute myeloid 
leukemia patient samples. All samples expressed hENT1 [9/43 (21%) low; 26/43 
(60%) medium and 8/43 (19%) high] and hCNT1 [2/42 (5%) low; 35/42 (83%) medium 
and 5/42 (12%) high] at the cell membrane and cytoplasm. Statistical analysis showed 
a non-significant relationship between survival and transporter expression and in vitro 
drug sensitivity. In conclusion, the nucleoside transporters hENT1 and hCNT1 are 
broadly expressed in pediatric acute myeloid leukemia at diagnosis. 
 
Keywords: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), 
human equilibrative nucleoside transporter-1 (hENT1), human concentrative 




The human equilibrative nucleoside transporter 1 (hENT1; or SLC29A1) and 
concentrative nucleoside transporter-1 (hCNT1; SLC28A) are transmembrane proteins 
involved in nucleoside homeostasis and cellular uptake of deoxynucleoside analogs 
(NAs) by facilitated diffusion or concentrative uptake1-4. In leukemic cells, hENT1 is 
responsible for the uptake of around eighty-percent of cytarabine (Ara-C), a 
cornerstone NA in the treatment of acute myeloid leukemia (AML) 1, 5-7. In contrast, 
gemcitabine, which is used extensively for the treatment of solid tumors, is transported 
into the cell by both hCNT1 and hENT14, 8, 9  
Nucleoside transporters play a role in NA cytotoxicity and chemoresistance. Recent 
Cox regression analysis of AML patients (n=28) showed that patients with high or 
baseline hENT1 expression prior to treatment, had a 50% longer median OS 
(p=0.012) suggesting that hENT1 expression profiling might be of clinical 
importance10. Other studies show inconclusive results, for example, a survival study 
reported that hENT1 expression did not significantly contribute to Ara-C resistance in 
acute lymphoblastic leukemia (ALL) patients older than 15 years of age and analysis 
of 79 B-cell precursor ALL cell lines found no correlation between hENT1 gene 
expression and Ara-C resistance. Unexpectedly, higher hENT1 expression was seen 
in cell lines with Ara-C resistance, when compared with cell lines with low 
expression11,12.Apparently other parameters also play a role in Ara-C resistance.  
However, hENT1 mRNA levels in pediatric and adult AML samples are related to 
resistance and outcome, suggesting that low transporter expression is a relevant 
mechanism of Ara-C resistance13-15. Micro-array studies performed on Ara-C resistant 
human ALL cells demonstrated that a decrease in hENT1 expression was linked to 
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lower Ara-C activity and decreased intracellular drug metabolism16. Reconstitution of 
the hENT1 gene by transfection reversed Ara-C resistance 600-fold in human lymphoid 
H9 cells17. It has been shown that indirect modulation of hENT1 from the cell 
membrane of leukemic cells resulted in a significant decrease in nucleoside 
transporter activity and increased Ara-C resistance in AML cells in vitro18. Reversal of 
resistance due to decreased transporter activity has been attempted by bypassing the 
transporter, e.g. by lipophilic pro-drugs19. 
In addition, elevated hENT1 mRNA, which has been reported previously in infants with 
MLL gene-rearranged ALL (ALL-MLL+) explained the remarkable Ara-C sensitivity in 
this patient population20,21. It is plausible that elevated levels of transporter lead to 
increased Ara-C influx across the cellular membrane, resulting in increased 
intracellular drug accumulation and enhanced cytotoxicity22. Furthermore, in pediatric 
ALL-MLL+ indirect modulation of hENT1 expression affects significantly Ara-C 
cytotoxicity in pediatric AML in vitro21. Interestingly, certain genetic variants of hENT1, 
which may magnify genetic expression, are also associated with treatment outcome 
in AML2, 23, 24.  
The aim of our present study was to relate the immunohistochemical detection of 
protein expression of hENT1 and the pyrimidine-preferring hCNT1 transporter, and ex 
vivo sensitivity to nucleoside analogs.  
 
2. Materials and Methods 
2.1 Patient material. 
Bone marrow or peripheral blood samples were collected from 50 untreated children 
diagnosed with de novo AML. The patient population consisted of 32 boys and 18 girls 
with a median age of 10.7 years (range 0.1-16.8 years). The median white blood cell 
count (WBC) was 83.8 (range 2.1-524 x 106 /ml) and all FAB-types were represented 
(2 FAB-M0; 5 FAB-M1; 8 FAB-M2, 4 FAB-M3, 18 FAB-M4, 10 FAB-M5, 1 RAEB and 
2 unknown). A summary of treatment protocols for these patients (DCOG AML 87, 97, 
all including Ara-C) is given elsewhere15. 
 
2.2 Cell isolation and immunocytochemistry staining 
Mononuclear cells were separated by density gradient centrifugation (Lymphoprep, 
density 1.077 g/ml; Nycomed Pharma, Oslo, Norway) and where necessary the 
percentage of malignant cells was enriched as described previously25. All samples 
contained >80% blasts as determined morphologically by May-Grünwald-Giemsa 
staining. Immunocytochemical staining was performed on (cryo-preserved) cytospins 
standard alkaline phosphatase/anti-alkaline phosphatase (APAAP) method. Cells 
were fixed with acetone (10 minutes at room temperature). Slides were washed with 
Phosphate-buffered saline (PBS) twice, for 5 minutes) and incubated overnight with 
the primary antibodies, rabbit-anti human hENT1 and hCNT1 diluted 1:100 and 1:150, 
respectively, in PBS with 1% bovine serum albumin (BSA) and 0.1% Na-azide as 
described elsewhere21, 26. The following day, slides were washed (2x 5 minutes in 
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PBS) and incubated with the secondary antibody, biotinylated swine-anti-rabbit (Dako, 
Glostrup, Denmark) diluted 1:300 in PBS with 1% BSA and 0.1% Na-azide for one 
hour. After the wash steps, slides were incubated with the alkaline-phosphatase 
conjugated streptavidine (1:100 in PBS with 1% BSA and 0.1% Na-azide) for 30 
minutes (Dako, Glostrup, Denmark). Visualization of AP was performed by incubation 
in New Fuchsin/naphtol ASBI phosphate solution supplemented with levamisole. Cells 
were counterstained with using Mayer’s Hematoxylin Solution (Merck, Darmstadt, 
Germany) and embedded in Aquamount. hENT1 and hCNT1 protein expression was 
evaluated by two independent investigators by scoring the intensity of the staining as 
either low, medium or high. When compared to positive controls, “low” or weak staining 
was defined as less than one third of the intensity (<0.3) and “high” staining was 
defined as the upper fifth of the intensity (>0.8) and medium staining was in between 
these two intensities 26. 
 
2.3 MTT assay 
For assessment of drug sensitivity, the MTT colorimetric assay was performed on cells 
suspended in 96-well round bottom plates at a concentration of 2 x 106 cells/ml in 
RPMI-1640 cell culture medium containing 20% fetal calf serum (FCS), 200 µg/ml of 
gentamycin, 2 mM glutamine, and 0.5 ml ITS (insulin 5 µg/ml, transferrin 5 µg/ml, 
sodium selenite 5 ng/ml27. Treatment wells contained 80 µl of cell suspension and 20 
µl of the drugs of interest at different concentrations (refer to supplementary table A.4 
for concentrations). Control wells contained 20 µl of RPMI-1640 medium and 80 µl of 
cell suspension, while blank controls had 100 µl of RPMI-1640 medium. MTT was 
performed in duplicates and plates were incubated at 37°C, in a humidified 5% CO2 
incubator for 4 days. At the end of the incubation period, 10 µl of MTT dye (5 mg/ml) 
was added to each well and placed in the 37oC incubator for an additional 6 hours, 
followed by the addition of 100 µl isopropanol. After 5 minutes, the optical density (OD) 
was measured at 562 nm. For the analysis, the average OD of the blank wells is 
subtracted from the average OD of the control wells or the treatment wells. The lethal 
dose 50 (LC50) was then determined by calculating cell survival with the following 
equation: mean OD treatment well (minus blank)/ mean OD control well (minus blank) 
x100, as described elsewhere27. 
 
2.4 mRNA Extraction 
Total mRNA from these primary pediatric AML cells was extracted previously15 using 
the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s 
instructions and reverse transcribed to cDNA using random hexamers as described 
elsewhere15. For measurement of hENT1 and hCNT1 mRNA expression probes and 
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2.5 Statistical analysis 
Statistical analysis was done using SPSS Version 24.0 (IBM Corp., Armonk, NY, US) 
software. Overall Survival (OS) analysis was evaluated by constructing Kaplan-Meier 
curves. For comparisons between means we used Student’s t test and Spearman’s 
Rho for non-parametric correlations (hENT protein level and outcome). In order to 
evaluate any significant differences between categorical sets of data (FAB types and 
immunohistochemistry intensity scores) we used Pearson Chi-square test. 
 
3. Results 
HL60 consistently stained positive for both hENT1 and hCNT1 in the cytoplasm 
(Figure 1A, B, and C). Negative controls were performed by omitting the first antibody 
and did not have a staining (Figure 1A). Seven samples were non-evaluable due to 
poor morphology and one sample was lost during the procedure. hENT1 and hCNT1 
were localized at the membrane and in the cytoplasm in all AML patient samples 
(Figure 1 D, E, F, G). There was a relatively uniform staining within one patient, while 
there was no significant difference between samples obtained from peripheral blood 
or bone marrow. hENT1 staining intensity was low in 9/43 (21%) samples, medium in 
26/43 (60%) samples and high in 8/43 (19%) samples, and appeared to be slightly 
granular. hCNT1 staining intensity was low in 2/42 (5%) samples, medium in 35/42 
(83%) samples and high in 5/42 (12%) samples (Figure 2A, 2B and Table 2). In 8/42 
(19%) AML patient samples hCNT1 was located predominantly at the cellular 
membrane. hENT1 and hCNT1 expression were not associated with age or WBC at 
diagnosis. Both hENT1 and hCNT1 expression appeared to be higher in (myelo) 
monocytic (FAB M4/5) AML blasts compared to poorly differentiated/ myeloblastic 
(FAB M0-3) AML blasts (Table 1) but there was no significant difference (Pearson Chi-
square= 10.8, P= 0.37). There was no correlation between mRNA expression and 
immunocytochemistry staining intensity scoring (Spearman’s rho= 0.19, two-tailed). 
Additionally, hENT1 mRNA15 and corresponding immunohistochemistry intensities, 
were significantly different from each other (two tailed Student t-test, P= 0.044) (Figure 
2C). There was no significant correlation with cytogenetic markers such as 
chromosomal rearrangements.  
The sensitivity of primary AML samples to Ara-C in the high hENT1 and hCNT protein 
expression groups tended to be higher (lower LC50) than in the low hENT and hCNT 
group, but this was not significant (Figure 3A and 3B). We did not observe a difference 
for the other deoxynucleoside analogs cladribine, gemcitabine, fludarabine and 
decitabine. The immunocytochemistry staining intensity did not correlate with OS 
(Spearman’s Rho, P= 0.67) (Figure 4) and survival analysis for hCNT1 was difficult to 
determine due to the low number of samples allocated to low and high staining 






Table 1. hENT1 and hCNT1 staining in different AML FAB types. 
  Low Medium High 
hENT1 FAB M0-3 (n=14) 5 (36%) 8 (57%) 1 (7%) 
 FAB M4-5 (n=27) 3 (11%) 17 (63%) 7 (26%) 
hCNT1 FAB M0-3 (n=15) 1 (7%) 14 (93%) - 
 FAB M4-5 (n=25) 1 (4%) 76%) 5 (20%) 
 
 
Table 2. Frequencies of hCNT and hENT samples and staining intensities  
 hCNT-Low hCNT-Medium hCNT-High 
hENT Low 1 8 0 
hENT Medium 1 23 0 














Figure 1. Immunocytochemistry for hENT1 and hCNT1 proteins, as scored by two 
independent observers in several representative patient samples. Negative control in HL-60 
cells was done by omitting one antibody (1A). Positive controls (1B, 1C) are compared with 
AML samples of different color intensity (1D, E, F, G). Low staining was defined as less than 
one third of the intensity (<0.3) and high staining was defined as the upper fifth of the intensity 
(>0.8) and medium staining was in between these two intensities (- +). 
Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia 
 109 
 
Figure 2A: Frequencies (count) of samples in low (- -), medium (- +) and high (+ +) staining 
intensity for hENT1 and (2B) hCNT1. 2C: hENT1 mRNA levels of samples (from ref 15) 
allocated to score groups low, medium and high. 
 
 
Figure 3: Sensitivity of primary AML samples (depicted as Ara-C LC50 values) in hENT1 (3A) 
and hCNT1 (3B) immunohistochemistry score groups.  
 
4. Discussion 
The intracellular uptake of antimetabolites such as Ara-C, is transporter dependent. 
Both hENT1 and hCNT1 are essential for Ara-C uptake21. In this study, we find that 
hENT1 and the pyrimidine-preferring hCNT1 transporters are broadly expressed in the 
blasts of pediatric AML patients. Since the majority of patients scored medium levels 
of expression, a potential relation with in vitro sensitivity to deoxynucleoside analogs 
such as Ara-C was difficult to establish in this study. In addition, it is important to note 
that the effective concentrations of drugs used in the MTT assay were already so high 
that Ara-C would be taken up by diffusion, bypassing the transporters. Furthermore, 
hENT1 and hCNT1 expression are regulated at the posttranslational level, which may 
explain the lack of correlation between immunocytochemistry protein detection and 
mRNA levels2,13,18. Furthermore, this lack of correlation between hENT1 and hCNT1 
expression with OS of these patients, may be related to the multidrug regimens which 





Figure 4: Kaplan-Meier curves of pediatric AML patients with low (black), medium (dashed) 
and high (gray) hENT1 immunocytochemistry staining intensities. All patients received 
induction chemotherapy containing an anthracycline (idarubicin or daunorubicin) in 
combination with Ara-C and etoposide.  
 
The cells’ functional capacity is characterized by the enzyme activity within its cellular 
pathways. Proteomic profiling, (i.e. through immunohistochemistry) could be a useful 
tool to get a glimpse into the cells functional state. Further ex vivo cytotoxicity testing 
(i.e. MTT) can reveal the chemoresistance state of primary AML blasts and can 
therefore redirect and personalize treatment. In future studies, functional 
measurements in conjunction with immunocytochemistry might elucidate the precise 
role of hENT1 and hCNT1 in AML. Recently, a collaborative EORTC-GIMMEA trial 
has reported increased survival and a positive response rate with high-dose Ara-C in 
very high-risk setting patients, including AML-FLT3-ITD+ cases, which have 
notoriously high levels of hENT1 expression levels21, 29. This supports the notion that 
pre-treatment analysis of patient genetic profile might be a useful tool to classify 
treatment options for patients. 
 
5. Conclusions 
The nucleoside transporters hENT1 and hCNT1, which are crucial for the transport of 
clinically important deoxynucleoside analogs (e.g. cytarabine), can be visualized by 
immunocytochemistry showing that they are broadly expressed in almost all AML  
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Dexamethasone (DEX) is often used in the initial treatment of leukemia. Earlier we 
demonstrated that DEX decreased the activity of deoxycytidine kinase (dCK) which is 
essential for the activation of cytarabine (Ara-C). Therefore we investigated the effect 
of DEX on the in vivo sensitivity of acute myeloid leukemia (AML) to Ara-C and another 
deoxycytidine analog, gemcitabine, in the Brown Norway Myeloid Leukemia (BNML) 
rat model for AML, and its Ara-C resistant variant B-araC, in relation to the effects on 
dCK activity. The antileukemic effect was evaluated as survival of the rats, while dCK 
activity was measured in leukemic spleen (completely consisting of BNML cells) with 
liver as representative normal tissue, 24 hr after treatment with Ara-C or DEX with 
radioactive deoxycytidine (CdR) as a substrate. Treatment with Ara-C increased life-
span of BNML by 200%, which was not affected by DEX. Gemcitabine was ineffective. 
In the liver of BNML bearing rats DEX decreased dCK activity 33%, while Ara-C 
increased dCK activity slightly (to 129%), but in the combination of Ara-C/DEX dCK 
activity was also decreased. In the livers of Bara-C bearing rats dCK was 2.7- fold 
higher compared to BNML rats, which was increased 179% in the gemcitabine-DEX 
treated rats. In BNML leukemic spleens DEX decreased dCK activity 41% and 
gem/DEX 46%, but Ara-C increased dCK activity to 123%, but in the combination this 
effect was neutralized. In Bara-C spleens only Ara-C/DEX decreased dCK activity 
(32%). In conclusion; in an AML rat model DEX did not affect the antileukemic effect 
of Ara-C, nor the dCK activity. 
 
1. Introduction 
Glucocorticoids such as the synthetic steroid dexamethasone (DEX)[1,2–4] can inhibit 
the proliferation of several forms of lymphoid cancer [5–8]. Corticosteroids are known 
to induce changes in gene expression and protein synthesis, yet the molecular 
pathways involved have not been completely elucidated [9–11]. The interference of 
glucocorticoids with chemotherapeutics, such as cytarabine (Ara-C), and gemcitabine 
[2] is not completely clear even though they are commonly used together in the clinic. 
In pediatric oncology the combination of ondansetron and granisetron with 
dexamethasone is a well-known anti-emetic combination [12]. The antimetabolite 
cytarabine (Ara-C), has been the mainstay of chemotherapy in AML for decades.[13–
15] In order to exert its effect, Ara-C must be converted into cytosine arabinoside 
triphosphate (Ara-CTP) by the enzyme deoxycytidine kinase (dCK) [16] Around 30-
50% of patients relapse after induction treatment, mostly due to drug resistant 
leukemia [15,17–19], which might be related to decreased cellular Ara-CTP 
accumulation and retention, [20,21] or acquired deletion of the DCK gene as found in 
AML cell lines resistant to Ara-C and in Ara-C refractory patients [22]. Interestingly, 
previous data showed that AML patient samples with wildtype FLT3 (n= 10) and Ara-
C-resistant AML cell lines (n= 4) have increased sensitivity to glucocorticoids 
compared to mutated FLT3 [23]. Multidrug-resistance cells (both P-gP and MRP1) 
show collateral sensitivity to gemcitabine and Ara-C [24,25] which has been related to 
efflux of corticosteroids such as cortisol. It was shown that cortisol and DEX decreased 
dCK activity [2]. Therefore we hypothesized that DEX may affect Ara-C sensitivity in 
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AML. DEX use in AML is suggested to be ineffective and can even induce proliferation 
[12], but there may be a potential use of DEX in AML, [26] since DEX mediated 
proliferation induction might sensitize AML cells to Ara-C. For these reasons, we 
explored the effect of DEX on the anti-leukemic effect of Ara-C and gemcitabine, their 
toxicity and the role of dCK activity in the Brown Norway myeloid leukemia (BNML) rat 
model, which is considered to be characteristic for human AML [27]. 
 
2. Methods 
2.1. Materials and cell culture 
RPMI-1640 was purchased from Flow Laboratories (Costa Mesa, Ca, USA) and fetal 
calf serum (FCS) from Gibco (Thermo Scientific, Breda, the Netherlands). Ara-C was 
obtained from Upjohn (Capelle a/d IJssel, the Netherlands) and gemcitabine was a 
gift from Eli Lilly (Indianapolis, USA). [5-3H]-deoxycytidine (21.9 Ci/mmol) was from 
Moravek (Brea, USA). All other chemicals were of analytical grade and commercially 
available. The in vitro variant, BCLO, from the Rat leukemia Brown Norway myeloid 
leukemia (BNML) and the Ara-C resistant variant (Bara-C) [25] were cultured in RPMI-
1640 as previously described, [28] supplemented with 5% fetal calf serum (FCS) and 
5% rat serum, 3.2 mM glutamine and 250 ng/ml gentamycin (Gibco) and used to 
induce in vivo leukemia in Brown Norway rats [28]. Cells were regularly screened for 
mycoplasma contamination and were found to be negative. BCLO and Bara-C were 
generously provided by Dr A. Hagenbeek (Utrecht, The Netherlands) [27]. 
 
2.2. In vivo studies 
Ara-C was used at its maximum tolerated dose (MTD) as determined earlier [28] and 
given subcutaneously (s.c.) at 150 mg/kg twice a day for 3 days (q0.5d x 6). The MTD 
of gemcitabine in these rats was not known and had to be determined; doses of 50, 
25, 10 and 5 mg/kg caused an immediate weight loss of > 20%, at 3 mg/kg of about 
20%, while at 1 mg/kg (q3dx4) toxicity was acceptable (< 15% weight loss). Since the 
pharmacokinetics of gemcitabine in rats was also unknown and expected to be 
different from mice, we also measured plasma concentrations of gemcitabine by 
taking blood samples via the tail vein. Blood was processed and gemcitabine was 
measured as determined earlier [29]. The dose of dexamethasone was based on 
earlier studies and was 3 mg/kg. Body weight was determined on the first day of 
treatment (day 0) and set at 100%. Rats were weighed at least five times a week 
(starting on the first day of the treatment). Signs of sickness and mortality were 
recorded and moribund animals were euthanized and examined macroscopically for 
side effects. BNML and Bara-C were established as described earlier and maintained 
by isolation of leukemic cells from the spleen of a Brown Norway rat, as previously 
described [27]. Death was expected around day 25 after injection, and rats were 
euthanized when severe weight loss was found indicating that rats became moribund. 
Treatment was started when the spleen cells were completely replaced by leukemic 
cells (day 15) [28]. Anti-leukemic effect studies were performed at the MTDs. The 
randomized control and treatment groups each consisted of 5 rats. Survival times (day 
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of scarifying plus one) of the animals were used to calculate a median life span of the 
group (starting with the first day of treatment). The increase in life span (ILS) was 
determined using the following calculation: % ILS= T/C x 100 (T and C are the median 
days of death for the treated and control groups, respectively). Efficacy criteria were 
defined as follows: Inactive= ILS <125%, active= ILS >125% and very active= ILS 
>200% [28]. Significance of differences between control and treatment groups were 
calculated by using the non-parametric Mann Whitney U test.  
 
2.2. dCK activity 
In order to determine whether the potential interference of dexamethasone was 
mediated by changes in the activity of the key enzyme dCK, rats were euthanized one 
day after drug administration and livers (as a normal organ) and spleens (which were 
completely leukemic at the time of the experiment as was verified by FACS analysis), 
were immediately removed. Livers (without visible infiltration of leukemic cells) were 
immediately frozen in liquid nitrogen, while leukemic spleens were gently disrupted on 
a sieve, washed and the pellet was immediately frozen in liquid nitrogen. In order to 
determine dCK activity, livers were homogenized using a microdismembrator [30] and 
the powder was suspended in ice-cold assay buffer at a 1 to 4 ratio (300 mM Tris-
HCL, 1 mM EDTA, 50 µM β-mercaptoethanol, pH 8.0). Leukemic spleen cells were 
suspended in this buffer at 10 x 106 cells/ml. The suspension was centrifuged at 600 
g and the supernatant subsequently at 20,000 g. This supernatant was used for the 
enzyme assay, which was performed as described previously [2,31] (using 3H-labeled 
deoxycytidine (final concentration 230 µM, specific activity 0.04 Ci/mmol) in the 
presence of 2.5mM MgCl2, 5mM ATP and 1mM thymidine to inhibit thymidine kinase 
2 which may also catalyze deoxycytidine phosphorylation [32]. Interference of the 
reaction by degradation of deoxycytidine by cytidine deaminase (CDA) could be 
neglected since rats do not express CDA. The enzyme assay was linear in time (assay 
time 15-60 minutes) and with protein (in the range of 50-500 µg protein per assay). 
Enzyme activity was expressed as pmol dCMP formed per hour per mg protein 
(pmol/hr/mg protein). Protein was determined using the Bradford assay. Statistics 
were performed using the Student’s t-test for unpaired samples. 
 
3. Results 
3.1. Effect of dexamethasone on the anti-leukemic effect of Ara-C in BNML and 
Bara-C bearing rats 
Rats inoculated with the leukemia cells showed some increase in weight, which was 
not affected by either Ara-C or gemcitabine, (no weight loss, except for the Ara-C alone 
of 6% in the Bara-C group and of 7% in the gem-dexamethasone BNML group). The 
combination of Ara-C/ Dexamethasone had the same significant (p<0.05) anti-
leukemic effect as Ara-C alone (ILS 200%), while the Dexamethasone monotherapy 
had a moderate anti-leukemic effect (ILS 140%) (Fig. 1). Gemcitabine did not show 
an anti-leukemic effect. In the Bara-C group, Ara-C monotherapy was ineffective with 
an ILS of 73%, which was possibly related to toxicity of Ara-C itself (20% weight loss 
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at day 7). Although dexamethasone by itself was ineffective, the combination had 
some non-significant anti-leukemic effect (ILS of 118%) activity, similar to that of the 
gemcitabine-DEX combination, while gemcitabine alone was ineffective (ILS 91%). 
 
Table 1: Activity of deoxycytidine kinase (dCK) in leukemic spleens and livers from BNML and 
Bara-C rats 
Tissue BNML rats Bara-C rats 
Leukemic spleen 964 ± 121 611 ± 116 
Liver 434 ± 173 1189 ± 215* 
Values (in pmol/hr per mg protein) are means of tissues obtained from 3 rats inoculated with 
either BCLO cells (BNML rats) or Bara-C cells (Bara-C rats). Value are means ± SEM. * The 
dCK activity in Bara-C livers was significantly higher than in the BNML rats (p< 0.05)  
 
 
Figure 1. Effect of dexamethasone (dex) on the Ara-C and gemcitabine (gem) treatment of 
BNML rats given as survival time (in days). Values are medians of five animals per group. 
Drug schedules consisted of Ara-C (s.c.) 150 mg/kg twice a day for 3 days (q0.5d x 6). 
Dexamethasone was dosed at 3 mg/kg. Only the effect of Ara-C and Ara-C/dex in the BNML 
rats was significantly different from the controls at p<0.05 (*).  
 
3.2. Effect of dexamethasone on dCK activity in leukemic spleens from BNML 
and Bara-C rats 
In this study we aimed to investigate the effect of treatment on dCK activity; therefore 
we measured the activity of dCK in leukemic spleens of control and DEX/Ara-
C/gemcitabine treated animals. In BNML leukemic spleens, DEX decreased the 
activity of dCK significantly (p<0.05), while Ara-C treatment led to a slight increase of 
123% (Fig. 2A). Gemcitabine did not affect the dCK activity. DEX decreased the dCK 
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compared to Ara-C (p<0.05) or gemcitabine alone. The dCK activity in leukemic 
spleens of Bara-C rats was about half of that in BNML rats, possibly explaining the 
lower Ara-C anti-leukemic effect (Fig. 2B). In these rats DEX, Ara-C and gemcitabine 
did not significantly affect dCK activity. However, co-treatment with DEX decreased 
the dCK activity compared to Ara-C and gemcitabine alone by 32% and 21%, 
respectively. 
 
Figure 2. Relative activity of dCK (in % from untreated animals; the bars provide the relative 
SEM) in leukemic spleens from BNML (A) and Bara-C (B) rats. dCK activities were measured 
one day after administration of dexamethasone (DEX), gemcitabine (gem), Ara-C and their 
combination. The SEM of absolute dCK activities from 3 treated and 3 untreated animals was 
less than 25%. Controls received saline. The mean value of the untreated animals (from Table 
1) was set at 100%. Significance was calculated based on these absolute activities; index and 
gem/DEX treated animals this activity in BNML spleens was significantly lower than in 
untreated animals at p<0.05 (*). 
 
3.3. Effect of dexamethasone on dCK activity in normal livers from BNML and 
Bara-C rats 
Livers were included in this study to determine whether treatment would also affect 
the dCK activity in a normal, non-leukemic organ. At the time of harvesting no visible 
leukemic cell infiltration in the liver was observed. This would have been visible as 
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white spots. In livers from BNML rats DEX decreased the dCK by 33%, while Ara-C 
and gemcitabine increased the dCK to 129 and 179%, respectively, compared to 
untreated rats (Fig. 3A). In these groups dexamethasone co-treatment decreased the 
dCK activity in the Ara-C/dexamethasone group by 39% and in the gemcitabine- 
dexamethasone group even by 23%. In contrast to the leukemic spleens the dCK 
activity in livers of leukemic Bara-C rats was almost 3.5 fold higher compared to livers 
from BNML rats (Fig. 3B). In these rats any treatment did not decrease the dCK 
activity, but both dexamethasone and gemcitabine increased the dCK activity to 119 
and 141%, respectively, while dexamethasone co-treatment even led to a further 
significant (p<0.05) increase to 172% in livers of the gemcitabine-dexamethasone 
treated rats. 
 
Figure 3. Relative activity of dCK (in % from untreated animals; the bars provide the relative 
SEM) in livers from BNML (A) and Bara-C (B) rats. dCK activities were measured one day 
after administration of dexamethasone (DEX), gemcitabine (GEM), Ara-C and their 
combination. The SEM of absolute dCK activities from 3 treated and 3 untreated animals was 
less than 25% (except BNML liver). Controls received saline. The mean value of the untreated 
animals (from Table 1) was set at 100%. Significance was calculated based on these absolute 
activities; in GEM/DEX treated animals this activity in BNML livers was significantly higher than 
in untreated animals at p<0.05 (*). 
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3.4. Gemcitabine pharmacokinetics 
In order to explain the low efficacy of gemcitabine against BNML we determined the 
plasma concentrations of gemcitabine (Fig. 4); in line with the known absence of CDA 
in rats, the pharmacokinetics was different from mice [29] and humans [33] with a peak 
level of 2.9 µM at 60 minutes (which is far below the effective concentration of at least 
60 µM), a half-life of more than 4 hours and no formation of the gemcitabine metabolite 
difluorodeoxyuridine (Fig. 4). 
 
Figure 4. Plasma concentrations of gemcitabine in healthy Brown Norway rats. Blood was 
drawn via the tail vein in heparinized tubes, centrifuged and the gemcitabine concentrations 
in plasma were determined as described in the Methods section. (n=3; SEM less 25%). No 
2’,2’-difluoro-2’-deoxyuridine could be detected. The half-life could not be determined reliably 




In this paper we demonstrate that dexamethasone does not affect the antileukemic 
effect of Ara-C, in a rat model which is considered to be representative for human AML 
[27]. Since the antileukemic effect of Ara-C is comparable (moderate) to that in 
humans, we chose this model to study the effect of dexamethasone. The activity of 
dCK was decreased by dexamethasone treatment. However, treatment with Ara-C or 
gemcitabine increased the dCK activity. In the combined treatment the effect was 
neutralized. Gemcitabine did not have any effect, which is possibly due to the 
observation that cytotoxic plasma levels of gemcitabine were too low in these rats to 
achieve any antitumor effect. The known deficiency of CDA explains the completely 
different pharmacokinetics of gemcitabine in these rats, so that plasma concentrations 
were too low. In humans and mice, the peak at a therapeutic dose is around 40 
(humans) and 225 (mice) µM with a half-life of about 15 minutes [29]. However, the 
low concentration of gemcitabine was maintained for a longer period, which was 
shown to be cytotoxic in cell culture and expected to be effective in this rat model as 
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well. However, the inefficacy of gemcitabine is in line with the lack of a clinically 
relevant antileukemic effect. In childhood acute lymphoblastic leukemia 
dexamethasone is often used as induction therapy, and in AML it may be used as an 
anti-emetic, similar to solid tumors. Indeed in the rat model system dexamethasone 
has some anti-leukemic effect. Interestingly in Bara-C rats, the basal dCK activity was 
lower than in BNML rats, as was also shown earlier in cultured BNML and Bara-C cells 
[25]. However, in livers of these rats the dCK activity was 3.5- fold higher in Bara-C 
rats. Apparently, the presence of the tumor causes an induction of dCK. Earlier it has 
been published that regulation of dCK activity in both normal and tumor cells is not at 
the mRNA levels nor at the protein level [34]. Although no leukemic cell infiltration was 
observed in the livers, we may assume that the extensive leukemic load in the rats 
may affect dCK activity. Since the Bara-C model seems more aggressive this effect 
may be more pronounced in the Bara-C rats. Moreover, Csapó et al [35]. showed that 
a stress like treatment (a drug, radiation) leading to inhibition of DNA synthesis can 
lead to an increased dCK activity, an effect that was usually higher in normal cells. 
Earlier we demonstrated a similar effect in tumor cells for radiation, which was not 
associated with an increased dCK protein level [36]. Smal et al provided evidence that 
this effect could be explained by phosphorylation of human dCK at the serine site [37]. 
Unfortunately we were not able to perform similar studies for the rat dCK due to the 
lack of a suitable anti-rat antibody. Therefore we concentrated in this study on the dCK 
activity itself. Indeed treatment with drugs (a stress like situation) increased dCK 
levels, which was most pronounced in gemcitabine and Ara-C treated BNML rats, but 
less in Bara-C rats. However, in the BNML livers addition of DEX decreased dCK 
activity compared to Ara-C and gemcitabine alone, which would fit with a protective 
effects in normal tissues. Only gemcitabine (not used in AML) would increase dCK 
activity in Bara-C rats. In conclusion: although dexamethasone had some 
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Background: Cannabidiol (CBD) is a popular natural medicine product which has 
anti-inflammatory and anti-epileptic effects. Beyond this, CBD gained interest as a 
potential anti-cancer drug given its antitumor effects described both in vitro and in vivo. 
Aim: To investigate the in vitro growth inhibitory effects of CBD in human acute 
lymphoblastic and acute myeloid leukemia cells and drug-resistant sublines, and 
explore underlying mechanisms of action of CBD.  
Methods: Models included CCRF-CEM acute lymphoblastic and THP-1 acute 
myeloid leukemia cells, a subline of CEM with acquired resistance to the proteasome 
inhibitor bortezomib (CEM/BTZ), CEM cells adapted for >3 months to 6250 nM CBD 
(CEM/CBD6250), and lastly normal bone marrow (NBM) cells. Cell growth inhibition 
was measured with the MTT assay and cell proliferation by flow cytometry using 
CellTrace™ Violet (Invitrogen, Thermo Fisher Scientific) dye. CBD-induced effects on 
apoptosis and cell cycle were assessed by flow cytometry. Mechanistic studies 
included Western blot analyses of CBD receptor 1/2 expression, G protein-coupled 
receptor GPR55 and GPR119 expression, p-4E-BP1 expression as an indicator of 
mTOR inhibition, and MARCKS expression as indicator of BTZ resistance and ER 
stress.  
Results: CBD inhibited growth of CCRF-CEM and THP-1 cells in the low micromolar 
range (IC50: 5.1 and 9.2 µM, respectively), whereas NBM were rather insensitive to 
CBD (IC50: 43 µM). Drug-resistant CEM/BTZ cells were 2.7 fold cross-resistant to 
CBD compared with CCRF-CEM cells, and CEM/CBD6250 cells were just two-fold 
resistant (IC50: 10.7 µM). Intriguingly, at low concentrations of CBD (i.e. 1 µM) CBD 
showed marked cell-density dependent cell growth stimulatory effects for CEM/BTZ 
cells (up to 3-fold) and CEM/CBD6250 cells (up to 7-fold). Moreover, CEM/CBD6250 
cells displayed a CBD-addiction phenotype requiring CBD for their growth.  
CBD also induced apoptosis but induction proceeded slowly (> 48 hrs) as compared 
to BTZ (< 24 hrs). CBD had minor impact on cell cycle distribution.  
CB1 and CB 2 expression was hardly detectable in (drug-resistant) CEM cells. CBD 
had minor impact on cell cycle distribution.  
CEM/BTZ and CEM/CBD6250 cells exhibited a marked down-regulation of GPR55 
and GPR119 expression. Interestingly, CEM/CBD6250 cells had a significantly 
enhanced MARCKs expression to levels observed in CEM/BTZ cells. Finally, inhibition 
of p-4E-BP1 expression paralleled CBD-induced growth inhibition in CCRF-CEM and 
drug-resistant sublines.  
Conclusions: CBD markedly inhibited growth of leukemia cells at concentrations >5 
µM, but induced cell growth stimulatory effects for drug-resistant leukemia cells at low 
CBD concentrations (~1 µM). CEM/CBD6250 cells acquired a CBD addiction 
phenotype which may serve as an excellent tool for further investigations into 
molecular basis for this property.  
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INTRODUCTION 
Acute lymphoblastic leukemia (ALL) is an aggressive hematological malignancy, 
which accounts for 20% of adult leukemia cases and is the most common type of 
cancer in childhood1. Failure of long-term remission occurs in ~20% of children and 
~40% of adult patients. Approximately 20% of children with ALL relapse, mainly due 
to chemotherapy resistance, and have a dismal five-year survival1,2 . Therefore, novel 
therapeutic strategies for the treatment of ALL are still needed2. In this context, 
cannabinoids have been proposed as potential anti-leukemic agents given their 
reported anti-tumor activity against solid tumors3–8. 
Cannabidiol (CBD) is one of over sixty phytocannabinoids derived from the plant 
Cannabis sativa9,10. Phytocannabinoids, such as CBD and delta-9-tetrahydro- 
cannabidiol (THC), along with endogenous endocannabinoids (anandamide, and 2-
arachidonoylglycerol [2-AG]), are capable of interacting with endogenous receptors 
distributed in different cell types. These include cannabinoid receptor CB1 and the ion 
channel receptor Transient Receptor Potential channel subfamily V member 1 
(TRPV1), mostly expressed on nerve cells, and CB2 and G protein-coupled receptor 
55 (GPR55) widely expressed on immune cells, together constituting the 
endocannabinoid system (ECS)10–13. In addition, another G protein-coupled receptor, 
GPR119, was identified as putative cannabinoid receptor14  
There is accumulating evidence suggesting that the endocannabinoid system is 
pivotal in modulating basic homeostatic functions such as appetite, metabolism, the 
immune response, and memory formation10,13. Even though cannabis products have 
been used in palliative care extensively15, recent data suggest that some 
cannabinoids exert an important role in both cell proliferation/tumorigenesis16–19. This 
has transformed the endocannabinoid receptors into attractive new targets for the 
treatment of several cancer subtypes. In fact, upregulated expression of various 
cannabinoid receptors and overexpression of the ECS components is correlated with 
tumour aggressiveness 20–23. Either by receptor-dependent or receptor-independent 
interactions, CBD initiates a signaling sequence including stimulation of de novo 
synthesis of ceramide, which triggers ER-stress, and increases reactive oxygen 
species (ROS) production, which ultimately leads to autophagy and apoptosis 
induction6,24–27; Furthermore, CBD-induced apoptosis was accompanied by down-
regulation of mTOR, cyclin D1 and up-regulation of PPARγ protein expression28.  
CBD has been evaluated for its anti-leukemic activity in leukemic cell lines revealing 
inhibition of differentiation29 and apoptosis induction30–32, usually at CBD 
concentrations above 10 µM.  
In this study we examined the anti-proliferative effects of CBD in leukemia cell lines 
and subclones of CCRF-CEM leukemia cells with acquired resistance to the 
proteasome inhibitor bortezomib (BTZ)33. Recently CBD was proposed to overcome 
BTZ resistance and was tested in combination regimens with proteasome inhibitors 
for treatment of hematological malignancies 24,34. In addition, we characterized the 
features of a CCRF-CEM line that was adapted to grow in sub-toxic concentrations of 
CBD for a period of 4 months after which cells exhibited a drug-addicted phenotype. 
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MATERIALS AND METHODS  
Chemicals 
CBD (>98%) (Merck, Germany) was diluted in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, USA) at 25 mM stock solutions and stored at -30°C. Bortezomib (Millennium 
Pharmaceuticals, USA) was dissolved in DMSO (Sigma-Aldrich, USA) and 1 mM 
stock solutions were stored at -300C.  
 
Human cell lines and patient samples 
The human myeloid leukemia cell line THP-1 (ATCC® TIB-202TM), human T-cell 
leukemia cell line CCRF-CEM (wild type / WT, ATCC® CCL-119) and its bortezomib 
(BTZ)-resistant sublines CEM/BTZ7 (10-fold BTZ-resistant) and CEM/BTZ200 cells 
(170-fold BTZ resistant)35,36 were used for cell growth inhibition assays. Additionally, 
we generated a subline of CCRF-CEM (i.e. CEM/CBD 6250) by gradually adapting 
CEM cells to increasing concentrations of CBD from 1000 to 6250 nM CBD over a 
period of 4 months. Cells were cultured in RPMI-1640 cell culture medium (Gibco, 
Thermo Fisher Scientific) containing 10% heat-inactivated fetal calf serum (FCS) and 
1% penicillin-streptomycin (5000 U/ml) (Gibco, Thermo Fisher Scientific) and 
incubated at 37°C in a humidified 5% CO2 incubator. Cell cultures were refreshed 
twice weekly at a density of 3 x 105 cells/ml. Normal bone marrow (BM) was obtained 
during cardiological or hip replacement surgeries after written permission according to 
Dutch law. Mononuclear cells (MNC) were isolated from fresh BM by filtering 
unprocessed material through a 70 µm strainer followed by centrifugation with Ficoll 
(Sigma-Aldrich, USA) at 1800 rpm for 20 minutes at room temperature (RT). 
Remaining red blood cell (RBC) were lysed for ten minutes on ice, with a buffer 
containing 155 mM NH4Cl, 10 mM KHCO3 and 0.1 mM Na2EDTA (pH 7.4), and cells 
were then washed twice with PBS with 0.1% FCS. Isolated BM MNCs were kept in 
RPMI-1640 medium supplemented with 20% FCS and were used for analysis 
immediately thereafter. 
 
MTT drug sensitivity assay 
For assessment of drug sensitivity the 4,5-dimethylthiazol-2-yl-2,5-
diphenyltetrazolium bromide (MTT) assay was performed essentially as described by 
van Meerloo et al37. Briefly, this colorimetric assay relies on the conversion of MTT 
into insoluble formazan crystals by the mitochondria of living cells and is widely used 
to assay drug sensitivity on primary patient cells or cell lines. For this purpose, cells 
suspended in culture medium were incubated in 96-wells plates. CEM and THP-1 cell 
lines were cultured in flat-bottom well plates at a concentration of 3 - 6 x 103 cells/well 
while primary cells were cultured in round bottom well plates at a concentration of 0.16 
x 106 cells/well. With cell lines each well contained a total volume of 150 µl, composed 
of 120 µl of cell suspension and 30 µl of culture medium only (control) or culture 
medium + drug (treatment) at different concentrations, as depicted in the layout below:  
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For primary cells, a total volume of 100 µl (80 µl cell suspension + 20 µl drug) was 
used. For blank controls, the wells only contained complete medium, for the control 
wells, cells were cultured in medium only. The MTT assay was performed in triplicates 
and plates were incubated at 37°C, in a humidified 5% CO2 incubator for 4 days. At 
the end of the incubation period, 15 µl of MTT solution (5 mg/ml in PBS) was added 
to each well of the cell lines and 10 µl of MTT solution to each well of the primary 
samples. These plates were incubated for an additional 4 hours at 37oC, followed by 
addition of 150 µl acidified isopropanol for cell line plates and 100 µl for the primary 
cell plates All wells were vigorously mixed until crystals were completely dissolved 
after 10 minutes and the plates were ready for readout. The optical density (OD) of 
each well was measured in a Glomax plate reader (Promax, USA) at 540. For the data 
analysis, the mean OD of the blank wells was subtracted from the mean OD of the 
control wells and of the treatment wells. The 50% lethal dose (LC50) -for primary cells- 
or the 50% growth inhibitory dose (IC50) -for cell lines- was then determined by 
calculating cell survival with the following equation: mean OD treatment well (minus 
blank)/mean OD control well (minus blank) x100%. 
 
Cell cycle analysis: 
To examine the effect of CBD on the cell cycle, CEM/WT, CEM/BTZ200, and 
CEM/CBD6250 cells were first incubated in individual wells of a 6-wells plate (3 ml cell 
suspension, initial cell density of 4 x 105 cells/ml) in the absence (control) or presence 
of 1, 10 or 20 µM CBD for different time points (24, 48, 72 and 96 hours). Thereafter, 
cells were washed once with PBS and fixed with cold 70% ethanol for 24 hours. Cells 
were then washed twice with PBS, pooled in 100 µl PBS and stained with propidium 
iodide (PI) solution (Invitrogen, Thermo Fisher Scientific) according to the 
manufacturer’s instructions; 5 x104 events were recorded in a LSRFortessaTM flow 
cytometer (BD, USA). For all flow cytometry analysis, FlowjoTM software v10.5.3 




To distinguish viable from early and late apoptotic cells after CBD incubations, 7AAD 
(BD Biosciences) in conjunction with annexin V (Biolegend, San Diego, California) 
staining was used. For this purpose, cells were plated in 6-well plates with different 
CBD concentrations and harvested at selected time points (1-4 days) as described 
above for the cell cycle analysis. After CBD exposure, cells were washed twice and 
pooled to obtain 106 cells in 100 µl PBS. Each fluorochrome was added according to 
the manufacturer’s instructions and incubated for 15 minutes in the dark at room 
temperature (RT). Samples for annexin V staining had annexin V binding buffer (BD 
Bioscience) in a dilution of 5:1 in PBS. Thereafter, all samples were measured using 
flow-cytometry, recording peak emissions in FL1 (488 nm, bandpass 30 nm) for 
Annexin V-FITC, and FL2 (488 nm, bandpass 40 nm) for 7AAD-PerCP-CY5.5. Cells 
stained negative for both Annexin V and 7AAD were considered as viable cells, those 
positive for Annexin V and negative for 7AAD were considered as early apoptotic cells, 
and those positive for both fluorochromes were considered as late apoptotic cells. Five 
x104 events were recorded per incubation condition. Cellular debris and multi-nucleate 
events were gated out by using forward scatter (FS)/ side scatter (SS). 
 
Cell proliferation assay 
For cellular proliferation assessment, cells were stained at the start of the culture with 
the cell-tracing dye CellTrace™ Violet (Invitrogen, Thermo Fisher Scientific) as 
follows: cells (max 50 x 106) were resuspended in 1 ml PBS and 1 µL of cell dye, after 
which cells were stored for twenty minutes at RT in the dark, during which cells were 
mixed frequently. Stained cells were washed twice with PBS and plated at different 
CBD conditions (0, 1, 10, 20 µM CBD and 100 nM BTZ) in 96-wells plates and stored 
at 37°C in a humidified 5% CO2 incubator. Cells were plated at the following densities: 
6000 cells/well CEM/WT, 4000 cells/well for CEM/BTZ200 and 7000 cells/well for 
CEM/CBD6250, based on their proliferation curves. Cells were plated in separate 
wells per time point and per condition. At each time point, 100 µl cell suspension was 
put into a FACS tube containing 10 µl of fluorescent counting beads and immediately 
proceeded to record 1 x 104 events/condition in an LSRFortessaTM flow cytometer 
(BD, USA). Singlet, alive mononuclear cells were gated and sub-gates were placed to 
trace and analyze cells according to their cell dye fluorescence intensity over time. To 
standardize gates for the varying passage numbers, each individual file generated 
was concatenated to create a single file containing the unified data of all time points 
for a specific condition. These gates were then applied to each separate file for each 
condition and time point. Additionally, a separate gate was made for fluorescent 
counting beads in order to normalize data. For this purpose, the number of cells per 
gate (total or passage specific) was divided by the number of counting beads for each 
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Western Blot  
Sample processing for western blotting was performed essentially as described 
previously33. Western blot was done on cell lysates, which were prepared by 
transferring a minimum of 3 x 106 cells of interest into 15 ml tubes, and centrifuged for 
10 min at 300g. The following antibodies were used: anti-cannabinoid receptor 1 
(rabbit-anti human, 1:200, ab23703, Abcam, UK), anti-cannabinoid receptor 2 (rabbit-
anti human, 1:500, ab3561, Abcam, UK), anti-GPCR GPR55 (rabbit-anti human, 
1:1000, ab203663, Abcam, UK), anti-GPCR119 GPR119 (rabbit-anti human, 1:1000, 
ab75312, Abcam, UK), Phospho-4E-BP1 (Thr37/46) (236B4) (rabbit-anti human, 
1:1000, #2855, Cell Signal Technology, USA), anti-MARCKs (D88D11) XP (rabbit-anti 
human 1:1000, #5607, Cell signal Technology, USA). After blocking the membrane, 
the primary antibodies were added to the PVDF membrane and incubated for 16 hours 
at 4 °C. After incubation the membrane was washed 3x with PBS/0.5% Tween-20 
(Sigma-Aldrich, USA) (PBST). The secondary antibody IRDye 800cw (goat-anti rabbit, 
1:10000, Li-cor, USA) was added to the membrane after washing and incubated at RT 
for 1 hour. After incubation the membrane was washed 3x for 15 min at RT with PBST. 
The membrane was scanned with the Odyssey scanner (Li-cor, USA). β-Actin 
(mouse-anti human, 1:3000, Cell Signaling, USA) and as secondary antibody IRDye 
680RD (goat-anti mouse , 1:10000, Li-cor, USA) was used as reference protein. 
 
Statistical analysis  
To determine significant differences between samples, the two-tailed student t-test 
was performed. Differences between means were considered statistically significant 
when p-values were < 0.05. Statistical analysis was performed using SPSS® Statistics 
for Windows, version 26 (IBM Corp. New York, USA). For graphical presentation, 
GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, 
California USA) was used. 
 
RESULTS  
CBD growth inhibition of (drug-resistant) leukemia cell lines 
The potency of CBD to inhibit the growth of the ALL cell line (CEM) and the AML cell 
line (THP-1) is presented in Figure 1A. IC50 values for CBD of CEM/WT were slightly 
lower (5.1 ± 1.7 µM SEM) than for THP-1 cells (9.2 ± 3.7 µM SEM). Moreover, 
leukemia cells were markedly more sensitive to CBD than normal BM cells (IC50: 42.9 
µM). To investigate whether CBD displays potency against drug-resistant leukemia 
cells, IC50 values were determined for BTZ-resistant and CBD-adapted CEM cells 
(Figure 1B). Notably, CEM/BTZ200 and CEM/CBD6250 cells were slightly cross-
resistant (1.5 -fold) to CBD with IC50 values of 13.7 ± 3.7 µM and 10.7 ± 1.1 µM, 
respectively, as compared to CEM/WT cells. Intriguingly, Figure 1B shows that the 
CBD dose-response curve for CEM/BTZ200 and CEM/CBD6250 cells showed a 
growth stimulatory effect at low concentrations of CBD with an apparent 3-fold 
increase over CEM/WT at CBD concentrations around 1 µM. Together, these results 
suggest a window of CBD sensitivity for leukemia cells vs NBM cells, moderate cross-
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resistance to CBD for drug-resistant cells and a biphasic dose-response curve with 
growth-inhibitory effects at CBD > 10 µM and growth stimulatory effects at low CBD 
concentrations.  
Figure 1. Dose-response curves of CBD in normal and leukemia cells 
(A) CEM/WT, THP-1, and normal bone marrow (NBM) MNC cells and (B) CEM/BTZ200 cells 
and CBD-adapted CEM/CBD6250 cells. Drug exposure time: 96 hr. Growth inhibition was 
assessed by the MTT assay. Results are the mean ± SEM of at least 3 experiments, except 
for NBM (n=1). 
 
CBD-induced apoptosis and cell cycle analysis in drug-resistant leukemia cells 
To examine whether CBD growth inhibition is associated with induction of apoptosis, 
CEM/WT, CEM/BTZ200 and CEM/CBD 6250 cells were incubated at a concentration 
range of CBD (1 – 20 µM) for 24 – 96 hr followed by an analysis of apoptosis induction 
by Annexin-V/7-AAD staining (Figure 2A). For comparison, apoptosis induction and 
cell cycle analysis are shown after 24 hr exposure to 100 nM BTZ. For CEM/WT, 
apoptosis induction was observed at CBD concentrations > 10 µM. At 20 µM CBD the 
percentage of apoptotic cells gradually increased from 50 % at 24 h drug exposure to 
77 % after 96 hr drug exposure. This profile distinguishes from BTZ which induced 
apoptosis at 100 nM in > 95% of CEM/WT cells after 24 hr drug exposure. Apoptosis 
induction by 20 µM CBD was markedly lower in CEM/BTZ200 cells than in CEM/WT; 
24 % after 24 hr to 30% after 96 hr, which is in line with the low level of cross-resistance 
to CBD in CEM/BTZ200 cells. Twenty-four hr exposure to 100 nM BTZ did not induce 
apoptosis in CEM/BTZ200 cells, consistent with their resistant phenotype. The 
apoptosis induction profile of CEM/CBD6250 largely paralleled the one of CEM/WT; 
at 20 µM CBD, gradual apoptosis induction was found increasing from 48 % to 72 % 
for 24 and 96 hr exposure times, respectively, and > 95% apoptotic cells after 24 hr of 
100 nM BTZ treatment.  
The impact of 24-96 hr CBD exposure on cell cycle distribution in CEM/WT and 
CEM/BTZ200 cells is depicted in Figure 2B. No major effects were observed other 
than a slight decrease of cells in S-phase after 96 hr 20 µM CBD exposure along with 
an increasing fraction in sub-G1 phase consistent with apoptosis induction described 
in Figure 2A.  
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Figure 2: Flowcytometric analysis of (A) apoptosis induction and (B) cell cycle of CEM/WT, 
CEM/BTZ200 cells following 24-96 hr exposure to the indicated concentrations of CBD. Cells 
cultured in medium without drugs where considered negative control while incubation with 100 
nM BTZ served as a positive control for apoptosis induction. Results depicted are the mean ± 





Cell density dependency of cell proliferation induction at low concentrations of 
CBD 
In Figure 1 it is shown that a low concentration of 1 µM CBD stimulated growth in drug-
resistant CEM/BTZ200 and CEM/CBD6250 cells and to a lesser extent in CEM/WT 
cells. We extended these observations by exploring whether this effect was cell 
density-dependent. Figure 3A shows a representative example of the read-out of the 
MTT plate for CEM/WT, CEM/BTZ200, and CEM/CBD6250 at initial seeding densities 
of 4500, 1500 and 4500 cells/well, respectively. Visual inspection revealed a clear 
peak in colorimetric signal for CEM/BTZ200 and CEM/CBD6250 cells spikes at 1 µM 
CBD. When the results were analyzed as a function of different cell plating densities 
(Figure 3B) it became clear that growth-stimulating effects were most pronounced at 
low cell densities, up to 3-fold for CEM/BTZ200 and 7-fold for CEM/CBD6250 around 
1 µM CBD, and dampened with increasing cell densities.  
Since the colorimetric read-out of the MTT assay is based on mitochondrial activity in 
viable cells, we determined with two other assays whether the CBD-growth stimulatory 
effect indeed involved increased cell numbers rather than increased mitochondrial 
activity per cell. To this end, we used the Violet trace assay with flow cytometric 
fluorescent counting beads to measure the proliferation rate of cells cultured at various 
concentrations of CBD over a 72 hr period. By comparing the ratio of cells/ bead 
events, absolute numbers of CBD-treated vs non-treated cells can be calculated. As 
shown in Figure 3C, CEM/BTZ200 and CEM/CBD6250 cells exposed to 1 µM CBD 
had a two-fold higher ratio of cells/beads when compared to untreated cells. Moreover, 
results from the Violet trace assay (Figure 3C) recapitulates CBD concentration-effect 
curves shown in Figure 1 and as a control BTZ resistance in CEM/BTZ200 cells. 
Lastly, manual counting of viable cells in the MTT plates showed increased cell 
numbers of up to 4-fold for CEM/BTZ200 at CBD concentrations close to 1 µM and 
similar effect for CEM/WT cells albeit less pronounced (Figure 3D). Together, by 
various lines of evidence, these results show that low concentrations of CBD exert 
growth stimulatory effects, notably for drug-resistant cells.  
 
CBD-mechanistic studies 
To gain insight into the mechanism of action of CBD on leukemia cells and their drug-
resistant variants, Western blot analyses were performed for various CBD-interacting 
receptors and down-stream effects. First, since CEM/BTZ200 cells had a low level of 
cross-resistance to CBD, we examined whether CEM/CBD6250 cells harbor markers 
of BTZ resistance, such as the myristoylated alanine-rich C-kinase substrate 
(MARCKS) which has been associated with ER stress and was previously shown to 
be upregulated in BTZ-resistant leukemia cells38,39. This is illustrated in Figure 4A, 
which also shows that MARCKS expression is markedly upregulated in 
CEM/CBD6250 cells, suggesting some (in)direct interaction of CBD with the ubiquitin 
proteasome system. Next, expression levels of CBD interacting CB1 and CB2 
receptors were determined in CEM/WT, CEM/BTZ7, CEM/BTZ200 and 
CEM/CBD6250 cells. CB1 expression in these cells appeared to be below the 
detection limit (results not shown). CB2 was also barely detectable in these cells and 
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was not different between the cells (Figure 4B). Expression of two novel CBD 
receptors, GPR55 and GPR119, was visible in CEM/WT cells, but markedly reduced 
in drug-resistant CEM/BTZ7, CEM/BTZ200 and CEM/CBD6250 cells (Figure 4C). 
Other studies indicated that CBD may impact mTOR signaling 25,40, reflected by 
reduced phosphorylation of downstream 4E-BP1. Baseline p4E-BP1 expression was 
increased in CEM/BTZ7, CEM/BTZ200 and CEM/CBD6250 cells compared with 
CEM/WT cells (Figure 4D). All cells exposed to 1 µM CBD showed an upregulation of 
p4E-PB1 expression. At 10 µM CBD the expression of p4E-PB1 was reduced in 
CEM/BTZ7 and BTZ200 and almost completely abolished in CEM/WT and 
CEM/CBD6250 cells. At the highest CBD concentration tested (20 µM), p4E-BP1 
expression was still detectable in CEM/BTZ7 and CEM/BTZ200 cells. p4E-BP1 
expression was also retained in BTZ-resistant CEM/BTZ7 and CEM/BTZ200 cells 
exposed to 100 nM BTZ, whereas in BTZ sensitive CEM/WT (IC50 BTZ: 1.3 ± 0.4 nM) 
and CEM/CBD6250 cells (IC50 BTZ: 2.3 ± 0.7 nM) p4E-BP1 expression was 
minimized also because of loss of cell viability (reduced β-actin signal) (Figure 4D).  
Together, these results show that drug-resistant CEM cells had down-regulated 
GPR55 and GPR119 expression, which may contribute to diminished CBD sensitivity. 
Additionally, low concentrations of CBD stimulated mTOR signaling reflected by 
increased 4E-BP1 phosphorylation.  
 
Discussion 
In this study, we demonstrated that the phytocannabinoid CBD, has a biphasic effect 
on cell vitality and proliferation of leukemia cells, in particular drug-resistant leukemia 
cells. On the one hand, at 1 µM CBD, the proliferation of BTZ-resistant and CBD-
adapted CEM cells were markedly enhanced in association with increased mTOR 
activation, represented by increased phosphorylation of 4E-BP1. On the other hand, 
CBD concentrations >10 µM conferred cytotoxicity and induced apoptosis in CEM/WT 
and resistant subclones but not in healthy NBM, suggesting a therapeutic window for 
CBD in the treatment of leukemia. Moreover CEM/BTZ200 and CEM/CBD6250 
showed a low level of resistance to CBD and expressed MARCKS protein, previously 
proposed as a marker for BTZ resistance38, suggesting that CBD and BTZ resistance 
converge in an acquired common drug-resistance pathway. Finally, the growth of 
CEM/CBD6250 cells was characterized by a CBD-addiction phenotype which was 
most pronounced at low cell densities.  
CBD has been investigated for its potential anti-cancer activity in vitro and in vivo in 
different types of solid tumors and hematological malignancies, including ALL and 
AML cells. In most in vitro studies, anti-tumor effects of cannabinoids were only found 
when high concentrations of CBD, usually > 10 µM, were used 3–5,7,8,21,23,27,32,41. 
Similarly, in CEM and THP cells, apoptosis induction and cell growth inhibition were 
found at high CBD concentrations (around 10 µM). CBD had a minor impact on cell 
cycle distribution of CEM/ WT and CEM/BTZ200 cells which is in line with previous 
reports for Jurkat41 and CEM cell lines cultured42 in vitro with CBD in combination with 
other chemotherapeutics, such as doxorubicin41, vincristine and cytarabine,42. 
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Figure 3. Concentration-dependent effect of CBD in CEM cell lines. 
(A) Representative picture of 96-well MTT plates after 96 hr CBD exposure. (B) Density 
concentration effect on CBD sensitivity. Results are the mean ± SEM of at least 3 experiments. 
(C) Violet Cell Trace™ flow cytometric analysis of cell growth stimulation/inhibition with the 
indicated concentrations of CBD for 72 hr. BTZ (100 nM) was included as control for resistance 
in CEM/BTZ200 cells and drug sensitivity control for CEM/WT and CEM/CBD6250 cells. 
Fluorescent beads were used in each condition and relative counts were defined as number 
of cells per bead. (D) Manual cell counting of cell growth stimulation/inhibition of CEM/WT and 
CEM/BTZ200 cells incubated with the indicated concentrations of CBD for 72 hr. Results are 
the mean ± SEM of at least 3 experiments.  
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Figure 4. Protein expression of CBD affected pathways 
Protein expression analysis of (A) MARCKS (B) cannabinoid receptor CB2, (C) GPR55 and 
GPR119 cannabinoid receptors, and (D) of phosphorylated 4E-BP1 (p4E-BP1) protein of 
CEM/WT, CEM/BTZ200 and CEM/CBD6250 cells incubated for 24 hr at the indicated 
concentrations of CBD or 100 nM BTZ. Expression of β-actin served as protein loading control.  
 
It is not clear whether CBD holds potential against drug-resistant leukemia cells and/or 
whether leukemia cells are prone to acquire resistance to CBD. With respect to the 
latter, we exposed CEM cells to stepwise increasing concentrations of CBD over a 
period of 4 months, but were unable to push CBD concentrations beyond a point of 
6250 nM (approximately IC50 values) without introducing delayed cytotoxic effects. 
Therefore these low level resistant CBD-adapted CEM/CBD6250 cells were further 
characterized.  
One of the major obstacles in cancer treatment is multidrug resistance at the cell level, 
which is in part mediated by the overexpression of some ATP-binding cassette (ABC) 
transporters43. Previously CBD has been evaluated as a potential reversal agent for 
multidrug-resistant cells overexpressing common drug efflux ABC transporters, such 
as ABCB1 (P-glycoprotein, P-gp) and ABCC1 (multidrug resistance-associated 
protein 1, MRP1). In fact, CBD interacted with ABCB144 and ABCC145 and reduced 
expression levels of these transporters, but CBD concentrations required for these 
effects were at cytotoxic levels, i.e. ~ 10 µM.  
In the present study we chose BTZ-resistant CEM cells as a drug resistant model 
since this proteasome inhibitor is active in multiple myeloma and is also investigated 
in an acute leukemia setting 46. Somewhat surprisingly, it was observed that 
CEM/BTZ200 cells had a low level of cross-resistance to CBD and had an increased 
expression of a marker of BTZ resistance, MARCKS protein38. These results suggest 
partly overlapping mechanisms of action for BTZ and CBD. Indeed, several studies 
described that both BTZ and CBD impact mitochondria and calcium homeostasis32,47. 
Moreover, Scuderi et al 48 reported in an Alzheimer Disease model of SHSY5Y 
neuroblastoma-like cells that CBD promoted the ubiquitination of amyloid precursor 
protein. Given that one of the proposed functions of MARCKS proteins is to facilitate 
the extrusion of vesicles containing polyubiquitinated proteins as a mechanism to 
reduce ER stress in leukemia cells38, these mechanisms may also hold for CBD-
induced accumulation of ubiquitinated proteins in other cell types. This notion warrants 
further investigations.  
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Despite overlapping activities, CBD and BTZ have been tested in combination for 
multiple myeloma cells in vitro, revealing synergistic effects24. We noted that CBD was 
unable to reverse BTZ resistance in CEM/BTZ cells (unpublished observation), which 
may have been anticipated since the underlying resistance mechanism is due to point 
mutations in the PSMB5 gene leading to impaired binding of BTZ in the binding pocket 
of the β5 subunit of the proteasome33. Since BTZ resistance may also have other 
underlying mechanisms49, combinations of CBD and BTZ deserve further evaluation.  
CBD mediates its effects via interactions with either CB1/CB2 receptors, ion channel 
receptor TRPV1 and or orphan G protein-coupled receptors GPR55 and 
GPR1196,14,50,51. Although CB2 is preferentially expressed in immune-related cells, 
this receptor was barely detectable in CEM/WT and drug-resistant CEM cells. It cannot 
be ruled out that is due to a technical shortcoming in the western blot analysis since 
the proposed positive control of MCF-7 breast cancer cells also showed a faint band 
and thus this experiment needs re-examination with alternative CB2 antibodies. 
GPR55 and GPR119 expression were readily detectable in CEM/WT but markedly 
down-regulated in CEM/BTZ7, CEM/BTZ200 and CEM/CBD6250 cells which were 
moderately cross-resistant to CBD. To what extent GPR55 and/or GPR119 contribute 
to CBD-induced growth inhibitory effects is still unexplored and future studies with 
agonist and antagonists for these receptors may provide insight in their differential 
relevance compared to other CBD receptors.  
One of the downstream effects of CBD receptor interaction involves the 
downregulation of the phosphorylation of mTOR and 4E-BP1 6. Phosphorylation of 
mTOR and 4E-BP1 are pivotal in promoting cell proliferation and cell survival 52,53. 
CBD-induced down-regulation of mTOR and 4E-BP1 phosphorylation has been 
demonstrated in breast cancer cells and leukemia cells exposed to micromolar 
concentrations of CBD 25,28,31. Consistently, we noted the same in CEM leukemia cells 
exposed to 10 µM CBD, although drug-resistant cells with moderate CBD cross-
resistance retained higher p4E-BP1 levels than CEM/WT cells. As such, inhibition of 
p4E-BP1 may be further explored as a useful indicator of CBD sensitivity in leukemia 
cells.  
The most remarkable observation in this study was that low concentrations of CBD 
induced marked growth stimulatory effects in drug-resistant leukemia cells. Studies by 
Derocq et al16,17 already demonstrated that sub-micro molar concentrations of 
cannabinoids had growth stimulatory effects on human B-cells and murine lymphoid 
and myeloblastic cells. This process was cannabinoid receptor-independent and 
proliferation effects were 30-40% based on [3H]-thymidine incorporation. Later studies 
by Hart et al18 demonstrated that nanomolar concentrations of THC (and other 
synthetic cannabinoids) could accelerate proliferation in glioblastoma cells (1.2-fold) 
and lung carcinoma cells (2-fold), by a mechanism that involved activation of ERK1/2, 
MAPK and Akt signaling. Our studies demonstrated a cell density-dependent growth 
stimulatory effect by CBD up to 3-fold in CEM/BTZ200 and up to 7-fold in 
CEM/CBD6250 cells. For CEM/CBD6250 cells this growth stimulatory factor is partly 
due to the fact that these cells acquired a CBD-addiction phenotype. Whether the 
underlying mechanisms for this involves activation of ERK1/2, MAPK or Akt signaling 
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is currently under investigation, but the increased 4E-BP1 phosphorylation in cells 
exposed to 1 µM CBD points in the direction of activation of signaling pathways. 
Conceivably, the CBD-addiction profile in CEM/CBD6250 cells is reminiscent of 
cancer drug addiction to MEK, ERK1/2, and BRAF inhibitors which are associated with 
hyperactivation of the ERK pathway and high levels of pERK1/254,55. In any case, 
CEM/CBD6250 cells might serve as an interesting in vitro model to further investigate 
molecular aspects of CBD-addiction.  
Considering the putative in vivo translation of low concentrations of CBD stimulating 
cancer cell growth, this will depend on the clinical pharmacology of cannabinoids. 
Bioavailability and pharmacokinetic studies56–58 documented maximal plasma 
concentrations (Cmax) of CBD that can be achieved in humans via the various routes 
of CBD administration. Low plasma levels of CBD, up to 0.04 µM, are monitored after 
smoking or inhalation, but after CBD intake by oral capsules or iv administration much 
higher peak plasma levels, 0.5 – 2.5 µM, are achievable56. Thus, dependent on the 
route of administration, plasma levels of CBD may approach concentrations that 
elicited growth stimulatory effects in vitro. There are case reports of cancer patients 
self- administering high dosing of CBD and reporting documented substantial 
decrease in symptoms and tumor size when taken together with standard oncological 
therapy59,60. However, caution may have to be exerted with CBD (co)treatment of 
recurrent/drug-resistant cancers. Currently, several clinical trials are underway to test 
the safety and efficacy of CBD and other cannabinoids in a cancer therapy setting 
(NCT03607643, NCT04428203, NCT04283019, NCT01812616, NCT02432612, 
etc.).The results of these studies will be informative on whether dosing of CBD should 
be guided and monitored to obtain optimal efficacy and avoid adverse effects of 
accelerating cancer progression. This also comes with the fact that CBD is a popular 
alternative-health product that is sold at very low and unregulated levels over the 
counter and might pose a health risk, especially in drug-resistant/therapy refractory 
cancer patients. Safety issues for CBD have recently been updated and published in 
scientific literature and by the World Health Organization which confirms the low 
toxicity profile of CBD 61–63. 
Taken together, our results point to be aware of growth stimulatory effects at low (1 
µM range) concentrations of CBD in drug-resistant leukemia cells. CBD can also exert 
antileukemic effects on (drug-resistant) leukemia cells, but only at high (> 10 µM) CBD 
concentrations which are hard to reach in vivo. Thus, the question arises: is CBD 
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In this thesis, three topics were investigated in the context of hematopoiesis, onset of 
acute leukemia and treatment of leukemia; (1) the role of bone marrow 
microenvironment in hematopoiesis, (2) drug resistance mechanisms for conventional 
anti-leukemic drugs, and (3) exploring cannabidiol (CBD) as experimental therapeutic 
agent for leukemia. Each of these topics will be discussed in greater detail hereafter.  
 
1. Bone marrow microenvironment in hematopoiesis 
The bone marrow microenvironment constitutes a milieu which supports and regulates 
normal hematopoiesis. The hematopoietic system, where HSCs in the BM differentiate 
into all blood cell types, facilitates the supply of billions of newly formed blood cells on 
a daily basis. Such a regulated and highly productive system requires a reliable and 
protective support mechanism. The BM microenvironment or niche acts as this 
support system and as such it can modulate HSC differentiation, quiescence or self-
renewal. Under stress or homeostatic conditions, the BM microenvironment is a 
dynamic and adaptable biological landscape1–3. In a leukemia disease setting, the BM 
environment also contributes to malignant transformation of leukemia cells and drug 
resistance including mediating pro-survival signaling processes and cell membrane 
transport systems involved in drug influx or efflux4,5. As such, investigating the 
components of the triad extracellular environment, cell membrane barrier and 
transporters, and intracellular processes (and their interactions) are highly relevant to 
uncover their role in hematopoiesis in health and disease.  
Endothelial cells (ECs) are key players in transforming the BM microenvironment and 
HSC behavior are the As described in Chapter 2, human regenerative associated 
endothelial cells or hRECs, phenotypically identified as CD31+/CD105+/CD9+ cells, 
originate during developmental (fetal BM) and regenerative (adult BM post-chemo) 
stages. hRECs are specialized ECs with a transcriptional program related to tissue 
regeneration, and are able to secrete factors, such as IL-33, which enhance precursor 
HSC expansion and osteogenesis2.  
The BM microenvironment has also the ability to promote regeneration through 
paracrine signaling1,3,6. When high jacked by LSCs, niche functioning can be 
redirected to favor malignant expansion and drug resistance, thus becoming a safe 
haven for leukemic cells1,3,5,7,8. Moreover, pro-inflammatory signaling by the 
microenvironment feeds into this negative feedback-loop, stimulating malignant 
transformation in an egg-or-chicken type conundrum9,10. 
Examining the capacity of hRECs to modulate the landscape of the BM 
microenvironment warrants further dissection and expansion in future studies. 
Relevant questions would be: how do hRECs contribute to osteogenesis and 
chondrogenesis in vivo? What is the transcriptional program responsible for this 
contribution? How does it direct HSC quiescence or activation? Once these questions 
have been answered, it would be possible to envision the application of hRECS in two 
specific fields: (1) regenerative medicine (RM) and (2) cancer therapy. In RM for 
example, the use of artificial 3D scaffolds has promising potential in tissue engineering 
for bone and BM renewal. In this approach, stromal cells can be utilized in an artificial 
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3D environment to recreate the BM niche and promote osteogenesis in order to aid 
HSCs to graft and reconstitute fresh blood cells11,12. Still, these methods have 
limitations, such as insufficient vascularization, mechanical load and transplantation 
challenges12. Nevertheless, the stimulatory signaling from hRECs could potentially 
promote vascularization as well as osteo/chondrogenesis which can increase the 
colonization and output potential of such systems. With respect to cancer therapy, the 
study of different regenerative capacities of niche cells (hRECs, MSCs, and others) 
could shed light on how leukemic cells can benefit from proliferation and migration 
signaling pre- or post-chemotherapy. 
In our own studies (Chapter 2), we observed that during 5-fluorouracil (5-FU) 
myeloablation studies in mice, hRECs were able to survive such treatment and that 
the absolute number of hRECs did not increase, but that the remainder of cells in the 
BM died. This finding suggests that under chemotherapeutic pressure, selective 
survival of hRECs, rather than absolute expansion, could be implicated2. It is still 
unknown if chemotherapy-surviving microenvironment cells influence LSC survival 
and their role in multidrug resistance in leukemia. It has been proposed that mapping 
transcriptional and epigenetic signatures in tumor environmental cells may reveal 
novel markers for malignant transformation and metastasis13. It is well known that ECs 
in the perivascular niche promote a stemness phenotype in cancer cells through e.g. 
Notch14,15, sonic hedgehog16–18 and nitric oxide19 signaling pathways, which stimulate 
cell migration14. Therefore molecular dissection of the vascular and perivascular niche 
in leukemia (and cancer in general) could provide a therapeutic opportunity for 
blocking malignant growth signals and metastasis. In light of our study in Chapter 2, it 
would be interesting to analyze the contribution of IL-33 to leukemia onset in a 
leukemic murine model, before and after chemotherapy. Recent studies by Taniguchi 
et al, showed in a murine model of squamous cell carcinoma, a signaling loop involving 
IL-33 and malignant progression. Under normal conditions IL-33 is stored in the 
nucleus, and its secretion into the malignant microenvironment by tumor initiating cells 
promotes invasion and differentiation of myeloid cells into macrophages. These cells 
release transforming growth factor beta (TGF-β) which further stimulates proliferation 
of malignant cells20. The involvement of IL-33 paracrine loops in leukemia progression 
is still unknown. It is plausible that additional mechanistic insights in the interactions 
of LSC and their niche could lead to pharmaceutical targets which can cause a 
blockade in supportive interactions between LCS and its perivascular niche. It may be 
critical to focus not only on treating the leukemic blast, but also its perivascular niche 
signaling loops, in order to develop effective personalized therapeutic strategies in the 
future13,21. 
Another critical aspect of anti-leukemic therapy and niche biology is to understand its 
contribution to multi drug resistance (MDR). How hRECs are related to drug resistance 
is not fully understood, but it is known that ECs in other tightly restricted areas such 
as the blood-brain barrier (BBB) express drug transporters that tightly regulate 
xenobiotic accumulation in order to protect the central nervous system (CNS)22,23. 
The ABC drug efflux transporter system is phylogenetically ancient, and well 
preserved across species. It also constitutes one of the largest superfamily of 
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transmembrane proteins24. These transporters are ubiquitously expressed in all three 
domains of life: archaea, bacteria and eukaryotes. ABC transporters are responsible 
for the active transmembrane transport of a broad diversity of xenobiotic substrates, 
which highlights their physiological and pharmacological importance25,26. Active efflux 
of xenobiotics results in reduced intracellular accumulation of drugs, which can 
contribute to chemoresistance. In a systems biology view of disease (cells and niche), 
multiple ABC transporters play a role in MDR since they are expressed on the 
membrane of both BM microenvironment cells and the HSC/LSCs22,27,28. 
How stromal cells and ECs contribute to MDR via cell membrane drug efflux 
transporters and how exactly they aid LSCs to tolerate chemotherapy, is still unknown. 
It has recently been postulated that mesenchymal stromal cells (MSC) can enhance 
survival of LSC “side populations” via activation of ABC transmembrane transporters 
in AML. When in contact with leukemic blasts, MSCs can promote the cellular 
programing required for drug efflux29. An important feature in this respect is functional 
redundancy of drug efflux transporters wherein transporters work in synchrony and 
can compensate each other. Since the microenvironment conditions promote MDR, 
future studies should focus on the role of (specific) drug transporters on specialized 
ECs and MSCs in the BM and how they can protect and detoxify the HSC/LSC niche 
from noxious drugs (in vivo, at regenerative and in steady-states). By this approach, it 
could be possible to identify sets of transporters in BM ECs, hRECs, MSCs and 
HSC/LSCs that might have a predictive value to therapy response. Moreover, new 
pharmacological targets or pathways could be identified in the malignant versus 
healthy state ECs. If so, it would be of interest to further investigate the relationship 
between malignant and healthy state compartmental relationship in terms of 
transporter expression and therapeutic intervention. 
 
2. Drug resistance mechanisms for conventional anti-leukemic drugs 
Cornerstone chemotherapeutic drugs such as MTX, Ara-C and glucocorticoids (GC) 
have been used for decades in clinical oncology. MTX is an essential prophylactic 
drug used for CNS involvement in childhood ALL30. Ara-C and GC are extensively 
used and continue to be the mainstream agent in the treatment of patients with AML31 
and childhood ALL32, respectively.  
One of the major challenges facing chemotherapy is the onset of drug resistance, 
which can be either innate or acquired. In drug resistance, there are multiple 
resistance mechanisms activated. These include: impaired drug influx/receptor 
binding, enhanced drug efflux, impaired drug activation, increased target enzyme 
expression and altered downstream effects such as survival pathway modulation and 
reduced apoptosis induction33,34. In this thesis we primarily focused on the role of 
transport-related resistance mechanism for these conventional anti-leukemic drugs.  
Several multidrug resistance-(MDR) related proteins can mediate export of 
conventional anti-leukemic drugs. For example MRP1-5 (MRP1-5, ABCC1-5) and 
breast cancer resistance protein (BCRP, ABCG2), which can extrude MTX, and high 
ABCC4 expression can confer resistance to Ara-C in AML cells ex vivo27(p4),35(p4). 
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These results point to functional redundancy of ABC transporters handling the efflux 
of particular drugs. This was also underscored in our studies (Chapter 4) 
demonstrating that ABC transporters ABCG2/ BRCP and ABCC4/MRP4 work in 
conjunction to extrude MTX and reduce the intracellular accumulation of MTX-
polyglutamates (MTX-PG). Furthermore, a coupled higher expression of 
ABCG2/BCRP and ABCC4/MRP4 correlated with ex vivo resistance to MTX and to 
poor survival. It is important to mention that many patients in this study are clinically 
considered high risk, yet they were selected because they fulfilled all required 
statistical data points for survival analysis (times of diagnosis, death or remission) plus 
had the high amount of cells necessary for all the laboratory procedures. Also, based 
on the limited number of samples and the strict guideline of sequential protocols, it 
was not possible to collect samples on risk stratification alone. Being aware of the 
limitations of our sample size and the impact on survival analysis, a large proportion 
of patients survived, yet valuable survival data was collected for over a decade and 
this enabled us to perform a Kaplan-Meier curve based on initial ABC transporter 
expression. We would have liked to analyze Kaplan-Meier curves based on risk 
stratification, but this process resulted futile since it divided an already small group of 
patients into several smaller cohorts composed of inconsequential sample numbers. 
For this reason we focused on the general survival of patients based on the 
combination of the expression of relevant ABC drug transporters. 
Ara-C resistance is seen in conjunction with a lower expression of its main transporter, 
the equilibrative nucleoside transporter 1(ENT1), in leukemia cells, and a lower 
expression of ENT1 mRNA has been correlated with a shorter disease-free survival in 
AML36,. Ara-C resistance is not only defined by ENT1 expression controlled by cell 
intrinsic mechanisms, but also by modulation of the microenvironment. For example it 
has been reported that BM MSC from AML patients can secrete soluble factors that 
lower ENT1 activity at the membrane of AML cells and simultaneously activate survival 
pathways. When this is seen ex vivo, it correlated with poor overall survival in AML38. 
 
2.1 Role of influx and efflux transporters in drug resistance 
The cell membrane is a first barrier for drug entry in cancer cells. Depending on the 
lipophilicity of the drug it can enter by passive diffusion, but active transport via solute 
carriers (SLCs) commonly applies for many drugs, in particular those with anionic or 
cationic properties39. This was elegantly shown in a recent functional screen for 60 
chemically diverse and widely used anticancer drugs in a CRISPR-Cas9 library 
targeting almost 400 SLC genes40. This screen readily confirmed SLC19A (Reduced 
Folate Carrier, RFC) and SLC46A1 (Proton Coupled Folate Transport, PCFT) as 
important influx transporters for MTX and confirmed that a knock-down of these SLCs 
led to MTX resistance. Likewise in this screen, SLC29A1 (human Equilibrative 
Nucleoside Transporter 1, hENT1) was also confirmed as Cytarabine/Ara-C influx 
transporter. Moreover, the screen identified functional redundancy in SLCs for multiple 
cytotoxic drugs.  
The role of ABC transporter family members in the efflux of cytotoxic drugs to confer 
MDR has been well characterized over the past decades24,27,34,41,42. ABC transporter 
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models proved useful at a pre-clinical level for developing molecular models of 
transporter physiology and pharmacology, determining substrate specificities and the 
design and testing of inhibitors of specific ABC transporters as potential strategy to 
overcome drug resistance mediated by ABC transporters (summarized in Chapter 3). 
Although these MDR-reversal strategies are successful in a laboratory setting, they 
unfortunately lack efficacy in clinical practice for various reasons43. Among others 
these include low, heterogeneous and interpatient differences in specific ABC 
transporters, interference with the physiological function of ABC transporters in 
specific organs, toxicity of the inhibitor and/or drug-drug interactions impacting 
chemotherapeutic drug pharmacokinetics42,43. 
The current positioning of ABC transporters in cancer drug resistance and underlying 
reasons for failures of resistance reversal studies in the clinic was recently 
discussed44. The main considerations include the fact of functional redundancy of ABC 
transporter and that no single efflux pump or transporter is solely responsible for drug 
resistance. Moreover, although in various types of solid tumors ABC transporter 
overexpression has been linked to MDR, results vary from sample to sample, 
underscoring the biological variation in the expression between individuals. Also, the 
ABC transporter activation pattern is heterogeneous and varies with age and 
tissue23,45,46,47,48. From a leukemia perspective, a diverse pattern of ABC transporter 
expression has been observed in stromal cells and leukemic blasts from the same 
(AML) patients29. These notions must be taken into account when weighing results 
from ABC transporter investigation and for personalized treatment considerations of 
leukemia patients. As future directions for ABC transporter research in leukemia cells, 
it is worthwhile to examine multiple ABC transporters, preferably in combination with 
micro environmental cell types (stroma cells and/or ECs). Moreover, even after several 
decades of MDR research further standardization is required for ABC transporter 
analysis of protein expression and functional activity. Drug evaluation assays could 
provide better insights of each individual patient’s needs based on actual, real-time, 
and tissue-specific analysis, and translate this information for precision medicine. 
 
2.2 MTX 
A folate analog was first evaluated in an oncological setting in 1948, when Farber et 
al. reported temporary remission in children with ALL treated with aminopterin49, which 
was later replaced by its less toxic analog MTX. Over 70 years MTX has served as an 
important drug in the chemotherapeutic arsenal of oncology, and later also as an anti-
inflammatory drug in auto-immune diseases such as rheumatology50 and 
inflammatory bowel disease (IBD). Extensive preclinical research has clarified the 
mechanism of action of MTX and also identified molecular mechanisms of acquired 
resistance to MTX, of which some were confirmed in the clinic51. The dominant 
resistance mechanisms to MTX include: (1) impaired cellular uptake via the reduced 
folate carrier (RFC, SLC19A1) or proton-coupled folate transporter (PCFT, SLC46A1), 
(2) MTX efflux via ABC transporters ABCC1-5 (MRP1-5) and ABCG2 (BCRP), (3) 
decreased MTX poly-glutamylation due to decreased Folyl- poly-glutamate synthetase 
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(FPGS) enzyme activity, and (4) increased expression, mutations and/or lowered MTX 
affinity of the main target enzyme for MTX; dihydrofolate reductase (DHFR)51. 
In our studies in Chapter 6, we focused on ABC transporters involved in MTX efflux 
and MTX polyglutamate accumulation in leukemic cells in relation to ex vivo MTX 
resistance. These results corroborated that in leukemia cells the intracellular retention 
of MTX polyglutamates is dependent on the “teamwork” of at least two efflux 
transporters (i.e. ABCC4/MRP4 & ABCG2/BCRP)52. Since our study included a 
relative small number of patients, it is conceivable that more relevant correlations exist 
between additional efflux transporters, which warrant confirmation in future studies in 
a large cohort of patients.  
Conceptually, the future design of a clinical study would incorporate the expression 
analysis of all relevant MTX influx and efflux transports, MTX-metabolizing enzymes, 
MTX-target enzymes, MTX-polyglutamate analysis to correlate these parameters with 
therapy response. Ideally more participants in general under a single treatment or by 
risk stratification system regimen would be helpful to attain better understanding of the 
relationship between the expression of these ‘MTX-response/resistance’ parameters 
on inter-patient variability, relapse and survival. Since almost all treatment regimens 
are based on a combination of several drugs, it should also be investigated which 
limiting factors for the other drug play a role and which parameters are important for 
the interaction.  
For ABC transporters to play a role in MTX efflux and resistance, an excellent 
efficiency of MTX polyglutamylation by FPGS in leukemia cells is crucial53–56 as only 
non-polyglutamated MTX is a substrate for ABC transporters (although ABCG2 can 
export di- and tri-glutamate forms). Recent research from our laboratory revealed that 
aberrant splicing of FPGS pre-mRNA is a novel factor accountable for diminished 
FPGS activity and consequently reduced MTX polyglutamylation and therapy 
response53,54,57. Another recent study revealed that FPGS mutations in relapsed 
leukemia would impact polyglutamylation efficiency58). These novel factors deserve 
further elaboration in studies assessing MTX efficacy/ resistance in leukemia.  
Based on the accumulated knowledge of MTX resistance mechanisms, rational 
approaches have been made to circumvent MTX resistance. One such approach is to 
prolong MTX infusion time above critical plasma levels, which could be more critical 
than peak plasma MTX levels alone, especially in childhood acute monocytic 
leukemia59. An alternative approach is to synthesize second generation antifolates 
aimed to circumvent MTX resistance in leukemias and solid tumors51,60,61. In particular, 
for AML treatment a novel antifolate would be of interest as MTX is less active in AML 
compared to ALL62. Since a might be an alternative as well. In this respect, recent 
studies pointed to targeting of mitochondrial folate metabolism, rather than cytosolic 
folate metabolism, by inhibiting a key mitochondrial enzyme 
methylenetetrahydrofolate dehydrogenase-cyclohydrolase-2 (MTHFD2), which is 
upregulated in cancer cells, including AML, and could potentially be targeted63–66. In 
fact, MTHDF2 inhibition by shRNA impaired AML progression and induced 
differentiation in vivo64. Moreover, suppression of MTHFD2 activity resulted in altered 
glycine metabolism and affected aerobic respiration by suppressing tricarboxylic acid 
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cycle in vitro, as well as colony formation in treated HSCs. Pre-clinical studies on its 
safety and toxicity are warranted, since not much is known about the toxicity of 
MTHFD2 inhibitors in vivo. Two interesting approaches worth exploring are (1) using 
computer modeling systems and (2) novel drug delivery formulations. The first one 
can aid to identify new antifolate molecules structures which may target folate-
dependent enzymes implicated in MTX resistance65,67. The second one, could help us 
deliver MTX more effectively and selectively by using lipid electrically charged 
nanoparticles68. Strategies considering inhibition of specific ABC transporters to 
reverse MTX resistance are likely to be less successful considering the functional 
redundancy of ABC transporters.  
 
2.3 Ara-C (and glucocorticoids) 
The nucleoside transporters hENT1 and hCNT1 constitute the dominant influx routes 
for nucleoside analogs Ara-C and gemcitabine. In fact, almost 80% of Ara-C influx is 
accounted for by these importers69,70. For this reason, hENT1 has been proposed as 
a predictive biomarker of gemcitabine efficacy for various solid tumors33–35 but clinical 
data showed conflicting results74–77. This inconsistency can be accounted for by using 
different methodologies in the evaluation of transporter expression (mRNA vs protein 
analysis) and lack of information on other relevant factors contributing to nucleoside 
analogue efficacy. Most importantly, crucial clinical studies have been performed 
using a non-validated antibody SP120, to determine hENT expression; therefore all 
studies using this antibody should be considered with care72,78. Other important 
resistance mechanisms include increased degradation by cytidine deaminase (CDA) 
and decreased activation by deoxycytidine kinase (dCK)79–81. This enzyme catalyzes 
phosphorylation of Ara-C and gemcitabine into their mono-, di- and triphosphate 
metabolites. Phosphorylation of nucleosides to their monophosphates is often a rate-
limiting step in the activation of these drugs. In addition, the phosphorylated 
monophosphate can be inactivated by dCMP deaminase to dFdUMP. All of these 
intracellular enzymes are limiting factors whose expression has been reported to be 
potentially involved in gemcitabine resistance69,82–85.  
In the future, molecular research should include standardized methods to study these 
contributing factors in nucleoside analogue efficacy78. A validated analysis may guide 
personalized treatment with these drugs. One of the challenges that we encountered 
in our immunohistochemistry study of hENT1 and hCNT1 expression in AML cells 
(Chapter 5) is the widespread expression of these transporters in ex vivo samples. 
This hampered setting accurate cut-off points to determine an association of high vs 
low hENT1 and hCNT1 expression with Ara-C sensitivity and resistance, respectively, 
and/or treatment outcome. Partly due to these limitations, our study did not reveal 
significant associations between these parameters. Moreover, AML patients are 
always treated with cocktails of different chemotherapeutics hampering the correlation 
between these transporter data and the ultimate response to therapy, which is 
dependent on the combined efficacy. To overcome the drug transporter related 
resistance, several lipophilic analogs of Ara-C86 and gemcitabine87 have been 
developed; however the gemcitabine prodrug CP-4126 (CO1.01) failed in clinical 
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studies due to the use of a non-validated antibody to select patients with a low hENT 
expression. However, a novel liposomal formulation of Ara-C and daunorubicin (at a 
fixed 5:1 molar ratio) has been investigated clinically88 and has been registered for 
treatment. The heterogeneous expression of hENT by ex vivo immunohistochemistry 
was also noted by others for pancreatic cancer cells. hENT1 expression categorized 
either as “low” or “high” overlapped a large percentage of samples, resulting in mixed 
survival results, and made cut-off points challenging to determine77. 
 
3. Cannabidiol (CBD) as experimental therapeutic agent for leukemia 
In the search for new anti-cancer drugs with novel mechanisms of action and for 
overcoming drug resistance, nature has provided (either by serendipity or 
intentionally) useful drug templates. In fact, most emerging and currently used cancer 
chemotherapeutic drugs in the twentieth century, come from natural sources. Ara-C, 
for example, was identified six decades ago in the sea sponge Cryptotheca crypta89, 
and served as prototype for next generation nucleoside analogues such as its 
fluorinated analog gemcitabine. Vinca alkaloids are also plant derived (Catharanthus 
roseus)90. GCs, such as dexamethasone and prednisolone, are analogs of our steroid 
hormone cortisol91. Cannabinoids, including cannabidiol (CBD) and 
tetrahydrocannabinol (THC), from the plant Cannabis sativa, emerged as novel drugs 
currently being studied in several clinical trials for its pleiotropic medicinal properties. 
Due to its low toxicity, CBD is an attractive compound, also because it is not 
psychoactive and has a high tolerability92. Cannabis sativa has been used for at least 
five millennia to treat many ailments, related to pain and inflammation93,94. Up-to-date, 
over 270 clinical trials are registered involving CBD and it is currently finding its niche 
as a drug in the field of refractory epilepsy, neurodegenerative diseases as well as 
pain management95,96, with a few trials involving different types of cancer (for example: 
NCT03607643, NCT04428203, NCT04283019, NCT01812616, NCT02432612).  
It is worth mentioning that in various non-malignant cells, CBD exerts anti-
inflammatory properties, inhibition of hENT (blocking adenosine uptake and promoting 
adenosine receptor binding97,98), and elicits mitochondrial-protective properties by 
modulating intracellular calcium levels and acting as an antioxidant99,100.  
In malignant cells, opposite effects are implicated by CBD treatment, including 
increasing mitochondrial stress and reactive oxygen species (ROS) levels101,102. In 
tumors with high glycolytic rates, the CBD-induced disruptive mitochondrial activity 
may add to metabolic stress and growth inhibitory effects103. 
The antitumor effects of various cannabinoids such as THC and CBD in several cancer 
types have been documented, in vitro and in vivo104–108. These effects may also relate 
to the fact CBD modulates the tumor microenvironment, inhibits tumor angiogenesis 
and decreases metastasis by blocking signaling loops and growth stimulation 
pathways in cancer cells and their niche104,108–110.  
Our in vitro studies with leukemic cells (Chapter 7) were aimed to examine the growth 
inhibitory potential of CBD, including drug resistant leukemic cells (CEM cells with 
acquired resistance to the proteasome inhibitor bortezomib, BTZ). Moreover, we 
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explored the effects of long-term exposure of leukemic cells to CBD. The outcome of 
these studies was that CBD exhibited growth inhibitory effects at concentrations >10 
µM by apoptosis induction, and that BTZ-resistant leukemia cells were modestly 
cross-resistant to CBD. The latter suggests some overlapping mechanisms of action 
between CBD and BTZ. The most striking observation was that long-term exposure of 
leukemic cells to CBD resulted in CBD-adapted cells which harboured a CBD-
addiction phenotype and displayed a marked growth stimulatory effect at low 
concentrations of 1 µM CBD. Moreover, CBD-adapted leukemic cells markedly 
induced MARCKs protein expression which had previously been shown to be involved 
in vesicular extrusion of polyubiquitinated proteins accumulating and BTZ-induced ER 
stress38. Thus, MARCKS overexpression may be an indicator of ER stress imposed 
by either BTZ or CBD. The notion that CBD also inhibited mTOR signalling as master 
regulator of protein synthesis further underscores an impact of CBD on protein 
synthesis/degradation.  
Although any extrapolation of the CBD in vitro data for leukemia treatment in vivo 
should be done with caution, the possible implications of our results encourage further 
research by addressing the following issues:  
 
3.1 CBD plasma levels.  
In order to envision whether the reported effects of CBD could hold clinical relevance, 
it is of importance to put them in perspective of CBD pharmacokinetics, i.e. what 
plasma and bone marrow microenvironment concentrations of CBD can be achieved 
and what is the CBD half-life therein? Pharmacokinetic studies in humans 
demonstrated that CBD smoking or inhalation resulted in plasma levels of up to 0.04 
µM. After oral or intravenous administration, much higher peak plasma levels (0.5 – 
2.5 µM) can be achieved. CBD plasma half-life vary from 24 hr after iv administration 
to 31 hr after CBD smoking92. No information is available for CBD levels in BM 
microenvironment. As noted for several other drugs, e.g. trastuzumab, MTX and 
cetuximab, microenvironment drug concentrations do not always correlate with 
circulatory plasma drug concentrations. In fact, the tumor microenvironment is 
enriched with proteins and metabolites (e.g. lactate and adenosine111), which can 
favor tumor growth and decrease drug toxicity112.  
These results would indicate that CBD concentrations > 10 µM are required to induce 
apoptosis in leukemic cells, but are not readily achievable in vivo; therefore anti-
leukemic effects may be limited.  
 
3.2 CBD growth stimulatory effects. 
 Given that maximal growth stimulatory effects by CBD for CBD-adapted cells and 
BTZ-resistant leukemia cells were observed at pharmacologically achievable CBD 
concentrations of 1 µM CBD, these effects may be potentially relevant in vivo. It still 
needs to be determined whether these effects are specific for CBD or also induced– 
and at what concentrations? - by other cannabinoids (e.g. THC) or endogenously 
secreted endocannabinoids such as anandamide (AEA) and 2-arachidonoylgycerol 
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(2-AG). These endocannabinoids molecularly resemble plant-derived 
phytocannabinoids and can also interact and modulate our endocannabinoid system 
(ECS). The ECS is involved in the regulation of a broad spectrum of physiological 
functions such as: cognition (pain sensation, memory formation, mood), fertility and 
pregnancy, sleep, appetite and energy metabolism, immune modulation and 
inflammation113,114.  
Indeed, one study reported that low concentrations (2 nM) of THC induced proliferation 
in human tonsillar B-cells in vitro115,116. Interestingly though in this aspect, is the very 
high level of proliferation induction that was observed in our studies with CEM 
leukemia cells in vitro. Remarkably, the endogenous cannabinoid anandamide (up to 
concentrations of 1 µM) lacked the same proliferative effect on B-cells as THC115. 
However, anandamide was able to induce proliferation at low serum concentrations in 
murine interleukin-dependent lymphoid cell lines116, suggesting that the level of protein 
binding is a factor in mediating these effects.  
3.3 CBD growth stimulation of drug resistant cells.  
The notion that low concentrations of CBD displayed growth stimulatory effects 
against BTZ-resistant leukemic cells raises the question whether this effect is specific 
for leukemic cells and/or proteasome inhibitor drugs, or also applies for other classes 
of anticancer drugs (antimetabolites, anthracyclines, TKIs, etc) and other tumor types. 
To this end, a survey for a broad array of tumor types and drug-resistant variants 
thereof would provide insights into the scale of this CBD effect. In case CBD growth 
stimulatory effects would be a common effect for drug-resistant cancer cells, this 
would call for awareness to cancer patients to be restrictive to recreative/medicinal 
CBD use in order not to promote, as a side effect, proliferation of latent drug-resistant 
clones.  
 
3.4 Dynamics of CBD addiction.  
Prolonged exposure of leukemic cells to CBD provoked a CBD-addiction phenotype 
of the dynamics deserve further investigations. Specifically, experiments to assess 
whether the addiction is a stable or reversible phenomenon warrant further studies. In 
case of a reversible effect, how rapidly is it reversed and how rapidly would it be re-
introduced upon rechallenge with CBD administration? This information may be 
relevant considering drug holidays of cancer patients in between therapy courses. In 
case the reversibility of the CBD addiction takes longer than the drug holiday period, 
this could negatively impact the efficacy of the next dose of chemotherapy.  
 
3.5 Molecular mechanism of CBD-drug addiction.  
Most importantly, further studies should be dedicated to unravel the molecular 
mechanism underlying CBD-drug addiction and growth stimulatory effects of low CBD 
concentrations. Drug addiction studies have been reported for solid tumors treated 
with signalling targeted drugs such as MEK, ERK1/2, BRAF-inhibitors117,118. A 
common feature in these studies appeared to be the involvement of the MAPK/ERK 
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and mTOR pathways119 117,118,120. In fact, hyper activation of the ERK pathway and 
high levels of pERK1/2117,118 establish excessive ERK1/2 signaling triggering cell cycle 
arrest or apoptosis via autophagy by inducing p21 and p53117,118,121. During drug 
addiction, ERK1/2 ensures delicate and specific, yet opposing functions. For example, 
while ERK2-JUNB-FRA1 pathway activation is observed in several cancer cell lines 
during treatment addiction, ERK1-JUNB is activated in drug withdrawal-surviving cells. 
These surviving cells express epithelial-to-mesenchymal transition (EMT)-related 
genes associated with cell migration genes and proliferation117,120,122. Future 
experiments, including genetic (RNAseq) and pathway analyses under conditions of 
CBD exposure, should reveal whether CBD-addiction shares overlapping 
mechanisms with drug addiction to MEK, ERK1/2, BRAF-inhibitors117,118 and even 
cross-addiction to these drugs in CBD-adapted leukemic cells. Specifically, a panel of 
genes deserving particular interest include MAPK1 (ERK2), MAP2K1 (encoding 
MEK1), JUNB, FOSL1 (FRA1) and MARCKS, as well as EMT-related genes such as 
VCAM. These studies should provide molecular insights on the regulatory programing 
involving vesicular trafficking (MARCKS), proliferation signaling (mTOR) and drug 
addiction pathways (ERK). In any case, CBD-adapted CEM/CBD6250 cells serve as 
an attractive in vitro model for future research on cellular CBD-addiction. 
 
3.6 CBD - leukemia treatment animal studies. 
 It would be unveiling to examine the in vivo effects of CBD in animal models engrafted 
with leukemic cells or solid tumors to monitor whether in vitro effects at low and high 
dosages of CBD are recapitulated. CBD has been evaluated in a breast cancer model 
in mice108,109, in which CBD suppressed EGF/EGFR signaling transduction pathway 
(and downstream AKT, ERK and NF‑kB) at dosages of 10 mg/kg/48 h. CBD treatment 
decreased metastasis and also inhibited CCL3 and GM‑CSF secretion from the 
cancer cells, resulting in low recruitment of tumor associated macrophages (TAMs) at 
tumor sites. Thus, CBD is able to modulate the malignant cell - microenvironment loop 
by inhibition of the adaptive immune response and inhibition of stromal invasion at 
multiple levels (TAMs, VEGF)108,109. Given the dual effects of low vs high CBD 
concentrations in our leukemia studies in vitro, testing different dosages of CBD would 
be recommended to better understand its activity profile regarding efficacy and 
adverse effects. A summarizing model of the mechanism of action of CBD in leukemia 
cells, including membrane receptor proteins and downstream affected pathways, is 
presented in Figure1.  
 
In summary, the results described in this thesis highlight the role of human 
regenerative associated endothelial cells (hRECs) in the bone marrow 
microenvironment and hematopoiesis. By being resistant to 5-FU therapy, hRECs 
remain active in secreting factors enabling enhanced expansion of precursor HSC. A 
second part of this thesis provides novel insights into the role of specific influx and 
efflux transporters implicated in the efficacy/resistance of MTX and Ara-C. Finally, a 
third part described the results of in vitro experimental anti-leukemia therapeutics with 
cannabidiol, revealing double-edged effects: anti-leukemic effects at high doses of 
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CBD and cell growth stimulatory effects at low doses of CBD. Together, these results 
may contribute to improve anti-leukemic chemotherapy efficacy and minimize toxicity.  
Figure 1: Possible hypothetical mechanisms of CBD-mediated proliferation or 
apoptosis in CEM cells in vitro. CBD at high concentrations (>10 µM) can: (1) diffuse 
through the cell membrane due to its lipophilic characteristics and interrupt signaling pathways 
vital for cell survival and proliferation (left). CBD is also able to induce ER stress and also 
mitochondrial stress, resulting in increased ROS production, autophagy and apoptosis. (2) 
Additionally high CBD concentrations, can activate unidentified GPRs that modulate 
negatively mTOR activation and 4E-BP1 phosphorylation, leading to reduced survival and 
apoptosis. (3) At low concentrations (around 1 µM) CBD activates unidentified GPRs that 
promote 4E-BP1 phosphorylation and stimulate cell proliferation. (4) Sustained, chronic CBD 
exposure at sub-toxic concentrations, induces CBD resistance, CBD addiction, and MARCKS 
protein upregulation. MARCKS facilitates the transport of vesicles containing ubiquitinated 
proteins to overcome proteolytic stress imposed on the ubiquitin/proteasome system and 
thereby constitutes a well-known mechanism of bortezomib resistance in CEM cells123. 
Abbreviations: G protein-coupled receptors (GPR), cannabidiol (CBD), reactive oxygen 
species (ROS), endoplasmic reticulum (ER), mammalian target of rapamycin (mTOR), factor 
4E (eIF4E)-binding protein 1 (4E-BP1), myristoylated alanine-rich C-kinase substrate 
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Leukemia is one of the most common types of hematological malignancies in both 
adults and children. Some of the fundamental traits of leukemia include the capacity 
for sustained, uncontrolled proliferation and impaired differentiation of white blood 
cells. Although chemotherapy remains the cornerstone for curative treatment, some 
leukemia cells will remain after therapy due to drug resistance, which is an important 
clinical challenge without a pharmacological solution for all patients at the moment. In 
addition, cell-specific and microenvironmental factors play a role in both the etiology 
and progression of leukemia.  
Because the bone marrow (BM) and the hematopoietic stem cells (HSC) respond to 
physiological stimuli, a systems biology perspective of leukemia can help to 
understand and elucidate the mechanisms underlying sustained, uncontrolled 
proliferation and drug resistance. This approach allows envisioning leukemia not only 
as a cell-specific phenomenon, but also as a tissue-based anomaly, in which the 
dynamic interaction between the leukemic cells and their microenvironment plays a 
key role in malignant transformation, drug resistance, and dissemination.  
In this thesis, we describe leukemia treatment and development through analysis of 
cell-specific features as well as the microenvironmental influence of endothelial cells 
in BM regeneration post-chemotherapy. This allows us to identify crucial drug 
resistance and pro-malignant mechanisms that could be potentially targeted 
pharmaceutically. Cell-specific factors that we investigated in this thesis include the 
expression and influence of drug transporters at the membrane level and the 
metabolic interaction of drugs in cancer therapy. The environmental factors studied 
include transcriptional expression analysis of specialized endothelial niche cells in the 
BM. 
In chapter 2 we demonstrate that the BM microenvironment harbors specialized 
endothelial niches responsible for the maintenance of HSCs and for their ability to 
provide paracrine signalling to sustain physiological HSC function. Notably, angiocrine 
factors, such as IL-33, secreted from specialized endothelial cells (human 
regenerative endothelial cells or hRECs) in the BM, can stimulate hematopoiesis, 
angiogenesis, and osteogenesis during BM development and regeneration post-
chemotherapy in acute myeloid leukemia (AML). Still, the precise role of IL-33 in 
leukemic transformation and drug resistance remains to be further elucidated. 
In chapters 3 and 4 of the thesis cell-intrinsic mechanisms contributing to drug 
resistance are described. One of the most studied mechanisms involves the role of 
ATP-binding cassette (ABC) drug efflux transporter proteins. These diverse and 
phylogenetically ancient membrane-associated proteins are expressed in all cell types 
and play a key role in protecting both prokaryotic and eukaryotic cells from toxic 
xenobiotics. Specifically, many of these transporters can also expel a myriad of 
chemotherapeutic molecules, including those relevant to leukemia, such as 
methotrexate (MTX), and therefore are able to impact cellular drug efflux. The clinical 
relevance of individual ABC transporters for therapy efficacy in leukemia still needs 
further elucidation in leukemia, but one lesson that is learned from these transporters 
is their overlapping capability/functional redundancy and working in tandem to 
complement each other’s function. The end result is lowered intracellular drug 
concentration (in this case MTX), thus leading to drug resistance. In chapter 3 we 
explored the molecular characteristics and clinical relevance of various ABC 
transporters such as P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein 
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(BCRP/ABCG2), and multidrug resistance-associated protein-1 (MRP1/ABCC1). We 
further reviewed and discussed recent insights on specific pharmacological 
mechanisms to overcome ABC transporter-related drug resistance. In chapter 4 we 
explored the joined expression of MRP1, MRP4, MRP5, and BCRP in childhood acute 
lymphocytic leukemia (ALL) samples ex vivo, and how their expression correlated with 
MTX intracellular concentrations and overall patient survival. Our analysis revealed 
that while MRP4 expression correlated with ex vivo MTX resistance, it did not correlate 
by itself with poor survival. Yet, when both MRP4 and BCRP expression is high, not 
only this was associated with a decreased intracellular MTX accumulation, but also a 
lower overall survival.  
Along this line, we also explored (chapter 5) other clinically relevant transporters in 
pediatric leukemia, such as the expression of the human equilibrative nucleoside 
transporter 1 (hENT1) and the concentrative nucleoside transporter-1 (hCNT1). These 
transporters are responsible for three-quarters of the cellular uptake of nucleoside 
analogs, such as cytarabine (Ara-C). Specifically, immunohistochemistry studies in 
primary pediatrics AML samples demonstrated that these transporters are widely 
expressed at the cell membrane and cytoplasm at the time of diagnosis. Interestingly, 
no significant relationship was found between survival and transporter expression and 
ex vivo drug sensitivity.  
In chapter 6, we examined the influence of dexamethasone (DEX) on the in vivo 
antileukemic effect of Ara-C and gemcitabine in a rat model of AML. Specifically, we 
studied the effect of DEX administration on the enzymatic activity of deoxycytidine 
kinase (dCK) . Since dCK catalyses the first step in the conversion of Ara-C into its 
active metabolite, cytosine arabinoside triphosphate (Ara-CTP) and previous studies 
showed that DEX administration diminished dCK activity, it was relevant to study this 
relationship further. It was not surprising to observe an increased life-span in Ara-C-
treated AML rats, and concomitant treatment with DEX had no impact on dCK 
enzymatic activity in leukemic cells. As this challenged results from previously 
published studies, further in-depth investigations on the impact of DEX in AML patients 
treated with cytarabine are indicated.  
Finally, in chapter 7, we explored the proliferating capacity and cytotoxicity profile of 
cannabidiol (CBD) in vitro in prototypical human (T) ALL cell line CCRF-CEM and its 
subline (CEM/BTZ) with acquired resistance to bortezomib (BTZ). CBD is an FDA-
approved anti-inflammatory, anti-epileptic, and cell-protective lipophilic molecule 
popularly sold over-the-counter. CBD is also a known modulator of mTOR activity, 
which is crucial for cell survival and proliferation, both in malignant and healthy cells. 
Notably, cell growth inhibition/toxicity assays revealed that high concentrations of CBD 
were needed (around 10 µM) to induce toxicity. Remarkably, low, clinically reachable 
concentrations of CBD (around 1 µM) were able to induce significant cell proliferation, 
which was cell-density dependent, which suggests a role for secondary cell-density 
growth stimulatory effects. Furthermore, chronic stepwise exposition to increasing 
concentrations of CBD resulted in subline (CEM/CBD6250) with CBD-addiction 
properties where CBD is required for its growth. The positioning of CBD as a potential 
treatment option for ALL in vivo still needs to be defined. The role of modulating the 
microenvironment might be relevant in CBD treatment, as it is also able to inhibit 
inflammation and angiogenesis in many tumor types. Since we did not yet investigate 
these features and the mechanisms of action of CBD in leukemia cells was not yet 
clarified, further research is warranted.  
Together, this thesis describes the multifaceted approach of leukemia treatment, BM 
microenvironment, drug resistance, and the bimodal (proliferative/cytotoxic) properties 
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of CBD. As new regenerative factors are revealed in specialized endothelial cells 
during regenerative and developmental stages, new questions arise on how these 
cells, niches, and factors are involved in leukemia development and protection from 
drugs and development of drug resistance. Furthermore, in the second part of this 
thesis, we focused on how cell-intrinsic factors are involved in drug resistance. Such 
can be conferred by the overexpression of drug-transporter proteins in cancer cells. 
Even though no single transporter is solely responsible for specific drug resistance, 
our analyses revealed significant correlations between overexpression of multiple 
drug efflux transporters and lowered intracellular chemotherapy (MTX) concentration, 
and poor survival. Some influx transporters (such as hENT1 and hCNT1) are so widely 
expressed, that this hampers clinically accurate classification of these transporters in 
leukemia. This implies that a broader approach needs to be applied to fully 
comprehend the relative distribution of various in- and efflux transporters in optimized 




• The BM microenvironment harbours specialized human endothelial 
regenerative cells (hRECs) within endosteal niches. hRECs are active during 
developmental stages and regeneration and post-chemotherapeutic insult. 
hRECs overexpress IL-33, which stimulates the expansion of hematopoietic 
precursor cells, endothelial cells, as well as osteogenic differentiation.  
 
• ABC transporters MRP4 and BCRP are major determinants in regulating the 
intracellular accumulation of MTX-polyglutamates in leukemic cells, which is 
associated with overall survival. 
 
• The human equilibrative nucleoside transporter 1 (hENT1) and the 
concentrative nucleoside transporter-1 (hCNT1) are responsible for cellular 
uptake of cytarabine (Ara-C). Immunocytochemistry staining revealed that 
hENT1 and hCNT1 are widely expressed during diagnosis in pediatric AML, 
hampering accurate clinical classification based on the expression of these 
transporters.  
 
• Dexamethasone (DEX) and Ara-C are important drugs in childhood ALL 
treatment. To this end, some studies showed that DEX might affect the 
activation of intracellular Ara-C by decreasing deoxycytidine kinase (dCK) 
activity. Our in vivo studies, however, showed that combined DEX-Ara-C 
administration did not lower dCK activity or affect the anti-leukemic effect of 
Ara-C in a rat AML model. 
 
• CBD has dual effects on leukemia cells in vitro: it has growth inhibitory effects 
at concentrations > 10 µM, but growth stimulatory effects, in particular in drug-
resistant cells, at concentrations around 1 µM. Given that prolonged CBD 
exposure also provokes drug-addiction phenomena, this would call for caution 








Leukemie is een van de meest voorkomende hematologische kankersoorten bij zowel 
volwassenen als kinderen. Enkele belangrijke eigenschappen van leukemie zijn het 
vermogen tot aanhoudende, ongecontroleerde groei en verminderde differentiatie van 
witte bloedcellen. Hoewel chemotherapie de hoeksteen blijft voor genezing, zullen 
sommige leukemiecellen na de therapie overblijven vanwege ongevoeligheid 
(resistentie) ontwikkeling tegen anti-leukemische geneesmiddelen. Dit is een 
belangrijke klinische uitdaging, maar helaas nog steeds zonder een farmacologische 
oplossing waar alle patiëntenbaat bij hebben. Bovendien spelen celspecifieke en 
micro-omgevingsfactoren een rol bij zowel de etiologie als de progressie van 
leukemie. 
Omdat het beenmerg (BM) en de hematopoëtische stamcellen (HSC) reageren op 
fysiologische stimuli, kan een systematische en biologische aanpak van leukemie 
helpen om de resistentie mechanismen te begrijpen die ten grondslag liggen aan de 
aanhoudende, ongecontroleerde groei en resistentie. Deze benadering maakt het 
mogelijk om leukemie niet alleen te zien als een celspecifiek fenomeen, maar ook in 
de context van de weefsels in de omgeving. Hier speelt de dynamische interactie 
tussen de leukemiecellen en hun micro-omgeving een sleutelrol bij kwaadaardige 
transformatie, resistentie en verspreiding. 
In dit proefschrift beschrijven we de analyse van celspecifieke kenmerken en de 
invloed van de micro-omgeving op de ontwikkeling van leukemie en op de 
behandeling en de rol van endotheelcellen bij BM regeneratie na chemotherapie. Dit 
stelt ons in staat om cruciale resistentie en pro-maligne mechanismen te identificeren 
die mogelijk farmacologisch kunnen worden aangepakt. Celspecifieke factoren die we 
in dit proefschrift hebben onderzocht, zijn onder meer de expressie en invloed van 
transporter eiwitten op membraanniveau en de metabole interactie van medicijnen bij 
kankertherapie. De bestudeerde omgevingsfactoren omvatten transcriptionele 
expressie-analyse van gespecialiseerde endotheel cellen in het BM. 
In hoofdstuk 2 laten we zien dat er in de BM-micro-omgeving gespecialiseerde 
endotheel niches zijn die verantwoordelijk zijn voor het overleven van HSC's en voor 
hun vermogen om paracriene signalen uit te zenden om de fysiologische HSC-functie 
te ondersteunen. Angiocriene factoren, zoals IL-33, worden uitgescheiden door 
gespecialiseerde endotheelcellen (menselijke regeneratieve endotheelcellen of 
hREC's) in het BM. Deze kunnen hematopoëse, angiogenese en osteogenese 
stimuleren tijdens de BM-ontwikkeling en regeneratie na chemotherapie bij acute 
myeloïde leukemie (AML). Toch moet de juiste rol van IL-33 bij leukemische 
transformatie en geneesmiddelresistentie nog verder worden opgehelderd. 
In de hoofdstukken 3 en 4 van het proefschrift worden cel-intrinsieke mechanismen 
beschreven die een rol spelen in de resistentie tegen geneesmiddelen. Een van de 
belangrijkste mechanismen betreft de rol van ATP-bindende cassette (ABC) 
transporteiwitten, die geneesmiddelen naar buiten kunnen pompen. Deze diverse en 
fylogenetisch oude membraangeassocieerde eiwitten komen tot expressie in alle 
celtypen en spelen een sleutelrol bij het beschermen van zowel prokaryote als 
eukaryote cellen tegen toxische xenobiotica. In het bijzonder kunnen veel van deze 
transporteiwitten ook een groot aantal geneesmiddelen naar buiten pompen, inclusief 
enkele geneesmiddelen die belangrijk zijn voor leukemie, zoals methotrexaat (MTX) 
en anthracyclines. De klinische relevantie van individuele ABC-transporters voor de 
werkzaamheid van therapie bij leukemie is nog steeds een belangrijke 
onderzoeksvraag. Het is de laatste jaren echter steeds duidelijker geworden dat deze 
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transporters een overlappende capaciteit en functie hebben en samenwerken om 
elkaars functie aan te vullen. Het eindresultaat is een verlaagde intracellulaire 
concentratie van bijv. MTX, wat leidt tot resistentie. In hoofdstuk 3 hebben we de 
moleculaire kenmerken en klinische relevantie van verschillende ABC-
transporteiwitten onderzocht, zoals P-glycoproteïne (P-gp / ABCB1), 
borstkankerresistentie-eiwit (BCRP / ABCG2) en multidrug-resistentie-geassocieerd 
proteïne-1 (MRP1 / ABCC1). ). We hebben recente inzichten beschreven over 
specifieke farmacologische mechanismen om ABC-transporter-gerelateerde 
resistentie te omzeilen. In hoofdstuk 4 hebben we ex vivo de gecombineerde 
expressie van MRP1, MRP4, MRP5 en BCRP onderzocht in monsters van acute 
lymfatische leukemie (ALL) bij kinderen, en hoe hun expressie correleerde met 
intracellulaire concentraties van MTX en de algehele overleving van de patiënt. Onze 
analyse liet zien dat MRP4-expressie correleerde met ex vivo MTX-resistentie, maar 
niet correleerde met een slechte overleving. In het geval dat zowel MRP4- als BCRP-
expressie hoog zijn, was dit niet alleen geassocieerd met een verminderde 
intracellulaire MTX-accumulatie, maar ook met een lagere algehele overleving. 
Langs deze lijn hebben we ook (hoofdstuk 5) andere klinisch relevante 
transporteiwitten bij kinder leukemie onderzocht, zoals de expressie van enkele 
andere nucleoside transporters zoals hENT1 en hCNT1. Deze transporters zijn 
verantwoordelijk voor driekwart van de cellulaire opname van nucleoside-analogen, 
zoals cytarabine (Ara-C). Specifiek, immunohistochemische kleuringen in primaire 
kinder AML-monsters toonden aan dat op het moment van diagnose deze 
transporteiwitten op grote schaal aanwezig zijn op het celmembraan en in het 
cytoplasma. Er werd echter geen significante relatie werd gevonden tussen overleving 
en expressie van transporteiwitten en ex vivo geneesmiddelgevoeligheid. Wellicht 
spelen andere factoren een rol. Een van deze factoren, het activeringsenzym.voor 
Ara-C, deoxycytidine kinase (dCK) werd in hoofdstuk 6 onderzocht. 
In dit hoofdstuk onderzochten we de invloed van dexamethason (DEX) op het in vivo 
antileukemische effect van Ara-C en gemcitabine in een rattemodel van AML. Daarbij 
concentreerden we ons op het effect van DEX-toediening op de enzymatische 
activiteit van dCK. dCK katalyseert de eerste stap in de omzetting van Ara-C naar zijn 
actieve metaboliet, cytosine arabinoside trifosfaat (Ara-CTP). Omdat we eerder in vitro 
aangetoond hadden dat behandeling met DEX de dCK-activiteit verminderde, hebben 
we onderzocht of dit ook in een relevant in vivo leukemie model het geval was. Zoals 
verwacht verlengde Ara-C behandeling de levensduur van AML-ratten, maar 
gelijktijdige behandeling met DEX had geen invloed op het antileukemisch effect en 
de enzymatische activiteit van dCK in leukemische cellen. DEX had wel een effect of 
de dCK activiteit in normale lever, terwijl in andere studies met DEX gevonden is dat 
het de bijwerkingen vermindert. 
Ten slotte hebben we in hoofdstuk 7 het effect van cannabidiol (CBD) in vitro 
onderzocht in de prototypische menselijke (T) ALL cellijn CCRF-CEM en zijn sublijn 
(CEM / BTZ) met resistentie tegen bortezomib (BTZ). CBD is een door de FDA 
goedgekeurde ontstekingsremmer, anti-epilepticum en celbeschermende lipofiele 
molecuul wat ook vrij verkrijgbaar is als cannabis. CBD is ook een bekende modulator 
van mTOR-activiteit, wat cruciaal is voor celoverleving en celgroei, in kwaadaardige 
en gezonde cellen. Om de celgroeiremming / toxiciteit te induceren waren echter hoge 
concentraties CBD nodig (ongeveer 10 µM). Het was opmerkelijk dat lage, klinisch 
relevante concentraties van CBD (ongeveer 1 µM) significante celgroei konden 
induceren. Dit was afhankelijk van de celdichtheid, wat een rol suggereert voor 
secundaire stimulerende effecten van de cellulaire dichtheid. Bovendien resulteerde 
chronische stapsgewijze blootstelling aan steeds hogere concentraties van CBD in 
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een “verslaving” van de subliin (CEM / CBD6250). Deze verslavende eigenschappen 
kunnen verklaren waarom CBD nodig is voor de groei. De mogelijkheid van CBD als 
een mogelijke behandelingsoptie voor ALL in vivo moet nog worden onderzocht. De 
rol van de micro-omgeving kan relevant zijn bij CBD-behandeling, omdat het ook in 
staat is om ontsteking en angiogenese bij veel tumortypen te remmen. Aangezien we 
deze kenmerken nog niet hebben onderzocht en de werkingsmechanismen van CBD 
in leukemiecellen nog niet zijn opgehelderd, is verder onderzoek nodig. 
Samengevat beschrijft dit proefschrift een veelzijdige aanpak van 
leukemiebehandeling, de BM-micro-omgeving, geneesmiddelresistentie en de 
bimodale (groei/ cytotoxische) eigenschappen van CBD. De nieuwe regeneratieve 
factoren die worden gevonden in gespecialiseerde endotheelcellen tijdens 
regeneratieve en ontwikkelingsstadia, roepen nieuwe vragen voor over de rol van 
deze cellen, de niches en factoren bij de ontwikkeling van leukemie, de bescherming 
tegen geneesmiddelen en de ontwikkeling van geneesmiddelresistentie. Daarom 
hebben we ons in het tweede deel van dit proefschrift gericht op hoe cel-intrinsieke 
factoren betrokken zijn bij geneesmiddelresistentie. Dit kan worden verklaard worden 
door de hoge activiteit van transporteiwitten die geneesmiddelen uit de kankercellen 
pompen. Het bleek echter dat niet een maar meerdere transporteiwitten 
verantwoordelijk zijnvoor specifieke geneesmiddelresistentie, omdat wij een 
significante correlatie vonden met niet alleen een lagere intracellulaire concentratie 
van het geneesmiddel MTX -maar ook met een slechte overleving. Wat betreft enkele 
transporteiwitten die verantwoordelijk zijn voor de opname bleek dat deze (zowel 
hENT1 als hCNT1) zo’n hoge expressie hebben dat een klinisch relevante classificatie 
bij leukemie niet mogelijk was, i.t.t. tot enkele solide tumoren zoals long- en 
alvleesklierkanker. Dit impliceert dat alleen de relatieve distributie van verschillende 
in- en efflux transporters niet voldoende is om een geoptimaliseerde en 







• De BM-micro-omgeving heeft gespecialiseerde menselijke endotheel regeneratieve 
cellen (hREC's) in endostale niches. hREC's zijn actief tijdens ontwikkelingsstadia en 
regeneratie en na de blootstelling aan chemotherapie. hREC's brengen IL-33 tot 
overexpressie, wat de expansie van hematopoëtische voorlopercellen, 
endotheelcellen en osteogene differentiatie stimuleert. 
 
• ABC-transporteiwitten MRP4 en BCRP zijn belangrijke factoren bij het reguleren van 
de intracellulaire accumulatie van MTX-polyglutamaten in leukemische cellen, wat 
wordt geassocieerd met de algehele overleving. 
 
• Twee nucleoside transporters (hENT1 en hCNT1 zijn verantwoordelijk voor de 
cellulaire opname van cytarabine (Ara-C). Immunocytochemische kleuringen toonden 
aan dat hENT1 en hCNT1 een hoge expressie hebben in kinder AML, wat een 
nauwkeurige klinische classificatie op basis van de expressie van deze 
transporteiwitten belemmert. 
 
• Dexamethason (DEX) en Ara-C zijn belangrijke geneesmiddelen bij de behandeling 
van ALL bij kinderen. Eerder was aangetoond dat DEX de activering van intracellulair 
Ara-Cdoor deoxycytidine kinase (dCK) zou kunnen verminderen. Onze in vivo 
onderzoeken toonden echter aan dat gecombineerde DEX-Ara-C-toediening de dCK-
activiteit niet verlaagde en het anti-leukemische effect van Ara-C in een AML-model 
bij ratten niet beïnvloedde. De verlaging van dCK in normaal weefsel zou kunnen 
verklaren waarom DEX wel een beschermend effect op toxiciteit zou kunnen hebben. 
 
• CBD heeft dubbele effecten op leukemiecellen in vitro: het heeft groeiremmende 
effecten bij hoge concentraties (> 10 µM), maar groeistimulerende effecten bij lage 
concentraties (rond 1 µM) in het bijzonder in resistente cellen, Aangezien langdurige 
blootstelling aan CBD ook verslavingsverschijnselen veroorzaakt, moet het gebruik 
van CBD met de nodige voorzichtigheid gepaard gaan en niet zonder toezicht als 






Resumen en Español 
La leucemia es una de las neoplasias hematológicas más comunes tanto en adultos 
como en niños. La proliferación descontrolada las células hemáticas y una 
diferenciación alterada son rasgos característicos y fundamentales de la leucemia. A 
pesar de que la quimioterapia sigue siendo de gran importancia en el tratamiento de 
la leucemia, algunas células malignas son capaces de sobrevivir el tratamiento y 
perduran debido a su capacidad de fármaco-resistencia. En añadidura, los factores 
microambientales a nivel tisular y factores celulares intrínsecos, son capaces de 
contribuir a la malignidad y progresión de la leucemia. Este fenómeno de fármaco-
resistencia resulta en un desafío clínico frecuente e importante, sin solución 
farmacológica actual. 
Para abordar este problema clínico, es necesario adoptar una perspectiva de biología 
de sistemas ya que esto nos puede ayudar a comprender y dilucidar los mecanismos 
que estimulan la proliferación crónica y la fármaco-resistencia en la leucemia, ya que 
la médula ósea (MO) y las células madre hematopoyéticas (CMH) responden a varios 
estímulos fisiológicos provenientes de diferentes partes del organismo (sistema 
nervioso, sistema renal, etc),y de su medio ambiente. Por tanto, el enfoque desde la 
biología de sistemas nos permite visualizar la leucemia no solamente como un 
fenómeno específico de la célula, sino también como una anomalía tisular, donde la 
interacción dinámica entre las células malignas y su microambiente tisular influye en 
la transformación cancerígena, la diseminación y la fármaco-resistencia a la 
quimioterapia. 
En la presente tesis, se describe el tratamiento y desarrollo de la leucemia a través 
de un análisis de las características específicas a nivel celular, así como la influencia 
microambiental de las células endoteliales en la regeneración de la MO después de 
la quimioterapia. Este abordaje nos permite identificar factores que influyen en la 
fármaco-resistencia y a los mecanismos de transformación maligna que podrían 
potencialmente ser tratados farmacológicamente. Específicamente hemos 
investigado la expresión e influencia de las proteínas transportadoras de fármacos a 
nivel membranal y la interacción intracelular de varios fármacos usados la 
quimioterapia, mientras que los factores microambientales estudiados incluyen el 
análisis extensivo de la expresión genética de células endoteliales especializadas, 
que se encuentran localizadas en nichos específicos de la MO durante dos periodos 
en específico: el desarrollo y la generación de la médula fetal y  la regeneración de la 
médula en adultos (después de la quimioterapia). 
En el capítulo 2 se describe cómo el microambiente de la MO alberga nichos 
endoteliales especializados responsables de la señalización paracrina necesaria para 
el funcionamiento fisiológico de las CMH. Específicamente, nos hemos enfocado en 
la interleucina-33 (IL-33) como factor angiócrino, que siendo secretados por células 
endoteliales especializadas (células endoteliales regenerativas humanas o hREC) en 
la MO, es capaz de estimular la hematopoiesis, la angiogénesis y la osteogénesis 
Chapter 9 
170 
durante el desarrollo fetal de la MO pero también in vitro  e in vivo. Además la IL-33 
es capaz de promover la regeneración de la MO después de la quimioterapia en la 
leucemia mieloide aguda (LMA). Sin embargo, el rol específico del factor IL-33 en la 
transformación leucémica y la fármaco-resistencia es un tema que aún no ha sido 
esclarecido. 
En los capítulos 3 y 4 de la tesis describimos mecanismos celulares intrínsecos que 
contribuyen a la fármaco-resistencia en la leucemia. Uno de los mecanismos más 
estudiados es el de las proteínas transportadoras ABC (del inglés ATP-binding 
cassette). Estas proteínas que se expresan en la membrana celular, forman parte de 
una familia hiper diversa y se caracterizan por ser filogenéticamente muy antiguas ya 
que se expresan en todos los organismos procariotas y eucariotas. Desempeñan un 
rol clave en la protección celular contra moléculas xenobióticas y tóxicas y son 
capaces de desintoxicar el interior de la célula de una gran cantidad de fármacos,  
incluyendo  quimioterapéuticos, como el metotrexato (MTX), entre muchos otros. Este 
proceso afecta la concentración intracelular de la droga y por ende,  afecta su eficacia. 
En nuestro estudio, hemos descubierto como grupos  específicos de transportadores 
ABC pueden trabajar en conjunto de una forma coordinada. Esta redundancia 
funcional y complementaria puede resultar ser importante en cuanto a la 
desintoxicación celular. La resistencia la quimioterapia puede ser medible desde un 
punto de vista clínico, como en el análisis realizado de la tasa de supervivencia 
general en pacientes con expresiones altas de proteínas ABC específicas y el 
tratamiento con MTX. Cabe destacar que al estudiar el impacto individual de los 
transportadores ABC (y no en conjunto), su relevancia clínica disminuye. Esto se debe 
a que el análisis individual de cualquier proteína ABC no nos permite ver el impacto 
real a nivel de la desintoxicación celular. Por tanto debemos analizar el rol de los 
transportadores cuando trabajan sincronizadamente en “equipo”. En el capítulo 3 
exploramos las características moleculares y la relevancia clínica de varios 
transportadores ABC, como la glicoproteína P (P-gp / ABCB1), breast cancer 
resistance protein (BCRP / ABCG2) y la multidrug resistance protein 1 (MRP1 / 
ABCC1). Además, revisamos los avances más recientes sobre mecanismos 
farmacológicos para circunvalar la fármaco-resistencia relacionada a los 
transportadores ABC. En el capítulo 4 investigamos ex vivo la expresión en conjunto 
de MRP1, MRP4, MRP5 y BCRP en muestras de leucemia linfocítica aguda (LLA) 
infantil, y cómo su expresión se correlaciona con las concentraciones intracelulares 
de MTX y la tasa de supervivencia a largo plazo. Nuestro análisis revela que, si bien 
la expresión de MRP4 se correlaciona con la resistencia al MTX ex vivo, no se 
correlaciona por sí sola con una baja tasa de supervivencia a largo plazo. Sin 
embargo, cuando hay una alta expresión de MRP4 y BCRP en conjunto, se da no 
solo una disminución intracelular del MTX, sino que también disminuye la tasa 
supervivencia general en pacientes con leucemia.  
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Igualmente en el capítulo 5, también analizamos la expresión tisular de otros 
transportadores clínicamente relevantes en la leucemia pediátrica, como el human 
equilibrative nucleoside transporter-1 (hENT1) y el concentrative nucleoside 
transporter-1 (hCNT1). Estos transportadores son responsables de en gran parte de 
la captación celular de citarabina (Ara-C). Nuestros estudios de tinción 
inmunohistoquímica en muestras diagnósticas de LMA pediátrica demuestran que 
estos transportadores se expresan ampliamente en la membrana celular y el 
citoplasma en muestras de diagnóstico. No se encontró una relación estadísticamente 
significativa entre la tasa de supervivencia de los pacientes y la expresión ex vivo de 
hCNT1/ hENT1, ni tampoco una relación estadísticamente significativa a la 
susceptibilidad farmacológica. Esto es seguramente debido a su amplia expresión en 
casi todas las muestras obtenidas. 
En el capítulo 6, examinamos si la administración de dexametasona (DEX) in vivo 
influye en la eficacia de Ara-C y gemcitabina dentro de un modelo de LMA en ratas. 
Específicamente, investigamos el efecto de DEX sobre la actividad enzimática de la 
desoxicitidina quinasa (dCK) ya que esta cataliza la conversión de Ara-C en su 
metabolito activo, la citosina arabinósido trifosfato (Ara-CTP). Previamente se ha 
demostrado que la administración de DEX disminuye la actividad de dCK, por tanto 
es relevante investigar a fondo esta posible interacción metabólica. En nuestro 
análisis observamos un aumento de la esperanza de vida en ratas con AML tratadas 
con Ara-C, como era de esperarse, mientras que el tratamiento en conjunto con DEX 
y Ara-C no tuvo impacto alguno en la actividad enzimática de dCK en las células 
leucémicas. Los resultados obtenidos están en contraste con lo que se ha venido 
observando anteriormente por otros investigadores anteriormente y por tanto, se 
debería investigar más a fondo el impacto de DEX en la eficacia de la citarabina en la 
LMA. 
Finalmente, en el capítulo 7, investigamos in vitro la capacidad proliferativa y el perfil 
citotóxico de la fitomolécula cannabidiol (CBD). Para esto usamos una línea celular 
CCRF-CEM y la sublínea (CEM / BTZ) que es fármaco-resistente al bortezomib 
(BTZ). Ambas son líneas celulares prototípicas de LLA de células T. El CBD es una 
molécula lipofílica con características antiinflamatorias, antiepilépticas y 
citoprotectoras que ha sido aprobada por la FDA (food and drug administration de los 
Estados Unidos), por lo que ha venido ganando notoriedad y que actualmente se la 
puede adquirir sin receta médica. El CBD también es un modulador de la actividad de 
la molécula mTOR (mechanistic targer for rapamycin), la cuál es crucial para el 
funcionamiento y proliferación tanto en células malignas como en células sanas. 
Nuestros análisis en ensayos de citotoxicidad indican que para inducir muerte celular 
en células leucémicas se necesitan altas concentraciones de CBD (alrededor de 10 
µM). Curiosamente, las concentraciones bajas y clínicamente alcanzables de CBD 
(alrededor de 1 µM) inducen en cambio, una proliferación celular significativa. Esta 
proliferación es dependiente de la densidad celular in vitro, lo que sugiere que la 
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densidad celular en un espacio determinado posiblemente secretan factores 
estimuladores del crecimiento de la densidad celular secundaria. Además la 
exposición a concentraciones incrementales de CBD de manera escalonada y 
permanente dio como resultado la creación de una nueva sublínea celular (CEM / 
CBD6250) la cual presenta propiedades de fármaco-adicción al CBD ya que lo 
requiere para su sobrevivencia y crecimiento. Cabe destacar que las células humanas 
sanas, no malignas, en cambio no demuestran citotoxicidad alguna incluso a altas 
concentraciones de CBD. Por tanto, el posicionamiento del CBD como una posible 
opción de tratamiento para la LLA in vivo aún debe definirse más aun. 
En resumen, esta tesis describe un enfoque multifacético al tratamiento de la 
leucemia tomando en cuenta tanto el microambiente de la MO, la fármaco-resistencia 
a la quimioterapia y las propiedades bifásicas del CBD (proliferación / citotoxicidad). 
A nivel de medioambiente tisular por ejemplo, a medida que se descubren nuevos 
factores regenerativos secretados por células endoteliales hREC durante etapas de 
regeneración y desarrollo, surgen nuevas preguntas sobre cómo estas células, nichos 
y factores están involucrados en el desarrollo de la leucemia y el desarrollo de la 
fármaco-resistencia. También nos enfocamos en factores intrínsecos celulares, tales 
como como las proteínas ABC, involucradas en la fármaco-resistencia, y su expresión 
amplificada en las células leucémicas. Vale recalcar, que es la acción conjunta de 
varios transportadores (en contraste a la acción individual) la que influye en la 
fármaco-resistencia, como se puede ver en las correlaciones obtenidas en durante 
nuestra pesquisa. Por tanto, concluimos que la sobreexpresión conjunta de varios 
transportadores está clínicamente ligada a una baja tasa de supervivencia, debido a 
una la disminución de la concentración intracelular de drogas usadas comúnmente 
en la quimioterapia (por ejemplo, el MTX). Sin embargo, algunos transportadores 
fisiológicos, como hENT1 y hCNT1 se expresan tan ampliamente, lo cual dificulta 
evaluar su verdadero impacto clínico en la leucemia infantil. Por tanto, para obtener 
un tratamiento personalizado y optimizado en cada paciente con leucemia, se debería 
aplicar un enfoque más amplio que incluya el análisis de expresión de transportadores 







• La MO alberga células endoteliales especializadas (hREC) que habitan en nichos 
endóseos. Las hREC aparecen en gran número durante las etapas de desarrollo fetal 
y secretan factores regenerativos durante el mismo y también después del 
tratamiento quimioterapéutico. Las hREC sobre expresan genéticamente IL-33, lo 
cual estimula la expansión de las células madre hematopoyéticas, las células 
endoteliales y la diferenciación osteogénica. 
 
• Las proteínas transportadoras ABC MRP4 y BCRP son determinantes en la 
regulación de la acumulación intracelular de poliglutamatos de MTX en las células 
leucémicas. La expresión de estas proteínas transportadoras se asocia con una 
disminución significativa de la tasa de supervivencia general. 
 
• Las proteínas transportadores de nucleósidos human equilibrative nucleoside 
transporter-1 (hENT1) y concentrative nucleoside transporter-1 (hCNT1) son 
responsables en gran parte de la captación celular de citarabina (Ara-C). Nuestro 
análisis inmunocitoquímico revela que hENT1 y hCNT1 son ampliamente expresadas 
en casi todas las células malignas en muestras de diagnóstico de LMA pediátrica, lo 
que dificulta una clasificación clínica precisa basada únicamente en la expresión de 
estos transportadores. 
 
• La dexametasona (DEX) y Ara-C son medicamentos importantes en el tratamiento 
de la LLA infantil. Con este fin, algunos estudios mostraron que DEX podría afectar la 
disminuir la actividad de la desoxicitidina quinasa (dCK) y por ende la activación del 
Ara-C intracelularmente. Sin embargo, nuestros estudios in vivo mostraron que la 
administración combinada de DEX y Ara-C no redujo la actividad de dCK ni afectó el 
efecto antileucémico de Ara-C en un modelo de LMA en ratas. 
 
• El CBD tiene efectos bifásicos en las células leucémicas in vitro: por un lado es 
citotóxico contra células de LLA a concentraciones > 10 µM, y al contrario, a 
concentraciones de 1 µM estimula el crecimiento celular, en particular en células 
resistentes a BTZ. Dado que la exposición prolongada al CBD también provoca 
fenómenos de adicción celular (en el cuál las células malignas necesitan de CBD para 
sobrevivir), se requiere precaución para el uso del CBD como fármaco experimental 
en el tratamiento de la leucemia a bajas concentraciones. 
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